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The FOXP3 transcription factor can regulate T cell migration by inhibiting 
expression of CXCR4, the receptor for the chemokine CXCL12. The increased 
expression of CXCR4 by breast cancer cells can drive metastatic migration towards 
sites that express CXCL12. Intracellular trafficking of FOXP3 to the nucleus is 
required in order for this factor to function. The presence of alternative splicing 
forms, mutations and post-translationally modified forms may disrupt FOXP3 
nuclear localization. We hypothesised that FOXP3 tumour suppressor is inactive in 
breast cancer causing an increase in CXCR4 expression and the development of 
metastasis. The expression of FOXP3 and CXCR4 were measured at mRNA and 
protein (immunohistochemistry, immunofluorescence, FACS) levels. FOXP3 DNA 
sequences of normal and cancer cells were analysed. Stable FOXP3 overexpressing 
breast cancer transfectants were used to investigate the potential of FOXP3 to 
regulate chemotaxis. Normal breast epithelial cells (both patient-derived tissues 
and laboratory cultured cell lines) expressed FOXP3 in their nuclei but did not 
express CXCR4. Breast cancer cells overexpressed CXCR4 (p<0.05), whereas 
FOXP3 expression was decreased (p<0.05) and confined to the cytoplasm with 
negligible nuclear expression. Metastases expressed less FOXP3 and more CXCR4 
than primary cancers (p<0.05). FOXP3 sequencing in breast cancer cell lines did 
not reveal mutations. However, there were at least three bands on the PCR 
electrophoreses gel. The predominant form in breast cancer cells contained an 
insertion of 120bp within the forkhead domain. Transfection of breast cancer cells 
with wild-type FOXP3 restored its nuclear expression, reduced CXCR4 expression 
and inhibited cell migration. This study demonstrated failure of nuclear 
localisation of FOXP3 in breast cancer cells and an inverse correlation between this 
failure and CXCR4 expression. Disruption of FOXP3 nuclear localisation may be 
due to abnormal co-expression of FOXP3 splice variants leading to increased 
CXCR4 expression and acquisition of the capacity to metastasize.  
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1.1 Breast cancer epidemiology  
Breast cancer is the most common cancer in women worldwide, comprising 16% 
of all female cancers (WHO, 2009), causing 470,000 deaths annually mainly as a 
result of metastatic spread of the disease (WHO, 2002). The lifetime probability of 
developing breast cancer in the next 10 years is evaluated as 13.2% worldwide 
(2005-2006). Mortality rates rose in the years 1951 to 1990 but have since fallen 
in most European countries including the U.K. The reasons for improvement in 
mortality rates in Europe, Australia and the Americas include screening (Eisner et 
al., 2002), accurate and precise diagnosis and improved treatment; most notably 
hormonal therapy, including tamoxifen (Peto et al., 2000). Breast cancer 
metastasizes to specific organs: lymph nodes, bone marrow, lung and liver. There 
is increasing evidence that immune modulation is involved in breast cancer 
progression and metastatic spread (Fulton et al., 2006). 
1.2 Risk factors associated with breast cancer 
Non-modifiable risk factors of breast cancer development are: increasing age, 
female gender, genetic factors, family history of breast cancer, personal history of 
breast cancer, and race. Modifiable risk factors for breast cancers include smoking, 
alcohol consumption, use of hormonal replacement therapy, decreased physical 
activity, obesity and increased intake of animal fat (McPherson et al., 2000). 
1.3 Structure of the human breast 
The breast is a milk-producing, modified sweat gland composed of glandular 
tissue, fat and connective tissue. It is subdivided into multiple lobes. Lobes consist 
of lobules of glandular secretory tissue from which secretions pass to the nipple 
via ducts. Breast tissue is present on the anterior chest wall and extends towards 
the axilla as an axillary tail. Lymph nodes within the axilla collect the majority of 






Figure 1-1: Structure of the human breast  
The figure demonstrates structure of the human breast showing lobules, ducts and stromal 
elements. Lymph from the breast drains mainly into the ipsilateral axilla, axillary lymph nodes 
being a common site of breast cancer metastasis.  
 





1.4 Pathogenesis and pathology 
Breast cancer tumorigenesis is a multi-step process progressing in the following 
manner: normal breast tissue, in situ carcinoma, invasive carcinoma and 
metastasis. 
Initial changes of neoplastic transformation identified morphologically are known 
as in-situ carcinomas or (lobular/ductal) intraepithelial neoplasia.  
The majority of breast cancers arise from the epithelial cells of the ducts or glands 
and are termed adenocarcinomas. Both ductal and lobular carcinomas arise from 
the terminal duct lobular unit. The most common invasive breast cancers are 
infiltrating ductal carcinoma (IDC) (80% cases) and infiltrating lobular carcinoma 
(ILC) (10% of cases).  
Some tumours have distinct patterns of growth and cellular morphology, and are 
termed carcinomas of special type (tubular, cribriform, medullary, mucoid, 
papillary and classic lobular), the rest are considered to be of non-special type.  
1.5 Oncogenes and Tumour Suppressor Genes 
The multistep development of breast cancer is dependent on one or more 
regulatory gene mutations occurring at each step (Beckmann et al., 1997). The 
mutations involved in the development of hereditary and sporadic breast cancer 
occur in different genes. Hereditary breast cancers are linked with one or more 
germline mutations, whereas sporadic breast cancers develop from the 
accumulation of gene mutation that are somatic in nature (Kenemans et al., 2004). 
These mutations occur most commonly in regulatory genes collectively known as 
oncogenes and tumour suppressor genes (see Table 1-1). 
Mutations in tumour suppressor genes can happen in both sporadic and hereditary 
breast cancer. Tumour suppressor genes are involved in the restraint of normal 
cell cycle progression especially when DNA damage is detected (Kenemans et al., 






The cell cycle is divided into four stages (Figure 1-2): 
 Post-mitotic phase (interphase) when the cell prepares itself to cycle (G0 
phase) 
 Synthesis of new organelles and DNA checkpoint (G1 phase) 
 DNA synthesis or replication (S phase) 
 Preparation for mitosis and DNA checkpoint (G2 phase) 
 Mitosis (M). 
Mutations in the genes involved at any stage of the cell cycle allow cells harbouring 
other mutations to escape cell death by apoptosis and to proliferate without 
restraint. 
There are a number of inherited breast cancer genes identified, of which mutations 
in the tumour suppressor genes breast cancer 1 (BRCA1) and breast cancer 2 
(BRCA2) account for about 30-40% of cases (Venkitaraman, 2001). The BRCA 
genes are extremely penetrant genes that present an autosomal predisposition to 
the disease and have a strong relationship with cancer arising at a young age. The 
presence of the wild type BRCA genes is associated with protection against the 
development of breast cancer and therefore they play a role in tumour suppression 
(Clarke, 2002). In the majority of hereditary cases mutations in the BRCA genes are 
present on one allele with the wild-type protein present on the other allele. For 
breast cancer to develop the loss of the wild type must occur, possibly through 
errors in DNA replication. Mutations in BRCA1 or BRCA2 increase the lifetime risk 
of developing breast cancer to 60-80% in women. Less common gene mutations in 
hereditary breast cancer include the cell cycle check point kinase gene (CHEK) 2 
truncating mutation 1100delC which accounts for 5% of cases and PTEN which is 
only responsible for 1% of cases (Sansal and Sellers, 2004) (Friedrichsen et al., 
2004).  
Recently, the x-linked breast cancer suppressor gene FOXP3 was identified (Zuo et 
al., 2007c). Following x-inactivation only one copy of FOXP3 is functional, allowing 










Figure 1-2: Cell cycle  
The figure demonstrates eukaryotic cell cycle divided into phases: G1 phase, S 










Tumour suppressor gene Normal function 
p53 Triggers/facilitates apoptosis 
p27 
Inhibit cyclin-dependent protein kinases; arrests cell-cycle in 
G1 phase 
BRCA-1 Regulates DNA transcription; acts to repair damaged DNA 
BRCA-2 Repairs damaged DNA 
FOXP3 
Master regulator in the development and function of 
regulatory T cells 
CHK2 
Cell-cycle checkpoint kinase, activates p53 after DNA 
damage 
ATM Checkpoint kinase, activates CHK2 
PTEN Phosphatase, negative regulator of Akt kinase 
Rb 




Oncogene Normal function 
HER-2 Tyrosine kinase receptor 
Ras G-protein 
PI3K Cell signalling kinase 
Akt Cell signalling kinase 
ElF-4E Initiator of protein translation 
Cyclin D1 Cell-cycle mediator 
Cyclin E Cell-cycle mediator 
c-myc Transcription factor 
cerbB1-4 Gene encoding EGF receptor 
Wnt1 Cell signalling 
Table 1-1. Tumour suppressor genes and oncogenes in breast cancer 
A list of tumour suppressor genes (A) and oncogenes (B) commonly associated with breast cancer, 





Generally mutations that affect the normal function of tumour suppressor genes 
differ from those seen with oncogenes. Unlike oncogenes, mutations must take 
place on both alleles for a change in the function of the majority of tumour 
suppressor genes, but this is not true for all tumour suppressor genes. Mutations 
in the tumour suppressor BRCA must occur on both alleles, whereas mutation of 
only one allele is sufficient to cause a pro-tumourigenic change with p53. The p53 
gene is the most commonly mutated gene in sporadic cancers with mutations in 
p53 occurring late in sporadic breast cancer (Elledge and Allred, 1998). Following 
stress signals p53 becomes active and binds to DNA leading to the transcription of 
a multitude of proteins including p21 (Elledge and Allred, 1998). p21, a G1 CDK 
inhibitor, complexes with cyclic dependent kinase (CDK) 2 causing G1/S arrest in 
the presence of DNA damage.  
Most of mutations in p53 are point mutations which prevent the binding of p53 to 
DNA and therefore the production of p21 (Liu and Kulesz-Martin, 2001). This 
allows cells containing mutations to progress through the cell cycle and proliferate. 
The retinoblastoma (Rb) tumour suppressor gene functions normally to prevent 
G1/S transition in the presence of DNA damage. Under normal circumstances Rb is 
phosphorylated by CDKs preventing its interaction with the transcription factor 
E2F which promotes transcription of genes required for cell cycle progression (Cox 
and Lane, 1995). In the presence of DNA damage Rb is not phosphorylated and 
binds E2F preventing the transcription of cell cycle proteins. Mutations in Rb are 
required on both alleles and results in permanent phosphorylation of Rb 
preventing its interaction with E2F and unchecked cell cycle progression (Gewirtz 
et al., 2001).  
Oncogenes develop as a consequence of a mutation or overexpression of proto-
oncogenes that function under normal conditions to regulate proliferation and 
differentiation. An example of an oncogene linked with breast cancer progression 
is cyclin D1. Cyclin D1 is essential for progression from G1/S phase in the cell-cycle. 
It binds to and activates CDK4 and CDK6 which then phosphorylate Rb. In the 





continuation of the cell-cycle (Harbour et al., 1999). Cyclin D1 expression is 
amplified up to 10-fold in 13-20% of breast cancers and functions to activate CDK4 
and CDK6 leading to progression to the S phase, independent of p53-mediated cell-
cycle arrest (Arnold and Papanikolaou, 2005). 
1.6 Hormone and Growth Factor Receptors 
A common feature of breast cancer is the upregulation of hormone receptor 
expression on the surface of the cells. Two hormone receptors upregulated in 
breast cancers are the oestrogen and progesterone receptors, which are present 
either individually or in combination in about 80% of all breast cancers. 
Oestrogen is considered a major risk factor in the development of breast cancer. 
Oestrogen applies its effects on cell proliferation by two mechanisms. Firstly 
oestrogen can directly stimulate receptors on the plasma membrane resulting in 
increased levels of Ca2+ or nitric oxide, and activation of kinases (Song and Santen, 
2006). The second mechanism of oestrogen action involves the diffusion of 
oestrogen into the cell and binding to the estrogene receptor (ER) located in the 
nucleus. Activation of the ER on the plasma membrane induces rapid responses to 
oestrogen whereas activation of the nuclear ER can be measured over the course of 
hours (Deroo and Korach, 2006). The ER exists in two forms the ER-a and the ER-
b; as cancer progresses the expression levels of ER-b decrease and the levels of ER-
a increase, which has led to the theory that ER-b may play a protective role in 
breast cancer through regulation of the ER-a, although most studies have focused 
on the ER-a (Bardin et al., 2004). About 50-70% of all breast cancers express the 
ER-a and are referred to as ER-positive tumours. These tumours have a lower 
proliferative rate and are better differentiated than ER-negative tumours. ER-
positive tumours have a better prognosis and can be treated with anti-oestrogen 
therapies such as tamoxifen and raloxifene (Putti et al., 2005) (Platet et al., 2004). 
Progesterone signals through the progesterone receptor (PR), which exists in two 
isoforms, PRA and PRB. The PR is induced by oestrogen through activation of the 





on the plasma membrane. Following binding of progesterone, the nuclear 
receptor/ligand complex translocates to the nucleus interacting with the genome 
leading to the transcription of downstream gene targets (Ismail et al., 2003). In the 
case of breast cancer, progesterone is thought to function in a parallel manner to 
oestrogen by increasing cell proliferation. About 55% of tumours demonstrate 
increased expression of the PRB receptor with 50% tumours being both ER-
positive and PR-positive and only 5% being ER-negative and PR-positive (Keen 
and Davidson, 2003). The tumours expressing both hormone receptors respond 
most favourably to hormone therapy, whereas those tumours that are either ER-
negative or PR-negative do not respond to the same level. 
The expression of growth factors receptors is frequently upregulated in breast 
cancer. One of these receptors is coded for by the oncogene HER2 or human 
epidermal growth factor receptor 2, also known as c-erbB2/neu, which 
participates in cell growth and proliferation (Brand et al., 2006). HER2 has no 
specific ligand but can form heterodimers with other members of the HER family, 
which increases their signalling potential and upon ligand binding activate a 
number of intracellular protein kinases leading to cell signalling. HER2 is 
overexpressed in 15-30% of breast cancers and is associated with poor prognosis 
and survival (Brand et al., 2006). HER2 amplification is associated with resistance 
to hormonal therapy and a decreased responsiveness to chemotherapy (De Placido 
et al., 1998, Shou et al., 2004, Giai et al., 1994, Stal et al., 1995, Muss et al., 1994). 
The growth of tumours and human breast cancer cell-lines overexpressing the 
HER2 receptor has been shown to be inhibited by the use of anti-HER2 monoclonal 
antibodies (mAbs), offering a potential target for cancer therapy. 
1.7 Tumour grading 
Prognostic information can be established by grading breast cancers according to 
their degree of differentiation. Nuclear pleomorphism, frequency of mitoses and 
the degree of glandular formation are scored from 1 to 3. The combine scores 





important predictor of disease free survival and overall survival (Hatteville et al., 
2002). 
1.8 Tumour staging 
The tumour node metastasis (TNM) staging system assesses the extent of local and 
systemic disease. It correlates with the UICC (International Union Against Cancer) 
system (Table 1-2). Increased sensitivity of techniques identifying metastases 
allow the identification of isolated tumour cells (<0.2mm), micrometastases (0.2-
2mm) and metastases (>2mm). However, the clinical importance of the smaller 
metastases remains unclear. There is evidence that the number of patients 
developing axillary progression of breast cancer is far lower than expected, given 
the prevalence of lymph node metastases identified on histology (Zurrida et al., 
2002). This suggests that the majority of tumour cells present in metastatic sites 
are not able to maintain tumour development and is consistent with a hypothesis 
that metastatic growth depends on the activation of tumourigenic stem cells.  It is 
also consistent with a hypothesis suggesting that both the tumour and the 
metastatic site must have a compatible gene expression signature in order to 
achieve a tissue-specific metastasis (Kang et al., 2003b, Kang et al., 2003a). 
1.9 Mutagenesis  
Metastasis requires close collaboration between cancer cells, immune and 
inflammatory cells, and stromal elements. The process of metastasis consists of 
four major steps.  
The first step is represented by epithelial-mesenchymal transition, in which cancer 
cells acquire fibroblastoid characteristics that increase their motility and allow 
them to invade epithelial and basal membranes and achieve efferent blood vessels 
or lymphatics (Kalluri and Weinberg, 2009). Loss of E-cadherin expression is 
considered as a key event in the epithelial-mesenchymal transition.  
In the second step, cancer cells intravasate into blood vessels and lymphatics. The 





In the third step, metastasis-initiating cells survive and travel throughout the 
circulation. It has been estimated that only about 0.01% of cancer cells that enter 
the circulation will eventually survive and give rise to micrometastases (Joyce and 
Pollard, 2009). Next, integrin-mediated arrest allows the extravasation of 
circulating cancer cells.  
Finally, single metastatic progenitors interact with immune, inflammatory, and 
stromal cells and start to proliferate (Polyak and Weinberg, 2009). Some of these 
cells may already be targeted to become premetastatic in response to tumor-
generated inflammatory signals prior to the arrival of metastasis-initiating cancer 
cells (Kaplan et al., 2005). One of these inflammatory signals is the extracellular 
matrix component versican, which leads to macrophage activation and production 





Primary tumour (T)  
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in-situ, or Paget’s disease of nipple with no associated 
mass 
T1 Tumour <2cm 
T2 Tumour 2-5cm 
T3 Tumour >5cm 
T4 Tumour involving skin, chest wall or an inflammatory cancer 
Regional lymph nodes (N)  
Nx Lymph nodes cannot be assessed 
N0 No regional lymph node metastases greater than 0.2mm 
N1 1-3 lymph nodes metastatic 
N2 4-9 lymph nodes metastatic 
N3 >10 lymph nodes metastatic or supraclavicular/ infraclavicular  
Metastasis (M)  
Mx Presence of distant metastases not evaluated 
M0 No distant metastases 
M1 Distant metastases present 
Stage Definition 
Stage 0 Tis, N0, M0 
Stage I T1, N0, M0 
Stage II 
Stage IIA 
T0, N1, M0 
T1, N1, M0 
T2, N0, M0 
Stage IIB 
T2, N1, M0 
T3, N0, M0 
Stage III 
Stage IIIA 
T0, N2, M0 
T1, N2, M0 
T2, N2, M0 
T3, N1, MO 
T3, N2, M0 
Stage IIIB 
T4, N0, M0 
T4, N1, M0 
T4, N2, M0 
Stage IIIC Any T, N3, M0 
Stage IV Any T, any N, M1 
Table 1-2: The Tumour, Lymph nodes and Metastasis system for classifying and 
staging breast cancer. 
Adapted from Singletary at al, (2003). "Revision of breast cancer staging: the 6th edition of the TNM 





1.10 Management of Breast Cancer 
Management of breast cancer depends on the stage of the tumour, its size, the 
expression of hormone and growth factor receptors on the tumour cells and 
patients factors.  
1.10.1  Surgery 
In majority of cases surgery initiates breast cancer treatment by removing the 
tumour. The majority (75-83%) of tumours are small and undergo “conservative 
therapy” which includes lumpectomy known as “wide local excision”(Sarrazin et 
al., 1989). Large primary tumours can be reduced in size by primary chemotherapy 
prior to the surgery (Veronesi et al., 1995). Mastectomy is indicated if the tumours 
are too large for conservative therapy and cannot be reduced in size by primary 
chemotherapy. During surgery lymph nodes are removed to determine metastatic 
spread. Resection of lymph nodes may involve sentinel node biopsy, lymph node 
sampling or axillary clearance. 
1.10.2  Radiotherapy 
Radiotherapy is administered to the remaining breast tissue following either 
conservative surgery or mastectomy. If sampled lymph nodes are shown to contain 
cancer then radiotherapy is applied to the remaining nodes. Locally advanced 
tumours are also successfully treated with breast conserving surgery followed by 
radiotherapy if the tumours respond to induction chemotherapy (Fisher et al., 
1997). 
1.10.3 Chemotherapy 
Chemotherapy reduces a patient’s risk of recurrence and attempts to eradicate 
micrometastatic process.  It can also be administered before surgery to reduce the 
size of a tumour as neoadjuvant therapy (Colleoni et al., 1998). 
1.10.4  Hormone Therapy 
Oestrogen (ER) and progesterone (PR) positive breast cancer are responsive to 





cancer cells. The ER receptor antagonist tamoxifen is recommended for 5 years 
following surgery in early breast cancers to prevent relapse of the cancer (Fisher 
et al., 1996). It has been proven that tamoxifen reduced the recurrence in 30-50% 
of women with ER-positive tumours (Fisher et al., 1998). Aromatase inhibitors 
block aromatase activity and prevent the production of oestrogen, which 
subsequently inhibits the development of ER-positive breast cancers. These 
medications are only effective in post-menopausal women since they cannot 
inhibit the ovaries of premenopausal women from producing oestrogen. 
Aromatase inhibitors can be used for treating both early and advanced breast 
cancer. These drugs are letrozole, anastrozole, and exemestane (Jelovac et al., 
2004, Ingle et al., 2006, Steele et al., 2006). They are given to post-menopausal 
patients instead of tamoxifen for 5 years following surgery.  
1.10.5 Molecular Therapies 
Molecular therapies target a wide range of molecules such as growth factors, 
angiogenic factors and their receptors. The most popular is Trastuzumab 
(Herceptin), what is a monoclonal antibody that binds and blocks the HER2 
receptor. HER2 is overexpressed in 15-30% of breast cancers and is associated 
with a poor prognosis. Herceptin is only effective in women with tumours 
overexpressing HER2. 
Other targets of breast cancer cells include tyrosine kinases (Gefitinib), insulin-like 
growth factor and vascular endothelial growth factor (VEGF) (Bevacizumab) 
(Fountzilas et al., 2005b, Fountzilas et al., 2005a). Increased research into the 
molecular based therapies of cancer has led to extensive interest in the role of 
chemokines (chemo-tactic cyto-kines) and their receptors in cancer evolution and 





1.11 Tumour inflammatory microenvironment  
A link between inflammation and cancer was observed over 150 years ago when 
Rudolf Virchow noted that cancers tend to occur at sites of chronic inflammation 
(Balkwill and Mantovani, 2001). Inflammatory and infectious diseases are often 
associated with an increased risk of cancer (Coussens and Werb, 2002). In many 
ways, the microenvironment of tumours mimics that of tissues during an 
inflammatory response to injury (Coussens and Werb, 2002). However, unlike the 
ultimate resolution of the inflammation that occurs during healing of healthy 
tissue, tumours exist in a state of chronic inflammation. The tumour 
microenvironment is a vastly complex entity with multiple components affecting a 
tumour's growth, invasion and metastasis. Its components include endothelial 
cells, pericytes, fibroblasts, inflammatory cells, leucocytes, elements of the 
extracellular matrix (ECM) and network of angiogenic and angiostatic chemokines 
(Ali and Lazennec, 2007, Harvey, 2005, Harvey et al., 2007, Mellor et al., 2007). 
Since alternative environments such as bone marrow and lymph node are not 
naturally compatible with cells from the breast, cancer cells must shape the 
tumour microenvironment to become conducive to survival and growth (Sica et al., 
2006, Friedl and Wolf, 2003). Pro-tumour inflammatory microenvironments 
support colonization of malignant cells in metastatic sites by enhancing neoplastic 
cell homing to target metastatic organs, extravasation out of vasculature, 
mobilization of bone marrow-derived progenitor cells, activation and sustained 
angiogenesis at secondary site, and enhanced neoplastic cell proliferation and 


























Figure 1-3: Pro-tumor inflammation potentiates metastatic progression 
Pro-tumour inflammatory responses potentiate malignancy and hematogenous metastatic spread 
process by promoting critical steps in the metastatic process. Productive metastases require, (a) 
oncogenic transformation and genomic instability in initiated cells, resistance to apoptotic and cell 
death programs, self-sufficiency for growth signaling and limitless replicative potential. (b) 
Interactions between neoplastic cells and pro-tumor pro-inflammatory microenvironments 
facilitate malignant conversion and favors selection for malignant cells with metastatic potential by 
engendering development of an aggressive malignant phenotype characterized by sustained 
angiogenesis, local invasion and vascular intravasation by neoplastic cells. (c) Pro-tumor 
inflammatory microenvironments support colonization of malignant cells in metastatic sites by 
enhancing neoplastic cell homing to target metastatic organs, extravasation out of vasculature, 
mobilization of bone marrow-derived progenitor cells, activation and sustained angiogenesis at 
secondary site, and enhanced neoplastic cell proliferation and survival in the ectopic site. 






Chemokines are a superfamily of small secretory proteins that have many diverse 
functions. They apply their effects locally in a paracrine or autocrine fashion. 
Chemokines play a fundamental role in immune and inflammatory reactions 
including the trafficking of immune cells (Rollins, 1997). Chemokines have been 
classified in terms of their physiological features into constitutive (homeostatic e.g. 
CXCL12) or inducible (inflammatory e.g. CCL2, 3, 4) expression (Table 1-3). 
Chemokines may be synthesised and secreted by practically all cell types. 
Inflammatory chemokines are usually secreted in response to stimuli such as from 
endogenous pro-inflammatory cytokines (e.g. TNF- and IFN- (Interferon-) or 
exogenous stimuli such as mitogens and bacterial lipopolysaccharide (Palmberg et 
al., 1998). Chemokine cDNAs encode proteins of 92 to 130 amino acids (Garton et 
al., 2001) and are synthesised in precursor form with a small signal peptide 
sequence (Gortz et al., 2002), which is cleaved prior to secretion (Baggiolini, 2001).  
1.12.1 Chemokine structure and classification 
Chemokines have three-dimensional structural similarity dictated by the 
conserved cysteine (C) residues. Four chemokine classes are recognised based on 
the location of the first two cysteines in the protein sequence (CXC, CC, C and 
CX3C) (See Table 1-3). The majority of chemokines belong to the CXC or CC 
families. CXC chemokines have been further divided into two groups based on the 
presence of a sequence of three residues in the amino-terminal region, Glu-Leu-
Arg (the so-called ELR motif). The ELR motif is an important factor in determining 
angiogenesis (ELR positive), or angiostasis (ELR negative) (Keane and Strieter, 
1999, Strieter et al., 1995), although not an absolute determinant of angiogenic 
status (e.g. CXCL12 is ELR negative but is angiogenic). All ELR positive chemokines 
bind CXCR2 but several also bind to CXCR1, while ELR negative chemokines bind 






Table 1-3: Chemokine and receptor nomenclature.  





1.13 Chemokine receptors 
Chemokine receptors enable the transduction of inflammatory or constitutive 
chemokine expression into a biological response (Hansell et al., 2006). Chemokine 
receptors are present on the surface of leukocytes in the peripheral blood and can 
bind to chemokines on the surface of endothelial cells. This enables reactivation of 
integrin and induces a firm adhesion of the leukocyte to the endothelial surface 
facilitating extravasation of the leukocyte from the blood into the surrounding 
tissue.  When the biological response no longer exists, the rapid removal of these 
chemokines is vital in order to resolve inflammation and restore tissue 
homeostasis. The chemokine receptor is recycled in the perinuclear region to be 
trafficked back to the plasma membrane, or it will enter the lysosome 
compartment for degradation (Neel et al., 2005). Internalisation of chemokine 
receptors may radically reduce the membrane surface expression of the receptor 
and is a likely mechanism for the downregulation of chemokine receptors (Neel et 
al., 2005).  
Chemokine receptors consist of a seven-transmembrane spanning domain 
composed of single polypeptide chains with three extracellular and three 
intracellular loops (Figure 1-4). Ten CC, seven CXC, one CX3C and one XCR 
receptors have been identified (Mantovani, 2004, Homey et al., 2002). An acidic N-
terminal domain is localised extracellularly and is involved in ligand binding. It has 
a role in ligand specificity as a conserved cysteine motif within the chemokine 
limits it to a specific receptor subgroup. A serine/threonine-rich C-terminal 
domain, which is placed intracellularly and G-protein coupled, is a component of a 
functioning chemokine receptor. It is involved in the transduction of signalling 
pathways when the receptor binds to the certain chemokine. The majority of 
receptors can respond to more than one chemokine and most of the chemokines 







Figure 1-4: Chemokine receptor structure 
The seven transmembrane domains are demonstrated along with an extracellular N-terminal 
region containing a generic chemokine binding pocket. The intracellular C-terminus and the 





1.14 CXCR4 Signalling 
Upon binding of CXCL12 the CXCR4 receptor undergoes receptor dimerisation, 
resulting in the activation of a variety of intracellular signalling pathways and 
effector molecules that regulate cell survival, proliferation, chemotaxis, migration, 
and adhesion (Vila-Coro et al., 1999). These pathways are summarised in the 
Figure 1-5. The initial stages of CXCR4 receptor signalling are mediated through G-
proteins. The specific downstream signalling cascades stimulated from the G-
proteins are dependent on the specific chemokine.  
Stimulation of CXCR4 activates the PI3K pathway that leads to activation of the 
protein kinase Akt (Vlahakis et al., 2002, Kayali et al., 2003). Following PI3K 
activation, Akt is recruited to the plasma membrane and activated through 
phosphorylation by phosophoinositide-dependent protein kinase (PDK)-1 and 
PDK2 (Sarbassov et al., 2005). The active form of Akt stimulates the transcription 
of genes fundamental for cell migration, proliferation and resistance apoptosis 
(Chinni et al., 2006, Vlahakis et al., 2002, Luo et al., 2003). NF-kB is an essential 
protein in the transcription of these genes and Akt activates it. NF-kB activation 
leads to the transcription of vascular endothelial growth faxtor (VEGF) and 
metaloprotein (MMP9) and increasing the expression of CXCR4 on breast cancer 
cells. In the breast cancer cell-line MDA-MB 231, CXCR4 expression was increased 
in response to activation of NF-κB, and blocking of this transcription factor 
genetically or pharmacologically reduces expression of CXCR4 (Helbig et al., 2003). 
NF-kB knockout mouse models of breast cancer demonstrated an increase in the 
apoptosis of breast cancer cells, linking NF-kB and hence Akt directly to the 
suppression of apoptosis in breast cancer (Sovak et al., 1997).  
Mitogen-activated protein kinase (MAPK) pathway is another pathway activated 
by CXCR4. Following CXCL12 binding CXCR4 activate the kinase MEK1/2, which 
then phosphorylates and activates p44/42 MAPK (ERK1/2). p44/42 MAPK 





The third pathway involved in CXCR4 signalling is the Janus kinase/signal 
transducer and activator of transcription (JAK/STAT) pathway. Following 
activation of CXCR4, JAK kinases activate the STAT family of transcription factors. 
These transcription factors then traffic to the nucleus to regulate gene expression 







Figure 1-5: Major signal transduction pathways activated by CXCL12 stimulation of 
CXCR4.  
SDF binding to CXCR4 leads to the activation of multiple signaling pathways, resulting in diverse 
biological outcomes such as migration, adhesion, and transcriptional activation. Pathways activated 





1.15 CXCR4 and CXCL12 interactions 
Particular malignancies have a tendency to metastasise to specific distant organs, 
suggesting a crucial role of the organ microenvironment for the localisation and 
proliferation of the metastatic tumour cells (Hart and Fidler, 1980). It appears that 
breast cancer cells are able to metastasise to specific organs in a manner that is 
dependant upon the ability of the organ to mediate tumour cell adhesion, 
extravasation and to support subsequent viability and proliferation. In 19th 
century Paget described that breast cancer has a distinct metastatic pattern, with 
metastases commonly localising to lung, liver, lymph nodes and bone (Paget, 
1889).  
The pathway of tumour metastasis shares many similarities with that of leukocyte 
localisation and chemokines play a vital role in both of these processes (Figure 
1-5). The most widely studied chemokine in breast cancer is CXCL12, and its 
chemokine receptor CXCR4 is expressed on primary breast tumours but not on 
normal breast cells (Muller A, 2001). Moreover CXCL12 is expressed at common 
sites of breast cancer metastasis. CXCR4 plays important roles in cancer cell 
adhesion and migration (Muller A, 2001). Glycosaminoglycans (GAG) bind 
chemokines for presentation to responsive cells (Sadir et al., 2001, Amara et al., 
1999, Valenzuela-Fernandez et al., 2001, Sweeney et al., 2002, Pablos et al., 2003). 
CXCL12 is bound and presented by heparan sulphate on the apical surface of 
endothelial cells, potentially inducing immobilisation of haematogenous breast 
cancer cells followed by extravasation during metastasis (Harvey et al., 2007).  
Work within our group explores the importance of CXCR4 in breast cancer 
metastasis, and demonstrate inhibition of CXCR4/CXCL12 by soluble GAG 
molecules. Heparinoids disrupt normal presentation of CXCL12, reducing the 
metastasis of CXCR4-expressing breast cancer cells (Harvey et al., 2007, Harvy, 





CXCL12 is expressed in bone marrow (Semerad et al., 2005), lung (Phillips et al., 
2003, Muller et al., 2001), liver (Sun et al., 2005, Wald et al., 2004), adrenals (Sun 
et al., 2005) and the brain (Bonavia et al., 2003). CXCL12 is also produced by many 
different cell types within the primary tumour site, including breast cancer cells, 
immune cells, stromal fibroblasts and myofibroblasts (Kang et al., 2005, Lee et al., 
2004, Orimo et al., 2005, Allinen et al., 2004). CXCL12 production by 
myofibroblasts associated with invasive breast cancer is significantly higher than 
that of myofibroblasts in normal breast tissue (Allinen et al., 2004). Localisation of 
CXCL12 to tumour myofibroblasts was confirmed by immunohistochemistry 
(Allinen et al., 2004). The overall significance of CXCL12 production at the site of 
the primary lesion is not understood. CXCL12 may stimulate tumour growth, 
promote survival and suppress an immune response, conversely, it may act to 
retain tumour cells within the tumour or stimulate an immune response (Balkwill, 
2004, Dunussi-Joannopoulos et al., 2002, Luker and Luker, 2005). 
 CXCR4 is expressed on various cell types, including endothelial cells (Volin et al., 
1998, Feil and Augustin, 1998), bronchial epithelial cells (Eddleston et al., 2002), 
lymphocytes (Bleul et al., 1996b, Bleul et al., 1996a), intestinal (including colonic) 
epithelial cells (Dwinell et al., 1999, Jordan et al., 1999), primitive haematopoietic 
progenitor cells (Aiuti et al., 1997), microglia, neurons and astrocytes (Bonavia et 
al., 2003), vascular smooth muscle cells (Schecter et al., 2003) and fibrocytes 
(Phillips et al., 2004). CXCR4 is also expressed in pluripotent stem cells, including 
mammary stem cells (Dontu et al., 2003).  
Recently, several studies have demonstrated the existence of a small subset of 
cancer cells that share many characteristics with stem cells and named cancer 
stem cells (CSC). They constitute a reservoir of self-sustaining cells with the ability 
to maintain the tumor growth. In particular, most of them express CXCR4 receptor 
and respond to a chemotactic gradient of its specific ligand SDF-1, suggesting that 





2005). This suggests that CXCR4 expression may define the progenitors of breast 
cancer (Liu et al., 2005). 
1.16 CXCR4 and CXCL12 in breast cancer 
The role of the CXCR4-CXCL12 axis is well established in the pathogenesis of breast 
cancer progression (Ali et al., 2003, Ali S, 2007 ). CXCR4 expression in breast 
cancer cells is confined to a small population of cells (Kang et al., 2003b). Amongst 
breast cancer cell lines, MDA-MB-231 is the most commonly used CXCR4 
expressing metastatic cell line (Muller et al., 2001, Lee et al., 2004, Tamamura et 
al., 2003, Kang et al., 2005, Matteucci et al., 2005b, Fernandis et al., 2004). 
Approximately 10-15% of early passage MDA-MB-231 cells demonstrate CXCR4 
expression (Lee et al., 2004, Helbig et al., 2003). Immunohistochemical staining of 
primary breast tumours has revealed that normal breast epithelial cells do not 
express CXCR4, whereas, between 5 and 73% of primary breast cancers express 
this receptor (Muller et al., 2001, Kato et al., 2003, Cabioglu et al., 2005c) as do 
more than 90% of specimens with atypical ductal hyperplasia (Schmid et al., 
2004). CXCR4 expression in the primary tumour has been positively correlated 
with the degree of lymph node metastasis, homogenous metastasis to the lungs, 
bone metastasis, poor patient overall survival and tumour grade (Altundag et al., 
2005). High levels of CXCR4 have also been correlated with poor patient overall 
survival (Li et al., 2004). CXCR4 expression has been correlated with the ability of 
breast cancer cells to metastasise to lungs (Helbig et al., 2003). In a mouse model 
of breast cancer, low CXCR4 expressing parental MDA-MB-231 breast cancer cells 
were injected into the mammary fat pad. Primary breast tumours that grew in the 
mammary pad and cells that had metastasised to the lungs demonstrated very high 
levels of cell surface CXCR4 when compared to parental cells (Helbig et al., 2003). 
The angiogenic effects of CXCR4 are also important in breast cancer. CXCR4 is 
expressed by endothelial cells (Heidemann et al., 2004, Molino et al., 2000) as well 
as breast cancer cells. CXCR4 signalling induces tube formation by endothelial cells 





et al., 1999, Guleng et al., 2005). Importantly, CXCR4 inhibition decreases 
endothelial cell migration (Salcedo et al., 1999), endothelial tube formation (Chen 
et al., 2003, Heidemann et al., 2004) and intratumour blood flow (Guleng et al., 
2005). In vivo, high expression of CXCR4 by prostate cancer cells promoted tumour 
vascularisation, invasion and metastasis, similar effects to those occurring in 
CXCR4 expressing breast cancer cells (Darash-Yahana et al., 2004). The angiogenic 
effect of CXCR4 expressing breast cancer cells may be mediated at least in part by 
VEGF which has autocrine effects upon breast cancer cells (Bachelder et al., 2002). 
In summary, these results suggest an important role for CXCR4 in tumour 
angiogenesis, and growth. 
CXCL12 is known to function as an important chemoattractant for the homing of 
multiple cell types including lymphocytes and steam cells. This suggests that 
CXCL12 may have a similar role upon breast cancer cells. Indeed, the chemotaxis of 
CXCR4 expressing breast cancer cells in response to the chemokine in vitro has 
been demonstrated by number of authors (Tamamura et al., 2003, Lee et al., 2004, 
Fernandis et al., 2004, Muller et al., 2001). A chemotactic response to CXCL12 can 
also be inhibited by anti-CXCR4 protein and RNA targeted treatments; such as anti-
CXCR4 antibodies, anti-CXCR4 peptides (T140) and siRNA (small interfering RNA) 
(Muller et al., 2001, Tamamura et al., 2003, Lapteva et al., 2005). 
CXCR4 expressing breast cancer cells grow significantly faster than CXCR4 
negative cells in vitro, (Lapteva et al., 2005) and in vivo, subcutaneous implants of 
cells overexpressing CXCR4 demonstrated significantly faster tumour growth than 








Figure 1-6: The role of CXCR4/CXCL12 interaction in breast cancer metastasis 
formation.  
Chemokine CXCL12 has an effect upon the site-specific metastasis of breast cancer cells. Two 
receptors for CXCL12, CXCR4 and CXCR7, are found to be upregulated in primary breast cancers 
compared with normal breast tissue. CXCL12 ligand for this receptor exhibited peak levels of 
expression in the organs that represent the common metastatic sites for breast cancer (lung, liver, 
bone, brain).  





1.17 CXCR4 and CXCL12 targeted therapies in breast cancer 
CXCL12/CXCR4 interactions in breast cancer are targeted by anti-CXCR4 therapies. 
Due to the fact that CXCR4 is a major co-receptor for HIV infection, compounds 
that target CXCR4 to prevent infection have been developed (Hatse et al., 2005).  
1.17.1 AMD3100 
AMD3100 is a CXCR4 receptor antagonist which underwent Phase I and II trials in 
HIV, but development was terminated due to its side-effect profile and its inability 
to reach efficacy (Onuffer and Horuk, 2002).  
1.17.2  siRNA 
Small interfering RNA (siRNA) RNA is more effective than AMD3100 in preventing 
haematogenous breast cancer metastasis in mice (Smith et al., 2004). It is used in 
murine models of breast cancer as monoclonal antibody therapies (Muller et al., 
2001). Silencing of CXCR4 expression using siRNA has been a successful method of 
inhibiting both breast cancer growth and metastasis in multiple studies (Smith et 
al., 2004, Lapteva et al., 2005, Liang et al., 2004, Li et al., 2004). In mice inoculated 
with CXCR4 expressing breast cancer cells into the mammary fat pad, RNA 
interference against CXCR4 prevented all growth of the primary tumours and 
consequently no metastases were found (Lapteva et al., 2005).  
1.17.3 T140 
T140 is a 14-residue peptide with high CXCR4 antagonistic activity, developed as 
an anti-HIV therapy. The T140 analogue 4F-benzoyl-TN14003 was shown to 
significantly inhibit the area of lung metastasis in a haematogenous murine model 
of breast cancer metastasis.  
1.17.4 Heparin 
Tinzaparin treatment in SCID mice, at clinically relevant dosages, was found to 
prevent both the number and area of metastases following intravenous injection of 





between CXCL12 and CXCR4 and may be useful as agents to prevent breast cancer 
metastasis (Mellor et al., 2007, Harvey et al., 2007, Abd Hamid et al., 2008). 
1.18 Regulation of CXCR4 expression 
In order to understand the role of CXCR4 in cancerogenesis, a fundamental 
understanding of the factors regulating its expression is critical. CXCR4 expression 
on breast cancer cells is regulated by both autocrine and paracrine factors 
including NF-kappa B (Helbig et al., 2003), HER2/ERBB2 (Li et al., 2004),  hypoxia 
(Schioppa et al., 2003) and nitric oxide (Yasuoka et al., 2008), vascular endothelial 
growth factor (Bachelder et al., 2002), Neuropilin-2 (Nrp2) receptor (Yasuoka et 
al., 2009) induce functional CXCR4 expression. Thus, inhibitors of above factors 
should reduce breast cancer metastasis by reducing the expression of a number of 
prometastatic genes including CXCR4. 
High expression of CXCR4 was also linked with the downregulation of six MHC 
class II genes, proposing a mechanism by which CXCR4 aids in the evasion of 
detection of cancer cells by the immune system (Sheridan et al., 2006).  
1.18.1 HER2 
The activation of the human epithelial growth factor receptor HER2 (erbB2, neu) 
has been implicated in tumour progression. HER2 is a potent oncoprotein that is 
overexpressed in approximately 30% of primary breast cancers and is associated 
with a poor prognosis and with widespread metastasis (Yu and Hung, 2000). There 
is evidence of a link between HER2 and CXCR4 in HER2-mediated metastasis (Li et 
al., 2004). Overexpression of HER2 in breast cancer cells led to an increase in 
expression of CXCR4, whilst inhibition of HER2 led to a corresponding reduction in 
CXCR4 expression. Ubiquitination of CXCR4 is a modification regulating the 
expression of CXCR4 post-translationally. It has been found that breast cancer cells 
that are HER2/neu positive have increased expression of CXCR4 as a result of 
inhibition of receptor ubiquitination (Yu and Hung, 2000). HER2 may therefore 





CXCL12 ligand, thus potentially increasing their metastatic and growth potential. 
Immunohistochemical analysis revealed that approximately two thirds of HER2 
expressing primary breast cancers also express CXCR4 (Li et al., 2004). The link 
between HER2 and CXCR4, both of which play critical roles in cancer metastasis 
furthers our understanding of the mechanisms by which CXCR4 expressing cells 
home to their metastatic organs. 
CXCR4 and HER2 are not co-localised on the breast cancer cell surface (Cabioglu et 
al., 2005b). Stimulation of CXCR4 and HER2 expressing cells with CXCL12, induced 
HER2 phosphorylation and phosphorylation of downstream Src kinases. This effect 
was inhibited with the CXCR4 antagonist AMD3100 (Cabioglu et al., 2005b). 
1.18.2  NF-kappa B 
Extracellular signal-activated transcription factor NF-kappaB up-regulates the 
expression of matrix metalloproteinases, urokinase-type plasminogen activator, 
and cytokines in highly metastatic breast cancer cell lines (Helbig et al., 2003). NF-
kappaB regulates the motility of breast cancer cells by directly up-regulating the 
expression of CXCR4. Overexpression of the inhibitor of kappaB (IkappaB) in 
breast cancer cells resulted in reduced expression of CXCR4 and a corresponding 
loss of SDF-1alpha-mediated migration in vitro (Helbig et al., 2003).  
1.18.3  Hypoxia 
CXCR4 expression is increased on MCF-7 and MDA-MB 231 breast cancer cells in 
hypoxic conditions, which are characteristic of the tumour microenvironment 
(Matteucci et al., 2005a). Hypoxia induces the activation of hypoxia inducible 
factor 1 (HIF-1) which in turn promotes expression of a number of target genes 
including CXCR4 (Staller et al., 2003). In addition, CXCR4 expression was increased 
in MCF-7 breast cancer cells following stimulation with hepatocyte growth factor 
(HGF) (Matteucci et al., 2005a). In both hypoxia and stimulation with HGF there 
were significant increases in NF-κB activation. Furthermore, studies on tumour 
suppressor von Hipple Lindau (VHL) reviled that inactivating mutations of VHL, 





expression in renal cell carcinomas (Zagzag et al., 2005, Schioppa et al., 2003, 
Staller et al., 2003) 
1.18.4  Nitric oxide 
Nitric oxide can stimulate cytoplasmic CXCR4 expression in vitro. Cytoplasmic 
CXCR4 expression has been described as a significant prognostic factor for long-
term survival in breast cancer (Yasuoka et al., 2008). 
1.18.5  Vascular endothelial growth factor  
VEGF regulates expression of the chemokine receptor CXCR4, what is essential for 
invasion but not for cell survival. CXCR4 mediates migration of breast carcinoma 
cells toward stromal-derived factor-1, and this migration is dependent on 
autocrine VEGF. VEGF autocrine pathway induces chemokine receptor expression 
in breast carcinoma cells, thus promoting their directed migration toward specific 
chemokines (Bachelder et al., 2002). 
1.18.6  Neuropilin-2 receptor  
Neuropilin-2 (Nrp2) is a receptor for VEGF-C, a lymphangiogenic factor, important 
in lymph node metastasis of various human cancers, including breast cancer. The 
evidence suggests that Nrp2 can regulate expression of cytoplasmic CXCR4 in vitro. 
Nrp2 was shown to play a role in cancer by promoting tumor cell metastasis and 
its expression was correlated with lymph node metastasis, VEGF-C expression, and 
cytoplasmic CXCR4 expression. Nrp2 expression was suggested to serve as a 
significant prognostic factor for long-term survival in breast cancer (Yasuoka et al., 
2009). 
1.18.7  FOXP3 transcription factor 
FOXP3 in T cells is known to induce or repress a number of genes, including CXCR4 
(Marson A, 2007, Zheng Y, 2007). It binds to the gene region upstream of the 
transcriptional start site of CXCR4 and CCR7 two chemokine receptors reported to 
play a vital role in cancer invasion and metastasis (Marson A, 2007). The 





A, 2009) and it has been proven that FOXP3 in an important regulator of this 
oncogene (Zuo et al., 2007c). Hence, it is also possible that FOXP3 can regulate 
CXCR4 expression indirectly through its action on HER-2. Foxc transcription 
factors are important regulators of the chemotactic motility of endothelial cells 
through the induction of CXCR4 expression (Hayashia H, 2008). Some members of 
forkhead family of transcription factors (Foxc1 and Foxc2) are able to directly 
induce CXCR4 expression by activating its promoter in endothelial cells. 
Furthermore, Foxc1-deficient endothelial cells show a significant reduction in 





1.19 FOXP3  
The X-linked gene FOXP3 is a member of the forkhead-box/winged-helix 
transcription factor family. The forkhead gene product was initially identified in 
the fruit fly Drosophila melanogaster as factor required for the terminal pattern 
formation in the terminal regions of the embryo (Weigel and Jackle, 1989). The 
gene was identified during position cloning of Scurfin, a gene responsible for X-
linked autoimmune diseases in mice and humans (Brunkow et al., 2001, Bennett et 
al., 2001a, Bennett et al., 2001b, Chatila et al., 2000, Wildin et al., 2001). 
Since description of the first forkhead transcription factor in Drosophila over 10 
years ago, more than 100 different family members have been identified in 
organisms ranging from yeast to humans. These proteins have in common a 100 
amino acid “winged-helix” DNA binding domain, the forkhead (FKH) domain, with 
a folded motif made up of three α- helices and two loops, or “wings.” Outside this 
conserved domain, forkhead proteins are diverse in sequence, structure, and 
function. The convention for naming human FKH proteins has been established as 
capital letters (eg. FOXP3), mouse proteins with only the first letter capitalized 
(Foxp3), and with the subclass denoted with a capital letter for all other chordates 
(FoxP3). To refer to the gene rather than the protein, the convention for the above 
list is FOXP3, foxp3, FoxP3 (Kim, 2007). 
FKH proteins are transcriptional activators or repressors, with a broad range of 
cellular functions including embryonic development, speech and language 
development, and regulation of the immune system (Coffer and Burgering, 2004).  
1.20 FOXP3 gene 
The FOXP3 gene is well conserved in mammals (Ziegler and Buckner, 2006, 
Ziegler, 2006). The human FOXP3 genes contain 11 coding exons. The FOXP3 gene 
maps to the p arm of the X chromosome (specifically, Xp11.23) (Bennett et al., 





1.20.1 FOXP3 gene mutation 
In mice, a Foxp3 frameshift mutation in the forkhead domain results in lethality in 
hemizygous males 16 to 25 days after birth (Brunkow et al., 2001). The mutation 
in some human IPEX patients (Immunodysregulation, Polyendocrinopathy, and 
Enteropathy, X-linked) is analogous as they cause frameshift and early termination 
of translation (Brunkow et al., 2001, Chatila et al., 2000, Bennett et al., 2001b, 
Bennett et al., 2001a, Wildin et al., 2001). In breast cancer patients, a total of 27 
somatic mutations in all 11 coding exons and intron-exon boundary regions have 
been identified in 36% of 65 patients by PCR (Zuo et al., 2007d, Zuo et al., 2007b) 
(Figure 1-7 B). In these mutations, there are 18 nonsynonymous mutations, 3 
synonymous mutations and 6 mutations in the intron-exon junction 12 (Zuo et al., 
2007b). Interestingly, the mutations are not randomly distributed in FOXP3 gene 
and the overwhelming majority of them are either in the functional domains or 
within intron 11 which can affect the forkhead domain sequence (Zuo et al., 
2007b). In prostate, the FOXP3 gene plays a critical role in suppressing cancerous 
transformation of this gland (Wang L, 2009). Four somatic FOXP3 mutations were 
identified in prostate cancer and three of them prevent nuclear localization of 
FOXP3 which is a major mechanism to inactivate FOXP3 tumour suppressor 
function (Wang L, 2009, Wang L, 2009) (Figure 1-7 B). The exact role of the 
somatic FOXP3 mutations in breast cancer remains unknown. The question 
whether, like in prostate cancer, it is responsible for failure of nuclear localization 
of FOXP3 protein, is yet to be answered.   
1.21 FOXP3 protein 
FOXP3 gene encodes FOXP3 protein, which is 431-amino acid long, and its 
molecular weight is 47 kDa. It contains four potential functional domains including 
the repressor, zinc finger, the leucine zipper and fork-head (FKH) domains (Figure 
1-7 B). The FKH domain is critical for both DNA binding and nuclear localization 





immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) 
patients.  
The FKH domain of FOXP3 is capable of physically interacting with DNA (Ziegler 
and Buckner, 2006). FOXP3 interacts with DNA at consensus sequences found 
within the promoters of several genes (Schubert et al., 2001). Reporter and 
chromatin immunoprecipitation (ChIP) assays indicated that FOXP3 binds such 
sequences in the promoters of IL-2, CD25, CTLA-4 and CD127 genes (Wu et al., 
2006). The FKH domain also contains a nuclear localization sequence. A mutation 
in the forkhead domain, which affects the nuclear localization of FOXP3, leads to 
severe autoimmunity (Zuo et al., 2007d). 
Leucine zipper structures are involved in protein-protein interactions, often 
leading to homo- and hetero-oligomerization. Many FKH proteins have been found 
to homo- or hetero-oligomerize, including FOXP3. It has been reported that FOXP3 
self-associates and can complex with FOXP1, and that the ability to form these 
interactions is elemental for normal protein function (Li et al., 2007b). IPEX 
patients with deletions in this region (∆250, ∆251) suffer from severe disease due 
to the inability of FOXP3 to self-associate, and/or associate with other forkhead 
family members such as FOXP1 (Li et al., 2007b). 
1.21.1  Isoforms of FOXP3 protein 
In contrast with mouse Treg, in which Foxp3 is only expressed as a full-length 
protein, human Treg express at least two alternatively spliced isoforms of FOXP3 
in approximately equal amounts: a full-length isoform (FOXP3FL, apparent 
molecular weight: 58 kDa) an alternative-splicing product lacking exon 3 
(FOXP3D3, apparent molecular weight: 54kDa) (Allan et al., 2005). It should be 
emphasized that several reports refer to exon 3 as exon 2, because exon 1 is often 
not considered due to its position within the 5’ untranslated region (Ebert et al., 
2008). FOXP3 exon 3 (aa 72–106) encodes a domain that inhibits retinoic acid 
receptor-related orphan receptors (ROR)a, which leads to the expression of genes 





FOXP3D3 negatively regulates Th17 differentiation in T cells (Du et al., 2008). 
Lately, a third splice variant has been described that in addition to exon 2 also 
misses exon 7 (FOXP3D2D7). Exon 7 encodes for a leucine zipper motif commonly 
used as structural dimerization element. Mutations in exon 7 have been linked to 
IPEX, a severe autoimmune disease suggested to be caused by impaired 
dimerization of the FOXP3 protein. FOXP3D2D7 could play a role in regulating the 
function of the other FOXP3 isoforms and may be involved in cancer pathogenesis 







Figure 1-7: FOXP3 gene and protein 
A) The location and orientation of FOXP3 gene on X chromosome; location: Xp11.23 
B) Schematic diagram of the FOXP3 gene and protein. ZF: zinc finger domain, LZ: leucine zipper 
domain, and FKH fork-head domain, showing FOXP3 and its somatic mutations found among 
human breast and prostate cancers. 
C) Splice variants of the FOXP3 that are predominantly expressed in human cancers. “…” represents 
any exons that is/are deleted in the variant forms of FOXP3. Breast Ca: Breast cancer; Sezary synd.: 
Sezary syndrome. 





1.22 Intracellular trafficking of FOXP3  
Intracellular trafficking of FOXP3 to the nucleus is required in order for this 
protein to function and maintain cellular homeostasis. FOXP3 is synthesised 
outside of the cellular nuclei but functions by interacting with DNA in the nuclei 
and when upregulated is rapidly translocated to the nuclei to bind chromatin. 
There are three distinct FOXP3 domains that contribute to its nuclear transport 
(Hancock W, 2009). The first domain (Domain 1) comprises the C-terminal 12 
amino acids. The second domain (Domain 2) is located immediately N-terminal to 
the forkhead domain (FHD), recently reported to be a binding site for the runt-
related transcription factor 1/acute myeloid leukaemia 1 (Runx1/AML1). The 
third domain (Domain 3) is located within the N-terminal first 51 amino acids. 
FOXP3 mutant protein missing domains 1, 2, and 3 is found almost exclusively in 
the cytoplasm with only trace levels in the nuclei (Hancock W, 2009). Identification 
of factors which interact with these domains will not only facilitate our 
understanding of how FOXP3 achieves its nuclear transport to regulate the 
expression of target gens, but may lead to therapeutic modulation of these systems 
and provide a novel approach to cancer treatment. Indeed, it has been 
demonstrated that the disruption of nuclear localization is sufficient to abrogate 
growth inhibition by FOXP3 in prostate cancer (Wang L, 2009). 
1.23 FOXP3 expression 
FOXP3 is expressed at high levels in nuclei of Tregs and lymphoid cells (thymus, 
spleen and lymph nodes) (Brunkow et al., 2001, Hori and Sakaguchi, 2004, Hori S, 
2003). Some epithelial cells express this protein at lower levels in the nuclei and 
cytoplasm (Chen G, 2008). In human cells, FOXP3 expression was detected in 
breast epithelial cells, lung respiratory epithelial cells, prostate epithelial cells and 
liver (Li et al.), although not in the heart, and intestine (Chen G, 2008), whereas in 





There are opposing reports in the literature regarding the expression of FOXP3 in 
breast cancer stating that it is increased (Merlo A, 2009, Gupta et al., 2007, Ohara 
et al., 2009), decreased (Zuo et al., 2007d, Zuo et al., 2007b) or not changed 
compared to the benign epithelium (Zuo et al., 2007d, Zuo et al., 2007b). It has 
been suggested that a significant loss of FOXP3 expression by breast cancer 
epithelium is associated with cancer development (Zuo et al., 2007b, Zuo et al., 
2007d) and FOXP3 was named the first X-linked breast cancer suppressor gene. 
Paradoxically, another group has demonstrated increased FOXP3 expression level 
in breast cancer (Andrea Merlo and Elda Tagliabue, 2009). Using 
immunohistochemical staining, FOXP3 expression was assessed in 397 primary 
breast carcinoma specimens from two clinical trials (Milan 1 and 3). FOXP3 stained 
positive in the majority of the breast cancer tissues and both cytoplasmic and 
nuclear staining was observed (Andrea Merlo and Elda Tagliabue, 2009). 
Surprisingly, most recently the results of the large screening study of FOXP3 
expression in breast tissue, examining 2200 cores, has reported that, in healthy 
and cancerous human breast tissue, FOXP3 protein expression is negligible (Wolf 
D, 2010). Expression of FOXP3 on cancer cells is correlated with the expression 
levels of IL-10 and TGF- β1 (Karanikas et al., 2008).  
The nuclear expression of FOXP3 in human benign breast, respiratory and prostate 
tissue is well documented (Chen G, 2008). However, immunocytochemical staining 
of tumour cell lines revealed predominant cytoplasmic expression of breast, colon, 
pancreas, lung cancer cell lines (Karanikas et al., 2008). There is disagreement 
amongst the authors with regards to the immunohistochemistry of malignant 
breast epithelium: some describe nuclear staining only (Zuo et al., 2007b, Zuo et 
al., 2007d), others state that expression of FOXP3 in breast cancer is 
predominantly cytoplasmic (Andrea Merlo and Elda Tagliabue, 2009). 
Immunohistochemistry of other human malignancies detected nuclear FOXP3 
staining in prostate cancers (Wang L, 209),  mixed cytoplasmic and nuclear FOXP3 





(Wang et al.) and solely cytoplasmic staining in ovarian cancers (Zhang and Sun, 
2010). Heterogeneous subcellular FOXP3 localization in cancer cells may reflect 
the presence of abnormal proportion of splice variants, somatic mutations or 





1.24 The function of FOXP3 
FOXP3 is a gene involved in immune system responses. It functions as the master 
regulator in the development and function of regulatory T (Treg) cells (Fontenot et 
al., 2003, Hori and Sakaguchi, 2004, Khattri et al., 2001). Tregs were initially 
defined as immunosuppressive CD4 positive T cells expressing constitutively the 
subunit of the interleukin (IL)-2 receptor (CD25) on their surface (Sakaguchi, 
2005, Setoguchi et al., 2005). The nuclear expression of FOXP3 is now considered 
as the most specific marker for these cells, which is essential for development of 
immune tolerance (Sakaguchi, 2005, Setoguchi et al., 2005). However, FOXP3 can 
be expressed transiently on human non-regulatory CD4 positive T cells upon T-cell 
antigen receptor (TCR) activation. Additionally, Foxp3 is also expressed in non-
lymphocytic normal or cancer cells, suggesting that FOXP3 may have a broader 
role in cancer than initially thought. 
The up-regulation of Foxp3 expression on T cells has, in animal studies, led to 
marked reductions in autoimmune disease severity in models of diabetes, multiple 
sclerosis, asthma, inflammatory bowel disease, thyroiditis and renal disease (Xia et 
al., 2007). Alterations in numbers of Tregs expressing FOXP3 are found in various 
pathological conditions. For example, patients with tumours have a local relative 
excess of FOXP3 positive Tregs, which inhibits the body's self defence(Mizukami et 
al., 2008, Paul Salama, 2008). On the other hand, patients with an autoimmune 
disease such as systemic lupus erythematosus (SLE) have a relative dysfunction of 
FOXP3 positive cells (Li et al., 2009). 
1.25 FOXP3 signalling in epithelial cells 
Various cascades and molecules are involved in FOXP3 signalling in epithelial cells 





1.25.1  HER2/neu (ERBB2) 
HER2 is a member of the transmembrane receptor tyrosine kinases and is involved 
in the regulations of various cellular functions like cell growth and survival 
(Blackwell et al., 2009, Hardee et al., 2009). FOXP3 can repress the transcription of 
HER2 in human breast cancers by binding directly to ERBB2 gene promoter (Zuo 
et al., 2007c). This repression of HER2 may be decisive for the tumour suppressor 
function of FOXP3 in the breast epithelial cells. 
1.25.2  C-MYC 
Overexpression of c-MYC contributes to more aggressive and poorly differentiated 
cancer phenotypes (Pelengaris et al., 2002a, Pelengaris et al., 2002b). c-MYC is a 
transcription factor which is vital for cell cycle and apoptosis. c-MYC directly 
activates CDK4 and CCND2 expression, while indirectly represses CDK inhibitors 
such as CDKN1A (p21) and CDKN2B (p15) expression (Pelengaris et al., 2002a, 
Pelengaris et al., 2002b). Furthermore, c-MYC directly up-regulates eIF4E and eIF2, 
the rate-limiting effectors of cell cycle (Pelengaris et al., 2002a, Pelengaris et al., 
2002b). In prostatic epithelial cells, FOXP3 directly represses c-MYC gene 
expression (Wang L, 2009). 
1.25.3 p21 (CDKN1A, CIP1, WAF1) 
p21 is a universal CDK inhibitor and plays an important role in regulating cell cycle 
progression, specifically at the G1-checkpoint (Park and Koff, 2001). It is often 
implicated in multiple malignancies including breast cancer (Park and Koff, 2001). 
Cancer cells with low levels of p21 can escape from G1 arrest, and thus cells 
acquire a growth advantage during tumour development. FOXP3 can activate the 
p21 promoter on breast epithelial cells (Liu et al., 2009). There is strong evidence 
that the activation of p21 contributes to FOXP3’s tumour suppressor function (Liu 
et al., 2009). 
1.25.4  SKP2 
High levels of expression of SKP2 have been reported in a wide variety of cancers 





dependent degradation of p27KIP1, a CDK inhibitor especially of Cyclin-E/CDK2 
and Cyclin-A/CDK2 (Fotovati et al., 2006, Nishitani et al., 2006). SKP2 is expressed 
during S and G2 phases of cell cycle and regulates p27 degradation. Therefore 
SKP2 facilitates progression of the cell cycle. Overexpression of SKP2 is frequently 
observed in human cancers and is correlated with poor prognosis of breast cancers 
(Fotovati et al., 2006, Nishitani et al., 2006). We found that FOXP3 directly 
represses SKP2 expression in human and mouse mammary epithelial cells (Zuo et 
al., 2007b). 
1.25.5  LATS2 
Defective expression of LATS2, a negative regulator of YAP onco-protein, has been 
reported in cancer of prostate, breast, liver, brain and blood origins (Li et al.). 
However, no transcriptional regulators for the LATS2 gene have been identified. 
Spontaneous mutation of the transcription factor FOXP3 reduces expression of the 
LATS2 gene in mammary epithelial cells. ShRNA-mediated silencing of FOXP3 in 
normal or malignant mammary epithelial cells of mouse and human origin 
repressed LATS2 expression and increased YAP protein levels. LATS2 induction 
required binding of FOXP3 to a specific sequence in the LATS2 promoter, and this 
interaction contributed to FOXP3-mediated growth inhibition of tumour cells (Li et 
al.). 
1.26 Regulation of gene expression by FOXP3 
In Tregs, there are pathways activating Foxp3 gene expression. TGF-β, Smad, IL-2 
and IFN-γ signals are known to set off Foxp3 expression in the development of 
Tregs (Lal et al., 2009). SMAD, NFAT and Rel family molecules can occupy Foxp3 
enhancer and/or promoter loci and activate Foxp3 transcription (Ruan et al., 
2009). In mammary epithelial cells, ATF-2 is crucial for FOXP3 expression (Liu et 
al., 2009). In cancer cells, doxorubicine, which induces activation of p53 via DNA 






FOXP3 forms complexes with the Rel family transcription factors, NFAT and 
NFkappaB, and FOXP3 blocks their ability to activate IL-2 and INF-γ signal 
transduction (Bettelli et al., 2005, Holmes et al., 2008). By making a repressive 
FOXP3: NFAT complex, FOXP3 inhibits NFAT: AP-1 complex at the IL-2 promoter 
(Holmes et al., 2008). AML1/RUNX1, which activates endogenous IL-2 and IFN-γ 
expression in CD4+ T cells, is reported to make a complex with FOXP3 (Ono et al., 
2007). AML1/RUNX1 could bind to the IL-2 enhancer with FOXP3 and exert 
optimal repression of the IL-2 in Tregs (Ono et al., 2007).  
FOXP3 is able to radically change histone modifications at its binding loci (Zheng 
and Rudensky, 2007) and function as a molecule which recruits other co-factors to 
the FOXP3-bound loci. The histone modifying enzymes such as TIP60, HDACs 7 and 
9, and EOS/CtBP1 have been found to be physically associated with FOXP3 to form 







Figure 1-8: A schematic view of the signaling networks of the FOXP3 in epithelial 
cells 
FOXP3 suppresses breast cancer and prostate cancer by inducing tumour suppressor genes while 
repressing oncogenes. The genes are direct targets for FOXP3 and their regulation is essential for 





1.27 Role of FOXP3 in cancerogenesis 
1.27.1  Inactivation of FOXP3 gene in cancer 
The identification of FOXP3 as an X-linked tumour suppressor gene has developed 
better understanding of the mechanism of a single genetic hit and challenge the 
traditional theory of “two-hit inactivation” in tumour suppressor genes. 
Nevertheless, the silencing mechanism of this gene in cancer cells is still not fully 
understood. Since females have two X chromosomes and males have only one, the 
inactivation mechanism of this gene in human cancers potentially ought to be 
different between females and males.  
X-chromosome inactivation silences gene expression from one of the two X 
chromosomes in females. Random X-chromosome inactivation occurs during 
embryogenesis. The inactivated X chromosome will remain idle throughout the 
lifetime of the cell. Therefore, in females an X-linked tumour suppressor gene is 
more susceptible to additional genetic damage since one of the alleles is silenced 
by X-chromosome inactivation. The suggestion of heterozygosity in cancer 
pathogenesis has been demonstrated with the identification of two X-linked tumor 
suppressor genes, FOXP3 (Zuo et al., 2007c) and WTX (Han et al., 2007, Rivera et 
al., 2007) that are inactivated by a single genetic hit. Female mice with a FoxP3-
heterozygous mutation develop spontaneous breast cancer at a higher rate than 
wild type mice (Zuo et al., 2007d). The majority of the mutations and all deletions 
of FOXP3 are heterozygous in human breast cancers (Zuo et al., 2007d). 
As men have just one X chromosome, the recessive X-linked inherited diseases are 
more frequently found in males than in females. Literature suggests the deletion of 
the FOXP3 gene in 23 (14%) of 165 prostate cancer samples (Wang L, 2009). 
Among the 23 cases, 5 showed an increase in the number of X chromosomes and 
the deletion of FOXP3 was complete in these chromosomes what may be 
suggestive that X chromosome duplications in cancer tissues likely occurred after 





by deletion and somatic mutation, approximately 70% of prostate cancers without 
nuclear FOXP3 expression are not fully explained by these identified somatic 
alterations (Wang L, 2009). Inactivation of FOXP3 in prostate cancer may also be 
caused by other additional events such as DNA methylation, histone 
hypoacetylation, upstream gene regulation, etc. 
1.27.2  FOXP3 in the cancer inflammatory infiltrate  
T cells can exert both tumour-suppressive and tumour-promoting effects, as 
determined by their effector functions (DeNardo et al., 2009, Langowski et al., 
2007). 
Cancers are able to escape CD8 positive T-cell cytotoxicity by promoting expansion 
of Treg cells. Treg cells normally function to protect tissue from autoimmune 
disease by suppressing self-reactive cells. Characterized by expression of CD4, 
CD25 and FOXP3, Treg cells can account for about 5–10% of all T lymphocytes in 
healthy tissues. In breast cancers the percentage of Treg cells, which are assessed 
by FOXP3 positivity, increases in parallel with the disease stage, from normal to 
DCIS and from DCIS to invasive carcinoma (Bates et al., 2006). In patients with 
invasive carcinoma the presence of high numbers of FOXP3 positive T cells 
predicts worse relapse-free survival and decreased overall patient survival (Bates 
et al., 2006), and may indicate that the presence of Treg cells promotes tumour 
progression by inhibiting immunosuppression.  
FOXP3 expression in regulatory CD4+ T cells may result in impaired 
immunological function with maintenance of low-level chronic inflammation. 
Inflammation is essential for the effective host defence. However, chronic 
inflammation may predispose to cancer. Increased and sustained inflammation 
may provide a mechanism for involvement of FOXP3 in cancer development. 
Mutation of an X-linked cancer suppressor gene, such as FOXP3, in females may 
result in its mosaic expression. In Tregs, the mosaic FOXP3 expression produces 





inflammatory cytokines. It consequently sustains inflammation (Medema and 
Burgering, 2007).  
Signalling pathways that mediate the protumourigenic effects of inflammation are 
often subject to a feed-forward loop, for example, activation of NF-kB in immune 
cells induces production of cytokines that activate NF-kB in cancer cells to induce 
chemokines that attract more inflammatory cells into the tumour (Grivennikov et 
al., 2010). 
FOXP3-induced down-regulation of genes, e.g. PDE3B (cyclic nucleotide 
phosphodiesterase 3B,cGMP inhibited) has been shown to give a survival 
advantage and a resistance to apoptosis in T cells (Gavin et al., 2007). 
It has been observed that poor prognostic factors (negative hormonal receptors, 
high tumour grade, and nodal involvement) were associated with a significantly 
higher number of CD3, CD8, and Foxp3 expressing cells in the infiltrate (Ladoire et 
al., 2008). Chemotherapy resulted in a decrease in Foxp3 positive cells in the 
infiltrate, whereas the level of CD8 and CD3 infiltrate remained unchanged 
(Ladoire et al., 2008). Pathologic complete response to chemotherapy was found to 
be associated with an absence of immunosuppressive Foxp3 cells and the presence 
of a high number of CD8 T cells and cytotoxic cells in cancer infiltrate. Since Tregs 
are potential inhibitors of anti-tumour response, the infiltration by FOXP3+ Tregs 
may be associated with increased relapse and shorter survival of patients with 
both in situ and invasive breast cancer (Generali et al., 2009). Oestrogen is able to 
induce immunotolerance by increasing the Tregs pull. The evidence suggests that 
aromatase inhibitors may have an indirect antitumor mechanism of action through 
reducing Tregs in breast tumours (Generali et al., 2009). FOXP3 in T cells has been 
also studied as a therapeutic target, and it has been shown that vaccination to 
eradicate FOXP3-expressing cells enhances tumour immunity (Nair S, 2007).  
Recently, a new explanation for the association of CD4 positive T-cell and Treg-cell 
markers with a more aggressive behaviour in advanced breast cancers has been 





FOXP3 positive Treg cells are a major source of RANKL, which stimulates the 
metastatic progression of RANK-expressing breast carcinoma cells (Tan et al., 
2010). Furthermore, the pro-metastatic function of T cells can be replaced by 
exogenous RANKL (Tan et al., 2010). 
1.27.3  FOXP3 as a tumor suppressor gene  
FOXP3 can be expressed by not only tumour-infiltrating Tregs but also by cancer 
cells. This raises the possibility that tumour cells themselves modulate T-cell 
function through FOXP3.  
Using microarray analysis, a large number of genes that are either up- or down-
regulated by ectopic expression of FOXP3 have been discovered and the genes 
involved in cancer were the most affected group (Wang L, 2009). Therefore, FOXP3 
will likely suppress development of breast cancer by targeting multiple genes, 
including both tumour suppressor and oncogenes. 
FOXP3 is expressed in normal human breast epithelial cells but is lost in 80% of 
human breast cancer cells (Zuo et al., 2007c). The significance of FOXP3 as an X-
linked tumour suppressor gene in humans is supported by the prevalence of 
somatic mutations (36%), gene deletion (13%), and lack of nuclear FOXP3 seen in 
the majority of breast cancer samples (Zuo et al., 2007c). The majority of these 
mutations are heterozygous and the deletion of the gene is heterozygous in all 
cases. FOXP3 inhibits breast tumour growth through directly repressing the 
transcription activity of two oncogenes, HER2 and SKP2, while inducing the 
transcription activity of tumour suppressor gene p21 (Figure 1-8) (Zuo et al., 
2007b, Zuo et al., 2007c, Liu et al., 2009). A cyclin-dependent kinase inhibitor p21 
is also major downstream target of other tumour suppressor genes, including p53 
(el-Deiry et al., 1993) and BRCA1 (Somasundaram et al., 1997). FOXP3 is essential 
for p21 expression in normal epithelia and that lack of FOXP3 is associated with 
p21 down-regulation in breast cancer samples (Liu et al., 2009). 
Ectopic expression of HER-2 completely reverses the anti-tumourigenic effect of 





cancer cells (Zuo et al., 2007d), thus Foxp3 can repress ErbB2 signalling and 
tumour growth by mechanisms other than ErbB2 expression. SKP2 was found to 
be critical for FOXP3-mediated growth inhibition in breast cancer cells that do not 
over-express ERBB2/HER2 (Zuo et al., 2007a).  
FOXP3 is frequently inactivated in prostate cancer samples by deletion (14%) or 
somatic mutation (25%) (Wang L, 2009). Inactivation of FOXP3 causes strong 
growth inhibition of prostate cancer cell lines upon addition of FOXP3 (Wang L, 
2009). Importantly, prostate-specific ablation of the FoxP3 in the mouse caused 
early onset of prostatic hyperplasia and prostatic intraepithelial neoplasia (PIN) 
(Wang L, 2009). FOXP3-mediated transcriptional repression of c-MYC is necessary 
to control c-MYC levels in normal prostate epithelial cells (Figure 1-8). 
Recently, FOXP3 has been described as a direct transcriptional activator for Lats2 
in both normal and malignant breast and prostate cells from mouse and human (Li 
et al.). This may be a novel mechanism of LATS2 downregulation in cancer and 
reveals an important tumour suppressor relay between the FOXP3 and HIPPO 
pathways that are widely implicated in human cancer. 
In pancreatic cancer FOXP3 expression may represent a type of molecular mimicry 
that enables immune evasion of tumour cells. Pancreatic cancer cells share 
growth-suppressive effects with Tregs mimicking Tregs function (Hinz et al., 
2007). 
FOXP3 was shown to be weakly or not expressed in ovarian cancer cells (Hai-Yan 
Zhang, 2010). Transfection of ovarian cancer cells with FOXP3 inhibited cell 
proliferation, decreased cell migration, and reduced cell invasion. Cells with 
upregulated FOXP3 showed decreased expression of Ki-67 and cyclin-dependent 
kinases. FOXP3 can inhibit cell migration and invasion by down regulating 
expression of matrix metalloproteinase-2 and urokinase-type plasminogen 





1.28 Hypothesis  
The tumour suppressor FOXP3 is inactive in breast cancer cells causing an increase 
in expression of CXCR4 chemokine receptor and acquisition of responsiveness to 
chemokines such as CXCL12, thus regulating the potential for metastatic spread.  
1.29 Aims  
 To characterise the relationship between FOXP3 and CXCR4 expression in 
breast cancer  
 To investigate FOXP3 translocation to the nucleus of breast cancer cells 
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2 Materials and Methods 
2.1 Cell culture 
2.1.1 Cryopreservation of Cells 
Cells were routinely cryopreserved in liquid nitrogen. Cells were detached from 
flasks, pelleted, and resuspended in 0.5 ml of medium. 0.5 ml of freezing medium 
was added, containing 20% dimethyl sulphoxide (DMSO, Sigma) in fetal calf serum 
(FCS), resulting in a final concentration of 10% DMSO. The cell suspension was 
transferred to a cryogenic vial and then gently cooled at 1C/min in an isopropyl 
alcohol containing freezing container (Nalgene, Cryo 1C Freezing container, 
Nalgene, Hereford) for 4 hours, prior to transfer into liquid nitrogen for long term 
storage. 
Recovery of the cells was achieved by rapid thawing of the cryogenic vial contents 
and their addition to 10 ml of complete medium in a 75 cm3 flask. After 18-24 
hours the DMSO-containing medium was replaced by appropriate complete 
medium. 
2.1.2 Cell counting 
Cells were counted prior to their use in experiments using 10 l of resuspended 
cells and a Neubauer chamber haemocytometer (Reichert, Buffalo, USA). Cells in 
the 25 squares of the grid were counted and the total multiplied by 1x104 to obtain 
the number of cells/ml. 
2.1.3 Cell lines 
Table 2-1 summarises cell lines used in protein and mRNA studies to analyse the 
expression of FOXP3 and CXCR4. 
2.1.3.1  Human Mammary Epithelial Cells (HMEpC) 
Purchased from Promocell, HMEpC are isolated from the human adult mammary 
gland. They were grown in the recommended Mammary Epithelial Cell Growth 




Medium (Promocell). Adherent cells were cultured at 37C in a humidified, carbon 
dioxide free system until 70-80% confluent and split in a ratio of 1:3.  
2.1.3.2  MCF-10A 
The MCF 10A cell line was a kind gift from Dr Felicity May (Northern Institute of 
Cancer Research, Newcastle University). It is a non-neoplastic immortal human 
breast epithelial cell line. The line was produced by long-term culture in serum 
free medium with low calcium concentration. It retains many characteristics of 
normal breast epithelium. Adherent cell line was cultured in a low calcium 
medium, at 37C in a humidified, carbon dioxide free system until 70-80% 
confluent and split in a ratio of 1:3.  
2.1.3.3  MCF-7 
MCF-7 is a human breast adenocarcinoma cell line (European Collection of Cell 
Cultures – ECACC, Salisbury). These relatively non-invasive cells were derived 
from the pleural effusion of a 69-year-old female Caucasian. These cells 
demonstrate a number of features of differentiated mammary epithelium including 
oestradiol synthesis and express oestrogen and progesterone receptors. Adherent 
cell line was cultured in complete DMEM without phenol red at 37C, 5% CO2 in a 
humidified atmosphere until 70-80% confluent and split in a ratio of 1:3. 
2.1.3.4  MDA-MB-231 
MDA-MB-231 (ECACC) is a human breast adenocarcinoma cell line derived from 
the pleural effusion of a 51-year-old female Caucasian. These cells have an invasive 
phenotype. They do not express oestrogen receptors. Adherent cells were cultured 
in complete Leibovitz L-15 medium, at 37C in a humidified, CO2 free system until 
70-80% confluent and split in a ratio of 1:3. 
2.1.3.5  TMD-MDA-MB-231 (TMD-231)  
TMD-231 cells were a gift from H. Nakshatri, Indianapolis, USA. They were isolated 
from the mammary fat pad of mice inoculated with MDA-MB-231. This cell line 
expresses high levels of CXCR4 (Helbig et al., 2003). Cells were cultured in 




complete Minimum Essential Medium and complete RPMI mixed in a 50:50 ratio at 
37C, 5% in a humidified atmosphere CO2 until 70-80% confluent and were split 
in a ratio of 1:3. 
2.1.3.6  LMD-MDA-MB-231 (LMD-231) 
LMD-231 cells were also a gift from H. Nakshatri, Indianapolis, USA. This cell line 
was cultured from a lung metastasis of mice inoculated with MDA-MB-231. This 
cell line expresses high levels of CXCR4 (Helbig et al., 2003). Cells were cultured in 
complete Minimum Essential Medium and complete RPMI mixed in a 50:50 ratio at 
37C, 5% in a humidified atmosphere CO2 until 70-80% confluent and were split 
in a ratio of 1:3. 
2.1.3.7  Flp-InTM T-RExTM-293  
This cell line originated from HEK293 cells. These Tet repressor expressing cells 
contain a single, integrated Flp recombination target (FRT) site for stable specific 
genomic incorporation of a gene of interest. Gene expression is then controlled 
with tetracycline.  Untransfected Flp-In™T-Rex™-293 cells were grown in complete 
DMEM medium in the presence of 10μg/ml Blasticidin and 100μg/ml Zeocin 
(Invitrogen). After transfection, Zeocin was replaced by 100 μg/ml Hygromycin B. 
The expression of FOXP3 was induced by Tetracycline (100 µg/ml). The cells were 
a kind gift from Marcin Pekalski (Institute of Cellular Medicine, Newcastle 
University, UK).  
2.1.3.8  Jurkat 
The leukaemic T cell line was (originally called JM) was established from the 
peripheral blood of a 14-year-old boy with T cell leukaemia. Jurkat cells were 
cultured in RPMI 1640 complete medium in 75 cm2 flasks in vertical position.   
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Fetal kidney hypotriploid 
human cell line 
FOXP3 Invitrogen 
Jurkat 
Human leukaemic T 
cell lymphoblast 
suspension RPMI Jurkat FHCRC CXCR4 ECACC 
Table 2-1: Cell lines used in protein and mRNA studies to analyse the expression of 
FOXP3 and CXCR4 




2.1.4 Cell media 
2.1.4.1  Mammary Epithelial Cell Growth Medium  
Mammary Epithelial Cell Growth Medium is a serum-free medium supplemented 
with bovine pituitary extract (0.004 ml/ml), Epidermal Growth Factor (EGF) 
10ng/ml, Insulin (5 µg/ml), Hydrocortisone (0.5 µg/ml). 
2.1.4.2  Medium for MCF-10A cells 
The growth medium for MCF-10A contains several additives and is composed of 
DMEM/F12 supplemented with 5% donor horse serum, 20 ng/ml epidermal 
growth factor (EGF), 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 100 ng/ml 
cholera toxin, and antibiotics (Debnath et al., 2003). 
2.1.4.3  Dulbecco’s Modified Eagle Medium (DMEM) 
Dulbecco’s Modified Eagle Medium (with 1000 mg/l D-glucose and 110 mg/l 
sodium pyruvate; Invitrogen) without phenol red was supplemented with 10% 
FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.146 g/l L-glutamine. 
2.1.4.4  Minimal Essential Medium 
Minimum Essential Medium Eagle with Hank’s salts, 0.292 g/l L-glutamine and 
0.35 g/l sodium bicarbonate was supplemented with 10% FCS, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2nM human insulin (Sigma). 
2.1.4.5  Leibovitz L-15 Medium 
Leibovitz medium (Sigma) is buffered to maintain physiological pH control in a 
carbon dioxide free system. Media was supplemented with 0.3 g/l L-glutamine, 
10% FCS, 100 U/ml penicillin and 100µg/ml streptomycin. 
2.2 Flow cytometry 
Flow cytometric analysis was performed using the BD FACS scan flow cytometer. 
1x106 cells were washed in 500 μl of PBS with 1% BSA. Cells were then 
resuspended in 100 μl of PBS with 0.1% BSA and appropriate monoclonal antibody 
was added at appropriate concentrations (CXCR4 10 l/ml). The appropriate 




secondary antibodies conjugated to fluorochrome were added after washing and 
the samples were incubated for 30 min at 4ºC. Cells were then washed and 
resuspended in 500 μl PBS prior to examination by flow cytometry. To control for 
non-specific binding, an isotype-matched primary antibody (at the same dilution 
as the test monoclonal antibody) was applied and subjected to the same secondary 
staining procedure as experimental samples.  
2.3 Immunofluorescence 
Cells were grown on chamber slides (90000 cells/chamber), fixed with 4% 
paraformaldehyde for 30 minutes, permeabilized using 0.1% Triton X100 in PBS 
for 15 minutes at 4°C and blocked in 5% FBS for 1 hour. Primary antibody was 
added to chambers and left overnight at 4°C at a concentration of 1:5 (Foxp3) and 
1:300 (CXCR4) diluted in 5% FBS. Slides were covered with FITC conjugated rabbit 
anti-mouse secondary antibody for two hours, stained with DAPI, mounted using 
VectaShield and examined with a Leica fluorescent microscope. 
2.3.1 Antibodies  
The primary antibodies used during the course of this work are summarised in 
Table 2-2.  Two anti-Foxp3 and one anti-CXCR4 antibodies were used:  
Non-commercial monoclonal mouse anti-human Foxp3 antibody (clone 150D/E4; 
isotype Ig1) is a cell culture supernatant and was a kind gift from Dr. Alison H. 
Banham, University of Oxford. It was diluted (1:5) in blocking buffer and incubated 
over night at 4C. 
Monoclonal mouse anti-human Foxp3 antibody (clone 326A/E7; isotype IgG1) was 
purchased from Abcam. Previously, it has been successfully used for staining 
prostate (Wang L, 2009) and breast cancer tissues (Wang L, 209). The antibody 
was diluted 1:50 in blocking buffer and incubated over night at 4C. 
Monoclonal mouse anti-human CXCR4 antibody (clone: 44716, isotype IgG2b) was 
purchased from R&D systems. It was diluted 1:300 in blocking buffer and 
incubated over night at 4C.  












(Biotinylated) Buffer Method 
FOXP3 Citrate PC Non commercial 1:5 1: 250 
FOXP3 Citrate PC Abcam 1:50 1: 250 
CXCR4 Citrate PC R&D systems 1:300 1:250 
CD45 Citrate MCW DAKO 1:100 1: 250 
Table 2-2: Primary antibodies used for Immunohistochemistry 
MCW=microwave, PC= pressure cooker 




2.4 Bacterial cell culture 
Bacteria were grown on Luria-Bertanni (LB Sigma) media agar plates or liquid LB 
medium at 37°C. For positive selection appropriate antibiotics were added to 
media and plates.  Bacterial stocks were stored at -80°C in 10% glycerol in LB 
(Table 2-3: Bacterial cell culture components. 
 
LB Medium (1 Liter) LB Agar (1 Liter) 
10g bacto-tryptone 10g bacto-tryptone 
5g bacto-yeast extract    5g  bacto-yeast extract  
10g  NaCl 10g  NaCl 
pH 7  30g  Agar (10g/L) 
Table 2-3: Bacterial cell culture components. 
 
2.4.1 Generation of chemically competent Escherichia coli  
Chemical competence is competence in the ability of a cell to take up extracellular 
DNA from its environment. In order to make Escherichia coli (XL1-Blue cells) 
chemically competent, cells in 10 ml of medium were grown overnight at 37C. 
Next day, 200 ml of medium was inoculated with 5 ml of overnight innoculum on 
shaker at 37C. The cells were grown to optical density of OD600. Following this 
cells were spun for 15 minutes at 3500 rpm at 4C and the pellet was resuspended 
in 50 ml of ice cold 10 mM NaCl, incubated for 10 minutes on ice and pelleted 
again. Following this, cells were resuspended in 50 ml of ice cold 75 mM CaCl2, 
incubated for 35 minutes on ice, pelleted again and resuspended in 3 ml of ice cold 
75 mM CaCl2, aliquoted and stored in -70°C.  




2.4.2 Transformation of competent Escherichia coli  
One aliquot of competent cells was defrosted on ice and incubated with DNA on ice 
for 30 minutes. This allows the DNA to adsorb onto the surface of the cells. The 
cells were then heat shocked for 90 seconds at 42°C and returned to ice for 2 
minutes. This process causes the DNA to be taken up by cells through pores in 
their membranes before these pores are closed by rapid cooling. Cells were then 
added to 1ml of LB growth medium and allowed to recover for 2 hours at room 
temperature with shaking, before being spread onto LB agar plates containing 
appropriate antibiotics (Ampicillin) as selection agents for the uptake of the 
desired plasmid type. Following overnight growth, individual colonies were picked 
off plates for further analysis. Positive (cells but no antibiotics on a plate) and 
negative (no cells or control cells with antibiotics on a plate) controls were used. 
2.5 DNA methods 
2.5.1  Recovery of plasmid DNA from bacteria culture  
Plasmid DNA was isolated from Escherichia coli (XL1-Blue cells) cultures using the 
Qiagen Mini-Prep kit in accordance with the manufacturer’s instructions. This 
technique uses silica-binding technology and spin columns. Briefly: 5 ml of 
overnight Escherichia coli culture was pelleted by centrifugation at 12,000 g for 1 
minute. Pelleted bacterial cells were resuspended in 250 µl of the re-suspension 
solution containing RNase. Cells were lysed with 250 l of alkaline-Sodium 
Dodecyl Sulphate lysis solution before neutralising with 350 l of neutralising 
solution. The lysate was centrifuged at 13,000 g for 10 minutes to pellet cell debris, 
proteins, lipids and chromosomal DNA. Clear lysate was added to the prepared 
silica column before centrifuging for further 30-60 s. Following two wash steps 
with wash solution, plasmid DNA was eluted from the column using 100 l of 
Elution Solution.  
For the large plasmid DNA preparation Maxi-prep (Qiagen) was used in 
accordance with the manufacturer’s instructions. This technique, similarly to Mini-
Prep, uses silica-binding technology and spin columns.  




2.5.2 Enzymatic digestion of plasmid DNA with restriction enzymes  
Restriction enzymes are bacterial enzymes that hydrolyse DNA that normally 
comprise the modification defence response against foreign DNA in bacterial cells. 
Restriction endonucleases recognise short, symmetrical base pair sequences and 
therefore cut foreign DNA into small segments. Hydrolysis of DNA by 
endonucleases results in either ‘blunt’ or protruding ‘sticky’ 3’-OH and 5’-OH ends. 
Blunt-ended digestions can be ligated to any other blunt-ended digestion, but if 
different enzymes are used the original restriction site will be disrupted. Sticky 
ends will bind to any other sequences with the same overhanging sequence, 
usually resulting in specific annealing of complementary ends and restoration of 
the original restriction site. 
Typically, one unit is defined as the amount of enzyme required to digest 1 g of 
DNA in 1hour at 37C. A standard 60 l reaction to digest 5 g of DNA would 
contain: DNA, 6 l 10x Buffer (optimal for the enzyme(s) being used), 6 l 
restriction enzyme, made up to 60 l with water. Digestions were left for 3-12 
hours at 37C. Restriction enzymes used were Xho1 and Not1. 
2.5.3 DNA and RNA ethanol precipitation 
Ethanol precipitation is a commonly used technique for concentrating and de-
salting nucleic acid (DNA or RNA) preparations in aqueous solution. Briefly: the 
volume of the DNA sample was measured, the salt concentration adjusted by 
adding 1/10 volume of sodium acetate, pH 5.2, (final concentration of 0.3 M). The 
sample was mixed and 2.5 volumes of cold 100% ethanol was added. The sample 
was placed on ice for 20 minutes, spun at a maximum speed in a microcentrifuge 
for 10-15 min, supernatant was removed and 1 ml of 70% ethanol added. Again, 
the sample was spun, air-dried and resuspended in water.  
2.5.4 DNA sequencing  
Automated DNA sequencing was used to determine the sequence of both DNA 
fragments and junctions with vectors containing inserts. Sequencing was carried 
out by GeneService (www.geneservice.co.uk) and chromatograms were produced 




using the Geospiza’s FinchTV v.1.4.0 freeware software 
(http://www.geospiza.com).   
2.5.5 Agarose gel electrophoresis 
1% agarose gel was produced by melting 0.5 g agarose (Sigma) with 50 mL 1x TAE 
(50x stock consists of 2 M Tris base, 1 M acetic acid and 0.5 M EDTA pH 8). To 
visualise DNA sample, Ethidium Bromide (Promega) at final concentration of 5 
g/ml was added to the gel and left to set in a plastic casting stand. Subsequently, 
the gel was transferred to an electrophoresis tank filled with TAE buffer. To 
establish an approximate band size 5 µl Hyperladder IV (Bioline) was added to one 
of the lanes. Once electrophoresis was completed, an Alpha Imager Instrument 
(AlphaImager®, Alpha Innotech Corp., San Leandro, Ca, USA) was used to visualise 
the DNA bands. 
2.5.6  Gel purification of DNA  
 Purification of DNA from a gel was performed by the QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacture protocol.  





2.6.1  RNA extraction 
Total RNA was isolated from cells using Trizol Reagent (Invitrogen) according to 
the manufacturer’s instructions. Trizol Reagent promotes the formation of 
complexes of RNA with guanidine and water molecules, while abolishing the 
hydrophilic interactions of DNA and proteins. Consequently, RNA remains in 
aqueous phase, separated from DNA and proteins. All RNA work was carried out 
with ribonuclease-free and contaminant-free apparatus. All water used in RNA 
work and analysis was Diethyl pyrocarbonate (DEPC) treated. 0.2 ml of Trizol 
Reagent was added to lyse 1x106 cells, which were solubilised by passaging lysate 
through a pipette. Following addition of chloroform at 10% of the volume of Trizol 
Reagent, the homogenate was shaken vigorously for 15 seconds, incubated on ice 
for 2-3 minutes and centrifuged at 12,000 g for 15 minutes. The aqueous phase 
was removed and RNA precipitated with the addition of an equal volume of 
isopropanol. This was left to incubate for further 10 minutes on ice. The RNA 
precipitate was centrifuged at 12,000 g for 10 minutes to pellet, supernatant was 
removed and the pellet washed by centrifuging with 75% ethanol, prior to 
resuspending RNA in water. The concentration and quality of the isolated RNA was 
assessed using nanodrop spectrophotometer (NanoDrop 1000, Thermo Scientific, 
Wilmington, USA). The integrity of the extracted RNA was assessed using agarose 
gel electrophoresis to identify 28S and 18S ribosomal RNA (rRNA).  
2.6.2 RNA/DNA quantification 
RNA and DNA preparations were quantified by nanodrop (Biophotometer, 
Eppendorf, Hamburg, Germany) at 260 nm and 280 nm. Small samples of RNA or 
DNA were diluted in water prior to spectrophotometry. The 260/280 ratio 
provides an estimate of nucleic acid purity. Pure preparations of DNA and RNA 
have OD 260/280 values of 1.8 and 2.0 respectively. 




2.6.3 Reverse Transcription 
First strand cDNA synthesis was performed using Superscript III RNase H Reverse 
Transcriptase. 5 g of total RNA was incubated at 65oC for 5 minutes with 1 g of 
Oligo (dT) and 1 l of 10 mM dNTP (deoxy-nucleotide tri-phosphate) and distilled 
water was added to the volume of 13 l. This mixture was then incubated on ice 
for at least 1 minute. Following this 4 l of First Strand Buffer, 1 l of 0.1M DTT 
and 1 l of Superscript III (200 U/l) were added and mixed by pipetting. The 
mixture was reverse transcribed at 50-55C for 50 minutes, before inactivating at 
70C for 15 minutes, prior to cooling. This was performed in a thermal cycler 
(Hybaid, Basingstoke). The cDNA can be used as a template for amplification in 
PCR. 
2.6.4 Primer Design 
All FOXP3 primers were designed manually. Nucleotide search tool from 
www.ncbi.nlm.nih.gov was used to search for target sequence of nucleotides for 
FOXP3 locus (AF277993). “Perfect Primers Design” tool (Invitrogen), 
www.tools.invitrogen.com, was used to determine final primer sequence. Forward 
and reverse FOXP3 primers were designed to have approximately the same 
number of G and C components and to be 15-35 nucleotides in length. Primers 
were designed with a G-C content producing a melting temperature (Tm) of 60oC. 
Table 2-4 summarises 3 pairs of FOXP3 primers designed to sequence three 





Forward primer VH Bio 
(Gateshead) 
CAAATGGTGTCTGCAAGTGG 2 
Reverse primer ATTGAGTGTCCGCTGCTTCT 2 
Forward primer 
Invitrogen 
AAGCCAGGCTGATCCTTTTCT 2, 3 




Reverse primer AGGCAAGACAGTGGAAACCTCACT 1 
Table 2-4: Primer sequence used in conventional PCR 




2.7  Conventional PCR 
The Polymerase Chain Reaction (PCR) is a method for amplifying specific sections 
of a DNA molecule. PCR is based on the fact that DNA polymerases are primer-
dependant. This means that a pair of primers is designed and synthesised 
complementary to sequences upstream to the sequence of interest on both the 
coding and complementary DNA strands. The polymerase will then extend these 
primers past the sequence of interest by incorporating new complimentary bases, 
thus copying it. Primers are generally 15 to 30 base pairs in length and have a large 
degree of sequence homology with the target. The two primers also have 
approximately the same ratio of G/C to A/T bases. The G/C to A/T ratio 
determines the annealing temperature for the reaction. The reaction can only be 
held at one annealing temperature. The PCR cycle comprises three phases: heating 
to denature DNA double helices, cooling to a low temperature allowing the specific 
annealing of helices carrying complementary base-pair sequences as well as 
primers and elongation when the polymerase extends the primers, copying the 
sequence of interest. A typical PCR cycle comprises 1 minute at 95°C to denature, 
30 seconds at around 55°C to anneal, followed by 1 minute at 72°C for polymerase 
function. The temperatures used are relatively high and therefore thermostable 
polymerases must be used which are able to withstand the heat without 
denaturing. Taq and Pfu polymerases were used in the course of this work. Taq 
was originally isolated from Hyperthermophilic archaea (Thermus aquaticus) and is 
stable at high temperatures and has an error rate of about 1.3 x 10-5 and mutation 
frequency of 5.1 %, Thermostable Pfu (Pyrococcus furiosus) DNA Polymerase with 
3  →5  exonuclease proofreading activity exhibits a higher fidelity than Taq DNA 
Polymerase. It has an error rate of about 1.8 x 10-5 – 8 x 10-7 and 5.1–0.3% 
mutation frequency and was used to reduce error rate in the amplified products.  
All polymerases used in PCR are dependant on magnesium, which stabilises DNA 
and RNA interactions. PCR reactions were evaluated with various concentrations 




of magnesium (MgCl2=1.5 mM, 2 mM, 2.5 mM) and with various annealing 
temperatures to increase their specificity. 
A standard 40 µl reaction for a PCR would comprise: 4 µl deoxynucleoside 
triphosphate solution, 4 µl of 10x PCR buffer concentrate, 0.8 µl of Taq polymerase 
enzyme, 4 µl (10 mM), forward primer solution, 4 µl (10 mM), reverse primer 
solution, 1.6 µl (50 mM) MgCl2, 2 µl (1 ng) template DNA, dH2O to make up to 40 µl. 
Negative control included experiments with no cDNA added to the reaction. 
Positive controls were performed with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) primers. GAPDH is constitutively expressed and would 
thus be amplified if conditions of the PCR were optimal. 







Figure 2-1: Chain extension and emission of fluorescence in real-time PCR. 
The probes anneal to specific sequences in DNA between the forward and reverse primers. When 
excited the reporter (F) transfers energy to the quencher (Q) preventing emission of fluorescence. 
As Taq polymerase copies the DNA the 5’ exonuclease activity of the enzyme cleaves the probe. This 
separates the reporter and quencher allowing the reporter dye to fluoresce.  
Adapted from App Biosystems www.appliedbiosystems.com: Real-time PCR 2009 




2.8 Real-Time PCR 
In comparison to normal PCR that detects the amount of final amplified product at 
the end-point, real-time PCR measures the initial amount of the template precisely 
and reproducibly. During a real-time PCR reaction each amplification cycle emits 
fluorescence in real time. Real-time PCR allows measurement at the relative gene 
expression compared to the expression of endogenous control. The endogenous 
control has to be abundant and remain constant in proportion to total RNA among 
the samples. Similarly to normal PCR, real-time PCR uses primers and follows the 
same three-step reaction of denaturation, annealing and chain elongation. Real 
time PCR employs three main types of fluorescing systems to monitor DNA 
amplification, which include hydrolysis probes, hybridizing probes and DNA-
binding agents. In this study hydrolysis probes were used, namely TaqMan probes. 
The TaqMan probe has a high-energy fluorescing dye, a reporter, at the 5’ end and 
a low energy quencher molecule at the 3’ end. When the probe is excited by a light 
source the fluorescent dye transfers energy to the quenching dye molecule rather 
than fluorescing. The probes anneal to specific sequences in DNA between the 
forward and reverse primers. As Taq polymerase copies a template of DNA to 
which a probe is bound the 5’ exonuclease activity of the enzyme cleaves the 
probe. This separates the reporter and quencher preventing the transfer of energy 
allowing the reporter dye to fluoresce (Figure 2-1). This cleavage increases with 
every cycle and is proportional to the accumulation of PCR products. In the early 
cycles there is no considerable change in fluorescent signal. This is referred to as 
the baseline and a fixed threshold can be set above this line. A noteworthy 
parameter for the quantification of initial template is the threshold cycle (CT). This 
is defined as the cycle number at which fluorescence passes the fixed threshold. 
Therefore the higher the initial amount of template, the lower the CT.  
In the present work 18S RNA and GAPDH were used as endogenous controls. Real-
time PCR was used to quantify the amount of FOXP3 and CXCR4 cDNA in breast 
cell lines and cells following TGF-β1 treatment and FOXP3 amount following 




transfection of MDA-MB-231 cells with FOXP3 vector. RNA was extracted and 
cDNA synthesised as outlined above. Random primers instead of oligo-dT have to 
be used during the RT-PCR reaction when working with 18S, as 18S RNA does not 
have a poly-A tail. Assays-on-Demand™ Gene Expression products consist of a 20x 
mix of PCR primers and TaqMan® probe (FAM™ dye-labelled). All Assays-on 
Demand™ Gene Expression products are optimized to work with TaqMan® 
Universal PCR Master Mix and with complementary DNA (cDNA). In the present 
work gene expression assays (Assays-on-Demand™) designed by Applied 
Biosystems were used (Table 2-5). 
Each well of real-time PCR plate contained 10 µl master mix (Stratagene), 7 µl 
distilled water, 2 µl template cDNA and 1 µl primer probes (Applied Biosystems). 
Each experiment was carried out in triplicates. For each set a reaction without 
cDNA template was used as a negative control. Experiments were performed using 
an Applied Biosystems ABI Prism 7000 plate reader. Results were normalised to 
the expression of endogenous 18S RNA and GAPDH (∆CT), the values of the 
negative controls were subtracted from that of the test samples (∆∆CT), and those 
values were expressed as a fold change in relation to the negative controls. In 
addition, the relative expression software tool 2008 (REST2008) was used to 
estimate changes in gene expression. 
 
Table 2-5: Assays-on-Demand™ Gene Expression Products (TaqMan® probes, 
FAM™ dye-labelled).  
Assay ID Reporter Dye Context Sequence Gene Name 
Hs99999901_s1 FAM  n/a 18S RNA human 18S rRNA 




Hs00203958_m1 FAM ATCCGCTGGGCCA- 
TCCTGGAGGCTC 
FOXP3 forkhead box P3 




2.8.1.1 Relative quantification of gene expression 
When the comparative CT method (CT) of real-time PCR data analysis is used, 
there is no need for a standard curve. Relative quantification is applied when 
determining the expression levels relative to the housekeeping gene.  
Efficiency of both primer pairs used in the experiment has to be assessed using 
serial dilutions and estimated to be between 90 and 100%, which means that the 
slope between linear phases of amplifications graphs should be between -3.6 and -
3.1. A standard method to check the efficiency of primer pairs is to examine how 
ΔCT varies with template dilution. The efficiency of the PCR reaction depends on 
some variables, including quality of the primers and length of the amplicon. Lower 
than 90% efficiency does not exclude valid results but it is recommended to use an 
optimized system. When the efficiencies of reaction of the two different dilutions 
are equal, the plot of logs input quantity versus ΔCT gives horizontal lines.  
To calculate the relative expression of two different samples, one of them should 
be chosen as the examined and the other as the reference. 
ΔCT = CT (examined) - CT (reference=housekeeping gene) 
The comparative ΔΔCT step involves finding the difference between ΔCT of the 
unknown sample and the sample to which expression is compared. The final 
calculation for the comparative expression level is performed as per following 
equation:  
Comparative expression level= 2 – ΔΔCT 




2.9 Statistical analysis 
The data was analyzed using the Microsoft Office Excel 2003 and Prism3 Graphpad 
statistical software packages. Quantitative values were expressed and plotted as 
mean ± standard deviation. Comparisons were evaluated by the unpaired 
Student's t-test and ANOVA and Bonferroni tests. Kappa statistics was used to 
compare inter-observer agreement in FOXP3 and CXCR4 immunohistochemical 
scoring for manual and digital microscopy interpretation. A linear regression 
analysis was used to determine the relationship between FOXP3 nuclear quick 
score on tissue sections and the patients’ age.  
A value of P < 0.05 was considered statistically significant. 
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3 Characterization of FOXP3 and CXCR4 expression in 
breast cancer  
3.1 Introduction 
3.1.1 CXCR4 expression 
CXCR4 is the physiological receptor for CXCL12, which belongs to a chemokine 
family that has potent chemotactic activity for lymphocytes. It is well known that 
peripheral lymphocytes preferentially localize to peripheral lymphoid tissues, such 
as lymph nodes, which is called the homing phenomenon (Blackwell et al., 2009). 
Metastatic breast cancer cells overexpress CXCR4 and this receptor plays a critical 
role in homing of cancer cells at specific metastatic sites (Muller et al., 2001).  
CXCR4 is expressed on various cell types, including: endothelial cells (Volin et al., 
1998, Feil and Augustin, 1998), bronchial epithelial cells (Eddleston et al., 2002), 
lymphocytes (Bleul et al., 1996b, Bleul et al., 1996a), intestinal (including colonic) 
epithelial cells (Dwinell et al., 1999, Jordan et al., 1999), primitive haematopoietic 
progenitor cells (Aiuti et al., 1997), microglia, neurons and astrocytes (Bonavia et 
al., 2003), vascular smooth muscle cells (Schecter et al., 2003), fibrocytes (Phillips 
et al., 2004) and pluripotent stem cells, including mammary stem cells (Dontu et 
al., 2003). CXCR4 expression by stem cells suggests that CXCR4 may mask the 
progenitors of breast cancer (Liu et al., 2005).  
CC and CXC chemokine receptor expression is described on a wide variety of 
cancer cell types (Tanaka et al., 2005, Dowsland et al., 2003, Balkwill, 2004). 
CXCR4 is the most common chemokine receptor expressed on both murine and 
human cancer cells, having been noted in at least 23 different haematopoietic, 
epithelial and mesenchymal tumours (Balkwill, 2004). On the other hand, within 
primary tumours and cancer cell lines e.g. ovarian and non small-cell lung cancer, 
only a subpopulation of cells express the CXCR4 receptor (Scotton et al., 2001, 
Phillips et al., 2003). Similarly, expression of CXCR4 in breast cancer cells is 
confined to a small sub-population of cells (Kang et al., 2003b). 




Immunohistochemical staining of primary breast tumours has revealed that 
normal breast epithelial cells do not express CXCR4, whereas, between 51% and 
73% of primary breast cancers express the protein (Muller et al., 2001, Kato et al., 
2003, Cabioglu et al., 2005c) as do more than 90% of samples with atypical ductal 
hyperplasia (Schmid et al., 2004). CXCR4 expression in the primary cancer has also 
been positively correlated with the degree of lymph node metastasis (Cabioglu et 
al., 2005c, Kato et al., 2003), tumour grade (Helms et al., 2005) and poor overall 
survival (Li et al., 2004). CXCR4 expression as demonstrated by flow cytometry has 
been linked to the ability of breast cancer cells to metastasise to lungs (Helbig et 
al., 2003).  
3.1.2 FOXP3 expression 
FOXP3 controls the function of thymically derived naturally occurring regulatory T 
cells (Hori and Sakaguchi, 2004, Fontenot et al., 2003), where it induces or 
represses a number of genes, including CXCR4.  
This protein is known to be expressed at high levels in the nuclei of Treg cells and 
lymphoid tissue (thymus, spleen and lymph nodes) (Brunkow et al., 2001, Hori and 
Sakaguchi, 2004, Hori S, 2003). However, epithelial cells express this protein at 
lower levels in the nuclei and cytoplasm (Chen G, 2008). In the human, FOXP3 
expression was detected in breast epithelial cells, lung respiratory epithelial cells, 
prostate epithelial cells, but not heart, and intestine (Chen G, 2008), In mice Foxp3 
is expressed on epithelial cells of multiple organs (Chen G, 2008). Recent 
publications described the expression of FOXP3 in human tumour cells (Andrea 
Merlo and Elda Tagliabue, 2009, Zuo et al., 2007c, Wang L, 2009). It has been found 
that FOXP3 expression was related to the regulation of several cytokines, such as 
IL-10 and TGF-β2, and FOXP3 might mediate the inhibiting efficacy of tumour cells 
to escape immune destruction. Those reports implicated that FOXP3 performs its 
functions in the regulation of tumour progression by expressing not only in Tregs, 
but also in tumour cells. 




Widespread confusion exists in literature regarding FOXP3 expression in human 
cancers. Some state that FOXP3 expression is increased in cancer (Merlo A, 2009, 
Gupta et al., 2007, Ohara et al., 2009), some suggest a decrease (Zuo et al., 2007d, 
Zuo et al., 2007b) in expression of this protein or change compared to benign 
epithelium (Zuo et al., 2007d, Zuo et al., 2007b).  
Since FOXP3 is a transcription factor, majority of authors considered the presence 
of nuclear FOXP3 as positive (Liu et al., 2009, Wang L, 2009, Zuo et al., 2007d). 
Using this criterion, FOXP3 positive tumours usually account for less than 30% of 
all tumour samples. On the other hand, if both nuclear FOXP3 and cytoplasmic 
FOXP3 are counted, then the number of FOXP3-positive samples can be 
considerably higher. When total expression of FOXP3 in 25 tumour cell lines was 
analysed, including lung cancer, colon cancer, breast cancer, melanoma, erythroid 
leukemia, and acute T-cell leukemia, in most cell lines, the authors observed FOXP3 
expression of both mRNA and its protein (Karanikas et al., 2008). 
Immunohistochemical staining of the cytospins of these cell lines showed 
cytoplasmic expression of FOXP3 predominantly in melanoma (GERL), colon (HCA 
2.6), and breast cancer (MCF7) cell lines and both cytoplasmic and nuclear 
expression in cell lines of lung cancer (GILI) and T lymphoblastic leukemia 
(JURKAT) (Karanikas et al., 2008). More recently, it has been revealed that FOXP3 
is only identified in the cytoplasm in all HER2 positive breast cancer samples 
(Ladoire et al., 2008, Martin et al., Ladoire et al.). The analysis of somatic FOXP3 
mutants indicated that the majority of the missense mutations disrupted their 
nuclear localization (Wang L, 2009). Crucially, the cytoplasmic localization is best 
correlated with the loss of growth inhibition (Wang L, 2009). Furthermore, there is 
evidence that FOXP3 alternative splicing forms also can disrupt localization of 
FOXP3 (Ebert et al., 2008, Katoh et al., Krejsgaard et al., 2008, Sun et al., Zuo et al., 
2007d). 




3.2 Specific Aims and Objectives 
 To examine expression of FOXP3 and CXCR4 in benign and malignant human 
breast tissue  
 To explore the relationship between FOXP3 and CXCR4 expression with 
clinico-pathological factors of breast cancer 
 To study CXCR4 protein expression in breast cancer cells  
 To compare FOXP3 and CXCR4 expression at the mRNA level in breast cancer 
cells 




3.3 Materials and Methods 
3.3.1 Immunohistochemistry  
3.3.1.1 Ethical Approval 
An amendment to the Ethical Approval for collection of paraffin embedded breast 
tumour human tissue sections was submitted to the Northumberland Local 
Research Ethics Committee and to Newcastle-upon-Tyne Hospitals NHS Trust. Full 
approval was granted for the study “06/Q0906/12- Role of Chemokine/GAG 
Interactions in Breast Cancer Metastasis” (Appendix: ethical approval 231). 
3.3.1.2  Principles 
Immunohistochemistry utilises the specificity and high affinity of antibodies to 
detect antigens in tissue sections. Immunohistochemistry visualises antibody-
antigen complexes within the tissue allowing the location of the antigen to be 
viewed in relation to tissue and cellular structure. 
The principle technique used in this project was avidin-biotin complex (ABC) 
method. This method relies on the strong affinity of avidin or streptavidin for the 
vitamin biotin. In avidin-biotin complex (ABC) method secondary antibodies are 
conjugated to both and function as links between tissue-bound primary antibodies 
and an avidin-biotin-peroxidase complex. The secondary antibody conjugated to 
biotin, which is detected with a streptavidin-biotin-HRP (horse radish peroxidase) 
complex (SABPx). The SABPx system improves the sensitivity of detection by 
amplifying the number of HRP molecules at the site of reaction by four-fold. HRP 
catalyses the conversion of H2O2 to water and oxygen. This oxidises soluble 
diaminobenzadine (DAB) or nickel-enhanced diaminobenzadine (NiDAB) 
producing an insoluble brown and black precipitate.  
Endogenous avidin and biotin activity is commonly found in human tissues and 
therefore endogenous biotin binding sites must be blocked prior to incubation 
with antibodies (Sternberger and Sternberger 1986). Endogenous peroxidase 
activity was quenched using methanol containing 0.45% H2O2. 




3.3.1.3  Antigen Retrieval 
Antigen retrieval was performed to unmask antigens to improve antigen antibody 
interactions using one of the following two methods: 
In Citrate Buffer retrieval method, the slides were immersed in preheated citrate 
buffer (0.1 M Tri sodium citrate and 0.1 M citric acid; pH 6.0) in a pressure cooker 
and exposed to full pressure for 1 min. The pressure cooker was then cooled under 
running tap water. In EDTA retrieval method EDTA buffer (EDTA 0.37; pH 9.0) was 
used instead of Citrate Buffer. 
3.3.1.4  Technique 
Paraffin embedded sections were dewaxed in xylene for 10 minutes then 
rehydrated by passing slides through decreasing ethanol concentrations of 100%, 
97% and 95% for 1 minute in each. Endogenous peroxidase activity was blocked 
for 10 min with 0.45% H2O2. in methanol. After a wash under tap water, the 
antigen retrieval was performed. Slides were then treated using Avidin/Biotin 
blocking kit for 15 minutes. After washing with TBS, pH 7.6, sections were covered 
in blocking serum for 20 minutes and optimisation of the antibody was performed 
using a range of concentrations of primary antibody. For CXCR4: 1:50, 1:100, 
1:200, 1:300, 1:400 dilutions were evaluated. Whereas for Foxp3: 1:5, 1:10, 1:50. 
Incubation with the primary antibody was over night at 4oC. Subsequently, 
sections were washed in two changes of TBS for 5 minutes per wash, then covered 
in biotinylated secondary antibody (DAKO Rabbit anti-mouse; dilution: 1:250) for 
60 minutes and washed as before. Sections were covered in tertiary reagent 
(Avidin/Biotin peroxidase complex) for 30 minutes and washed. Colour was 
developed using DAB or NiDAB solution for 2-3 minutes and sections were washed 
afterwards for 5 minutes in running tap water. Counterstaining with Haematoxylin 
was performed to reveal the tissue architecture. Slides were dehydrated through a 
series of alcohol concentrations (50, 70, 90, 95% and absolute alcohol), cleared in 
xylene and mounted using DPX (Dibutylphthalate xylene). 




3.3.1.5  Tissue sections 
All tissue samples were collected during breast cancer surgery at the Royal 
Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Trust, UK. Staining was 
performed on 4 µm thick serial sections of (10% neutral buffered) formalin fixed, 
paraffin embedded breast tissue specimens.  
To estimate the statistically significant number of sections to be used in the study, 
a pilot study of 10 sections was performed. A power calculation based on the pilot 
study of 10 whole tissue sections led to selection of 100 breast tissue sections with 
at least 5 sections in each analysed group to determine differences in FOXP3 and 
CXCR4 staining patterns. In total, 100 fixed sections were examined in total with 
each antibody. They were: 21 normal breast, 5 carcinoma in situ, 37 infiltrating 
carcinoma, 30 corresponding normal lymph nodes and 7 corresponding metastatic 
lymph nodes. 
3.3.1.6  Preparation of paraffin blocks from pelleted cells  
Cells were grown until 70-80% confluent, detached and resuspended in 10% 
phosphate-buffered formalin at room temperature, fixed cells were then 
transferred to tissue cassettes and processed into paraffin blocks using standard 
tissue processing. Paraffin blocks were prepared by the Department of 
Histopathology (RVI, Newcastle upon Tyne). 
3.3.1.7  Controls 
For immunohistochemical staining positive and negative controls were used. 
Positive controls for FOXP3 were normal human lymph nodes and HEK293 FOXP3 
transfectants; whereas for CXCR4 normal human lymph nodes and tonsils were 
used. Negative controls included: no primary antibody, no primary and no 
secondary antibody, IgG1 control for Foxp3 and IgG2b for CXCR4.  
3.3.1.8  Antibodies 
Two anti-FOXP3 and one anti-CXCR4 antibodies were used: 




Non-commercial monoclonal mouse anti-human Foxp3 antibody (clone 150D/E4; 
isotype Ig1) is a cell culture supernatant and was a kind gift from Dr. Alison H. 
Banham, University of Oxford. It was diluted 1:5 in blocking buffer and incubated 
over night at 4C. 
Monoclonal mouse anti-human Foxp3 antibody (clone 326A/E7; isotype IgG1) was 
purchased from Abcam. Previously, it has been successfully used for staining 
prostate (Wang L, 209) and breast cancer tissues (Wang L, 209). The antibody was 
diluted 1:50 in blocking buffer and incubated over night at 4C. 
Monoclonal mouse anti-human CXCR4 antibody (clone: 44716, isotype IgG2b) was 
purchased from R&D systems. It was diluted 1:300 in blocking buffer and 
incubated over night at 4C.  
3.3.2 Immunocytochemistry 
Cells were grown on chamber slides (90000 cells/chamber). These slides were 
fixed with 4% paraformaldehyde for 30 minutes, then permeabilized using 0.1% 
Triton X100 in PBS for 15 minutes at 4C and blocked in 5% fetal bovine serum 
(FBS) for 1 hour. Primary antibody was added to chambers and left overnight at 
4°C at a concentration of 1:5 (Foxp3) and 1:300 (CXCR4) diluted in 5% FBS. Slides 
were then covered with rabbit anti-mouse biotinylated secondary antibody 
(DAKO) at concentration 1:100. The procedure for visualisation was performed as 
described in immunohistochemistry.  
3.3.3 Manual microscopy and IHC interpretation  
The samples were analysed by two independent observers, one of whom was a 
clinical consultant breast pathologist, Dr Uta Kerlikowski (Department of 
Histopathology, RVI, Newcastle upon Tyne Hospitals NHS Trust). 
3.3.3.1  Quick Score algorithm 
The Quick Score pathological algorithm is a sum of the percentage of positively 
stained cells and the average staining intensity. It was adapted from the “quick 
score steroid receptors quantification in breast cancer” which is routinely used in 




the Department of Histopathology in Newcastle Hospitals for assessment of 
hormonal receptors in breast cancer (RCOP Publication, 2005). Each section was 
manually scored for both the percentage of positively stained cells (from 0 to 5) 
and the average staining intensity of the stained cells within the sample (from 0 to 
3). The Quick Score was calculated by adding the scores for both the percentage of 
positive cells and the staining intensity. On each section, multiple relevant regions 
were examined and the overall Quick Score was expressed as Mean Quick Score 
(MQS). Nuclear and cytoplasmic staining were scored separately for the Foxp3 
antibody. Only membrane staining was considered for the CXCR4 antibody. Kappa 
statistics demonstrated fair strength (kappa=0.29) of agreement between the two 
independent assessors.  
3.3.4 Digital microscopy and automated IHC image analysis  
Clinical Histology and Pathology practice is undergoing a “digital revolution” 
(Staniszewski, 2009). In order to improve reproducibility and standardization of 
interpretation, IHC quantification methods have been developed. Instead of 
classical light microscopes, virtual microscope and onscreen diagnosis is now 
practiced worldwide (Khramtsov et al., 2009, Rojo et al., 2009, Bruch et al., 2009, 
Soenksen, 2009b, Soenksen, 2009a, Dore et al., 2009, Staniszewski, 2009, 
Slodkowska et al., 2009, Rexhepaj et al., 2008). Currently, there are more than 30 
different systems for the Virtual Microscopy available on the market. However, 
none of them is as clinically established as the Aperio ScanScope system 
(Staniszewski, 2009). This system improves accuracy, objectivity and 
reproducibility for the quantification of biomarkers on tissue specimens (Rexhepaj 
et al., 2008, Staniszewski, 2009). The Aperio ScanScope system was used in this 
study for automated analysis of breast tissue immunohistochemistry. The machine 
and ScanScope software were kindly provided by Dr Steven Darby from Northern 
Institute of Cancer Research, Newcastle University. 
Prior to Aperio analysis a qualified pathologist, Dr Uta Kerlikowski, outlined a set 
of tumour-cell only regions that are representative of the tumour. Digital images of 




breast tissue were captured with the Aperio ScanScope XT slide scanner (Aperio 
Technologies, Vista, CA, USA) using brightfield imaging at x20 magnification. 
Specimen areas were selected and individual images were saved in a 24-bit RGB 
TIFF file format with a resolution of 1 μm/pixel using ImageScope software 
(Aperio Technologies). For each of the digital slides, the areas previously selected 
by the pathologist, were digitally marked as regions of interest (ROI). On average, 
8-10 ROIs per digital slide were analysed. The automated analysis of the TIFF 
image files was performed using Aperio image analysis algorithms, which were 
modified for the purpose of this study (Figure 3-1). 
3.3.4.1  IHC Nuclear algorithm  
The IHC nuclear algorithm was used to analyse FOXP3 nuclear staining. The 
software counted DAB negative and DAB positive nuclei and categorized them into 
four levels of intensity (0, 1+, 2+ or 3+). The algorithm was adjusted to segregate 
nuclei of specific size and shape for different cell types (Figure 3-2).  
3.3.4.2  IHC Positive Pixel Count algorithm 
The IHC Positive Pixel Count algorithm was used to measure the area and intensity 
of FOXP3 staining (positive DAB staining) in the cytoplasm. The software 
categorized positive pixels into four levels of intensity (0, 1+, 2+ or 3+) and 
counted the area occupied by each. The “negative marking pen” was used to 
subtract the nuclei from the image (Figure 3-3). 
3.3.4.3 IHC Membrane algorithm 
Originally, the IHC membrane algorithm was developed to test HER2 (Human 
Epidermal growth factor Receptor 2) IHC in invasive breast cancer (Bloom and 
Harrington, 2004). For the purpose of this project it was adapted to analyse IHC 
CXCR4 membrane staining. The algorithm quantified the intensity of staining into 
four levels of intensity (0,1+, 2+ or 3+) and percentage of stained cells (Figure 3-4). 




3.3.4.4 Digital Quick Score  
The Quick Score pathological algorithm is a sum of the percentage of positively 
stained cells and the average staining intensity. The Digital Quick Score algorithm 
was calculated in the same way as for the manual analysis. The sum of the digitally 
quantified percentage of positively stained cells (from 0 to 5) and the digitally 
determined average staining intensity (0-blue, 1-yellow, 2-orange, 3-red) gave a 
digital Quick Score. The nuclear IHC algorithm was used for calculation of the 
digital Quick Score of FOXP3 nuclear staining, the IHC Positive Pixel Count 
algorithm for the digital Quick Score of FOXP3 cytoplasmic staining and the IHC 
Membrane algorithm for the digital Quick Score of CXCR4 membrane staining 
(Table 3-1). 
For each of the digital slides 8-10 regions of interests were analysed and the 
overall digital Quick Score was expressed as a Mean Quick Score (MQS).  
The inter-rater kappa was used to compare inter-observer agreement in FOXP3 
and CXCR4 immunohistochemical scoring for manual and digital microscopy 
interpretation. Significant improvements in inter-observer agreement (kappa = 
0.29 versus 0.86 and 0.71 respectively; both: P < 0.001) were achieved when 
FOXP3 and CXCR4 immunohistochemical analysis were scored with the assistance 
of the digital microscope. 
3.3.5 The relationship of IHC results with pathological prognostic indicators 
The relationship between IHC analysis with pathological prognostic indicators of 
breast carcinoma (tumour size, grade, type, lymph node status, distant metastasis, 
oestrogen and progesterone receptors status) and the presence of early signs of 
metastasis (vascular and perineural invasion) was determined by an independent 
observer. The Mermaid Computer Patients Database was used for this purpose and 
it was kindly made available by RVI, Newcastle upon Tyne Hospital. Table 3-2 
illustrates the clinico-pathological characteristic of the patients analysed in this 
study. Distribution of the pathology in this study corresponds to the distribution of 
breast cancer types in the general population.  









of stained cells 
B. Staining intensity 







0 No staining 
Negative 
No staining at high 
magnification    
1 <1% 
Weak 
Only visible at high 
magnification    
2 1–10% 
Moderate 
Readily visible at low 
magnification    
3 11–33% 
Strong 
Strikingly positive at low 
magnification    
4 34–66% N/A N/A N/A N/A 
5 67–100% N/A N/A N/A N/A 
 
Table 3-1: Calculation of Quick Score algorithm  
A) Each section was manually or digitally scored for the percentage of positively stained cells (0: no 
staining, 1: <1%, 2: 1-10%, 3: 11-33%, 4: 34-66%, 5: 67-100%).  
B) The average staining intensity of the stained cells within the sample was determined by manual 
microscopy (0: negative, 1: weak, 2: moderate, 3: strong) or digital image analysis (0-blue, 1-yellow, 
2-orange, 3-red). N/A – not applicable. 
Quick Score is a sum of the percentage of positively stained cells (0-5) and the average staining 
intensity (0-3). It was adopted from “quick score steroid receptors quantification in breast cancer” 
routinely used in NHS for assessment of hormonal receptors in breast cancer (RCOP Publication, 
2005).  





Table 3-2: Clinico-pathological characteristic of the patients. Age 48 was chosen as 
a cut off in NHS Breast Screening Programme. 





Figure 3-1:  The representative example of an image processed using the IHC 
Nuclear algorithm 
A qualified pathologist outlined a set of tumour-cell only regions and “the negative pen” was used 
to exclude irrelevant areas; the appropriate algorithm  (here IHC Nuclear) analysed the selection. 
The software provided a table with results including: percentage of positive nuclei, average staining 
intensity of positive nuclei and percentages of 0, 1+, 2+, 3+. 
In the image above, the Quick Score was calculated by adding digitally quantified percentage of 
positively stained nuclei (from 0 to 5) and digitally determined average staining intensity of 
positively stained nuclei (from 0 to 3): 38 out of 175 nuclei stained =21.7% nuclei positive for 
FOXP3 (score 2), the average staining intensity was weak (score 1). Digital Quick Score =2+1=3. For 
each of the digital slides 8-10 regions of interests were analysed and the overall digital Quick Score 
was expressed as Mean Quick Score (MQS). 





Figure 3-2: IHC Nuclear algorithm 
A. HEK293 FOXP3 transfectants, B. Inflammatory infiltrate surrounding breast. The IHC Nuclear 
algorithm was used to analyse FOXP3 nuclear staining. It counted DAB negative and DAB positive 
nuclei, categorized them into three levels of intensity (0,1+, 2+ or 3+). It also allowed counting 
lymphocyte numbers per unit area of tissue across the section to quantify a degree of infiltration. 










Figure 3-3: IHC Positive Pixel Count algorithm 
A breast cancer section was analysed using the IHC positive pixel count algorithm to quantify 
FOXP3 cytoplasmic stain. The area and intensity of FOXP3 staining (positive DAB staining) was 
measured in the cytoplasm, positive pixels were categorised into four levels of intensity (0, 1+, 2+ 
or 3+) and the area occupied by each was assessed. The digital Quick Scores of FOXP3 cytoplasmic 
staining was then calculated. The IHC positive pixel count algorithm was useful in evaluating breast 
tissue IHC in particular if there is background or nonspecific DAB staining as Aperio software 
subtracted the background. Nuclei were also subtracted from the image (arrows).   





Figure 3-4: IHC Membrane algorithm 
Normal human lymph node was analysed using the IHC Membrane algorithm to quantify CXCR4 
membrane stain. The algorithm quantified the intensity of staining into four levels of intensity 
(0,1+, 2+ or 3+) and percentage of stained cells. The digital Quick Scores of CXCR4 membrane 
staining was then calculated.  
 




3.4 Results  
3.4.1 Manual microscopy of FOXP3 and CXCR4 IHC in human breast tissue 
In order to assess expression of FOXP3 and CXCR4 by breast cancer at a tissue 
level, 100 paraffin-embedded sections of human breast tissue were examined (21 
normal breast, 5 carcinoma in situ, 37 infiltrating carcinoma, 30 normal lymph 
nodes and 7 metastatic lymph nodes). 
Two anti-Foxp3 antibodies were tested on the same section of ductal breast 
carcinoma in order to identify the one, which gives stronger IHC staining in 
paraffin-embedded breast tissue (Figure 3-5) The result of IHC staining using both 
antibodies was comparable. However, the monoclonal mouse anti-human Foxp3 
antibody (clone 150D/E4; isotype Ig1, a cell culture supernatant) (A) had higher 
staining intensity and was chosen for further experiments. IHC was performed 
using a selected anti-Foxp3 antibody (Figure 3-5). FOXP3 expression has been 
previously established by Flp-In™ T-Rex™ -293 cells (Pekalski, 2009) which were 
used for positive control, demonstrating strong nuclear staining (Figure 3-6 A). 
Benign mammary epithelium (normal cells) had moderate to strong nuclear and 
cytoplasmic FOXP3 expression (Figure 3-6 D) while breast cancer cells had no or 
minimal nuclear staining and expression of FOXP3 transcription factor was 
observed mainly in the cytoplasm (Figure 3-6 F). FOXP3 positive T cells in the 
breast cancer infiltrate were provided as an internal positive control (Figure 3-6 
C). Ductal carcinoma in situ (DCIS) expressed more FOXP3 in the cell nuclei than 
invasive cancers, but less than benign breast (Figure 3-6 E).   
CXCR4 is predominantly a cell surface receptor, and IHC is likely to show cell 
surface expression with minimal cytoplasmic and perinuclear staining. 
Optimisation of the monoclonal anti-CXCR4 antibody (clone: 44716, isotype IgG2b, 
R&D) was carried out on human tissues (lymph node, tonsil, mammary 
epithelium) using various antibody dilutions (1:50, 1:100, 1:200, 1:300, 1:400) and 
antigen retrieval methods (no antigen retrieval, EDTA retrieval or citrate buffer 
retrieval).  Dilution of the anti-CXCR4 antibody (1:250) without antigen retrieval 




gave the best results. Positive control staining of normal human lymph node and 
tonsil demonstrated neat circumferential rings of CXCR4 around the cells (Figure 
3-7 A and B). Benign breast epithelial cells had less CXCR4 expression than cancer 
(Figure 3-7). However, IHC staining of CXCR4 on breast cancer tissues had 
significant cytoplasmic staining and background or nonspecific DAB staining 
(Figure 3-7 E). Therefore, Aperio digital image analysis was used to subtract the 
background.  






Figure 3-5: Selection of anti-Foxp3 antibody 
To identify an anti-Foxp3 antibody giving the strongest staining in paraffin-embedded breast tissue, 
two anti-Foxp3 antibodies were tested on the same section of ductal breast carcinoma: anti-Foxp3 
antibody (clone OD/E4 cell culture supernatant) at the optimum concentration of 1:5 in 20% of 
normal rabbit serum (A) and anti-Foxp3 antibody clone 326A/E7 from Abcam (B). The result of IHC 
staining using both antibodies were comparable. However, the monoclonal mouse anti-human 
Foxp3 antibody (clone 150D/E4; isotype Ig1, a cell culture supernatant) (A) had higher staining 
intensity and was chosen for further experiments. A section of invasive ductal carcinoma was used 
as negative control where no primary anti-Foxp3 antibody was used (Figure 3-6 B). 
 
 





Figure 3-6: IHC manual microscopy of FOXP3 in breast tissue 
A. Positive control: HEK-293 FOXP3 transfectants, B. negative control: no primary antibody, C. 
Internal positive control: FOXP3 positive cells in breast cancer inflammatory infiltrate, D. normal 
mammary duct, E. ductal carcinoma in situ, F. infiltrating ductal carcinoma. Tissue was stained by 
immunohistochemistry using monoclonal anti-Foxp3 antibody at the optimum concentration of 1:5 
in 20% of normal rabbit serum.  





Figure 3-7: IHC manual microscopy of CXCR4 in breast tissue 
A. Positive control: normal human lymph node, B. positive control: normal human tonsil, C. negative 
control: no primary antibody, D. normal mammary duct, E. ductal carcinoma in situ, F. infiltrating 
ductal carcinoma. Tissue was stained by immunohistochemistry using monoclonal anti-CXCR4 
antibody (R&D) at the optimum concentration of 1.250 in 20% of normal rabbit serum. Benign 
(normal). 




3.4.2 Digital microscopy of FOXP3 and CXCR4 IHC in human breast tissue 
Digital microscopy and image analysis enhance accuracy and reliability of HER-
2/neu IHC “quick scoring” (Bloom and Harrington, 2004). In order to validate the 
manual microscopy IHC interpretation and quantify FOXP3 and CXCR4 expression, 
Aperio digital image analysis was used. 
To exclude any DAB non-specific binding or false positives in paraffin-embedded 
human breast tissues, no primary and no secondary antibody controls were used. 
Sections were then examined by digital image analysis platform demonstrating no 



















Figure 3-8: Digital image analysis: IHC FOXP3 and CXCR4 without primary and 
secondary antibody negative controls.  
Sections of invasive ductal carcinoma were stained without primary and secondary antibodies. The 
ABC complex was incubated on the samples in the same way as usual. Aperio system was used to 
examine the section for nuclear and cytoplasmic FOXP3 and CXCR4 membrane expression. This 
experiment excluded any DAB non-specific binding or false positives.  
 




FOXP3 expression was assessed in nuclei, cytoplasm and inflammatory infiltrate. 
No staining was shown when omitting the primary Foxp3 antibody (Figure 3-9 A 
top panel). Staining with IgG1 for Foxp3 antibody excluded the presence of non-
specific antibody binding (Figure 3-9 A bottom panel). The nuclei of HEK293 
FOXP3 transfectants and inflammatory infiltrate around breast cancer sections 
were positive for FOXP3 and were used as positive controls (Figure 3-9 B panel). 
Breast cancer epithelium had no, or minimal, nuclear staining (Figure 3-10 C) and 
expression of the FOXP3 transcription factor was observed mainly in the 
cytoplasm (Figure 3-11 C). However, where nuclear FOXP3 expression was 
observed, it was mainly confined to certain areas of the malignant epithelium 
where nuclear translocation was not lost (arrow Figure 3-10 C). Staining, in benign 
breast tissue cells, was heterogeneous: only cytoplasmic, nuclear and cytoplasmic 
or only nuclear (Figure 3-10 D and Figure 3-11 D). Cytoplasmic FOXP3 expression 
was similar for benign and malignant tissues (Figure 3-11).  
Malignant epithelial cells, often forming ducts in a lymph node, provide evidence of 
metastatic disease (Figure 3-12 A). Seven metastatic lymph nodes were stained for 
FOXP3 expression and all analysed specimens expressed FOXP3. On average, 
nuclear staining (Figure 3-12 C, G) was negative or weak (score 0 or 1) and 0-10% 
(score 0-1) nuclei were stained. Above 80% (score 5) of cells expressed FOXP3 in 
the cytoplasm (Figure 3-12 D, H) and staining was weak to moderate (score 1 to 2).  
FOXP3 positive cells of inflammatory infiltrate were used for internal positive 
control. Staining was nuclear. On average, 22% of cells within inflammatory 
infiltrate were stained (Figure 3-13 D). There was no difference between total 
numbers or percentages of FOXP3 positively stained cells in benign (Figure 3-13 
B) and malignant (Figure 3-13 C) sections. 






Figure 3-9: Digital image IHC nuclear 
analysis of controls 
Panel A: FOXP3 negative control. Panel B: 
FOXP3 positive control. Left hand panel 
shows negative controls: normal human 
lymph node without the addition of primary 
anti-Foxp3 antibody (top) and the same 
section with IgG1 control (bottom). Right 
hand panel demonstrates positive controls: 
expression of FOXP3 by HEK-293 FOXP3 
transfectants (top) and normal human 
lymph node (bottom). Sections in right hand 
panel were stained using monoclonal Foxp3 
antibody (clone 0D/E4 cell culture 
supernatant) at the optimum concentration 
of 1:5 in 20% of normal rabbit serum. All 
sections were scanned and analysed using 
Aperio system. 
 





Figure 3-10: Digital image IHC nuclear analysis of human breast tissue. 
A, C: FOXP3 in breast cancer. B, D: FOXP3 in benign breast tissue. A, B: Tissue sections were stained 
with monoclonal anti-Foxp3 antibody at the optimum concentration of 1:5 in 20% of normal rabbit 
serum and scanned using Aperio scanner. The digital images were analysed with the IHC nuclear 
algorithm and staining was automatically quantified. The quick scores were calculated and plotted 
(E). Error bars represent SD; the P value indicates the significance of the change from benign 
(normal) cells. The arrow (C) points to the nuclear FOXP3 staining in breast cancer epithelium 
whch were limited to certain areas  (arrow).  





Figure 3-11: Digital image IHC cytoplasmic analysis of human breast tissue. 
A, C: FOXP3 in malignant breast tissue. B, D: FOXP3 in benign breast tissue. Tissue sections were 
stained with monoclonal anti-Foxp3 antibody (clone 0D/E4 cell culture supernatant) at the 
optimum concentration of 1:5 in 20% of normal rabbit serum, scanned using Aperio digital 
scanner; the digital image was analysed with IHC positive pixel count algorithm and staining was 
automatically quantified. The quick scores were calculated and plotted (E). Error bars represent SD. 
Cytoplasmic FOXP3 expression was similar for benign and malignant tissues. 





Figure 3-12: Digital image IHC 
analysis of lymph node metastases.  
A-D: early metastases. E-H: advanced 
metastases. Sections were stained with 
monoclonal anti-Foxp3 antibody (1:5 in 
20%), scanned using Aperio, digital images 
were analysed and staining was 
automatically quantified. 





Figure 3-13: Digital image IHC nuclear analysis of FOXP3 in inflammatory cells in 
human breast tissue 
A. Detection of leucocytes in the breast tissue, B. FOXP3 positive infiltrating cells in benign breast 
tissue, C. FOXP3 positive infiltrate in breast cancer, D. percentage of FOXP3 positive infiltrating 
cells, E. total number of FOXP3 positive infiltrating cells. Tissue sections were stained with 
monoclonal anti-Foxp3 antibody at the concentration of 1:5 in 20% of normal rabbit serum, 
scanned using Aperio digital scanner; the digital image was analysed with the IHC nuclear 
algorithm and staining was automatically quantified for percentage and total amount of FOXP3 
positive nuclei. The results were plotted using box plots (D, E). The whiskers on the box plots 
represent SD; *P>0.05. 
 




Table 3-3: Summary of the IHC FOXP3 results. The columns represent the total 
number of sections in each tissue type group, the overall percentage of stained 
sections in each group, nuclear and cytoplasmic MQS in each tissue type group.  
 
Figure 3-14: Graphic representation of FOXP3 expression in human breast tissue. 
The MQS were calculated by digital microscopy: red bars represent the nuclear quick scores (0-8) 
stacked with green bars representing the cytoplasmic quick scores (1-8). Error bars correspond to 
SD. 




Overall, 90% of benign and 77.77% of malignant breast samples expressed FOXP3. 
Out of these, about 70% of cancers and 100% of benign specimens expressed 
FOXP3 in the nuclei. Additionally, all samples expressed FOXP3 in the cytoplasm.  
Total FOXP3 expression (nuclear and cytoplasmic) was no different (p>0.05) 
between cancer and benign breast tissue. However, when only nuclear staining 
was compared, there was a statistically significant difference between these two 
tissue types (p<0.05). Normal breast epithelial cells had significantly greater 
nuclear FOXP3 expression than invasive ductal carcinoma: digital median quick 
score (MQS) 6.8 versus (vs.) 3.2 (p<0.05) and lymph node metastases: MQS 6.8 vs. 
1.7 (p<0.05) (Figure 3-14). Primary ductal cancers expressed more FOXP3 in their 
nuclei than lymph nodes secondaries: MQS 3.2 vs. 1.7 (p<0.05). The nuclei of ductal 
carcinoma in situ (DCIS) cells expressed FOXP3 similarly to invasive cancer cells: 
MQS 3.7 vs. 3.2 (Figure 3-14). On manual pathological assessment cancers showing 
early signs of metastasis (vascular and perineural invasion) expressed significantly 
less FOXP3 than tumours where vascular and perineural invasion was not 
observed (MQS 4 vs. 2). There was a trend towards decreasing nuclear FOXP3 
expression with increase in tumour size although this was not statistically 
significant. There was no difference in nuclear FOXP3 expression between various 
cancer types (p=0.41). However, lobular carcinoma had generally weaker nuclear 
staining for FOXP3 than ductal carcinoma. Oestrogen and progesterone positivity 
was not correlated with nuclear FOXP3 expression (p=0.51, p=0.36 respectively). 
The median age of patients was 67 and linear regression analysis showed no 
relationship between nuclear quick score and age (p=0.61).  
Cytoplasmic expression of FOXP3 was not significantly different between benign 
specimens (MQS=6.4), DCISs (MQS=6.5), ductal cancers (MQS=6.2) and lymph 
node metastases (MQS=5.2). However, in lobular carcinoma the cytoplasmic 
expression of FOXP3 was significantly (p=0.03) decreased (MSQ=3.3) compared to 
the benign breast epithelium.  




There was no significant difference between total numbers or percentages of 
FOXP3 positively stained cells within inflammatory infiltrate surrounding normal 
ducts (Figure 3-13 B) and ductal cancers (Figure 3-12 C).  
Aperio digital image analysis was performed in order to compare its results to the 
manual microscopy CXCR4 IHC and quantify CXCR4 expression. There was no 
staining when omitting primary anti-CXCR4 (Figure 3-15 A) antibody. Use of IgG2b 
isotype control for the anti-CXCR4 antibody excluded the presence of non-specific 
antibody binding (Figure 3-15B). Normal human lymph node was used as a 
positive control (Figure 3-15 C).  
Normal breast epithelial cells expressed less CXCR4 than invasive cancer cells 
(Figure 3-15 F: cytoplasmic median quick score - MQS (3 versus (vs.) 6 (p<0.05) 
and lymph node metastatic cells: MQS 3 vs. 6.5 (p<0.05). Lymph node metastases 
expressed more CXCR4 than primary invasive cancers: MQS 8 vs. 5 (p<0.05). DCIS 
expressed more CXCR4 than normal breast epithelial cells but it was not significant 
(p=0.6). Prognostic indicators of breast carcinoma like lymph node status and 
distant metastasis were associated with increased CXCR4 expression (p<0.05). 
Membrane CXCR4 expression was significantly correlated with early signs of 
metastases (vascular and neural invasion) and established lymph nodes metastasis 
when analysed manually. Linear regression analysis did not show statistically 
significant correlation between membrane CXCR4 expression and the type or 
grade of tumours, receptor status or patients’ age. 





Figure 3-15: Digital image IHC membrane analysis of CXCR4 
A, B: negative controls, C: positive control, D: breast cancer, E: benign breast tissue. Tissue sections 
were stained with monoclonal anti-CXCR4 antibody (R&D) at the optimum concentration of 1:250 
in 20% of normal rabbit serum. Slides were scanned using Aperio digital scanner; digital images 
were analysed with IHC membrane algorithm and staining was automatically quantified. The quick 
scores were calculated and plotted (F). Error bars represent SD; the P value indicates the 
significance of the change from benign (normal) cells.  




3.4.3 Comparative expression of FOXP3 and CXCR4 in breast tissue 
Analysis of the correlation between FOXP3 and CXCR4 manual and digital MQS was 
performed for nuclear FOXP3 and membrane as well as cytoplasmic CXCR4 
staining (Figure 3-16). In order to assess only the nuclear expression of FOXP3 in 
breast tissue epithelial cells, inflammatory cells, cytoplasmic FOXP3 staining and 
normal lymph nodes were excluded from calculations. More malignant sections 
were analysed using Aperio system than by a consultant pathologist because a 
number of additional sections were stained after the manual analysis. However, 
some sections could not be scanned using the Aperio system due to their uneven 
surface or excessive thickness of the sections. Early signs of metastasis (vascular 
and perineural invasion) were only assessed manually. The results demonstrated 
inverse correlation between MQS for nuclear FOXP3 and membrane CXCR4 
staining.  






Figure 3-16: Manual and digital IHC analysis: FOXP3 versus CXCR4 expression in 
breast tissue.  
Correlation of FOXP3 and CXCR4 manual (A) and digital (B) median quick scores (MQS) for nuclear 
FOXP3 and membrane CXCR4 staining was performed.  




3.4.4  CXCR4 protein expression 
Increased CXCR4 expression in breast cancer has been already confirmed at the 
tissue level (section 3.4.2). In order to examine CXCR4 expression at the cell level 
immunofluorescence and flow cytometry were performed. 
For immunofluorescence analysis of breast cancer cells, CXCR4 was stained green 
using primary anti-CXCR4 antibody (1:250 in 20% of NRS, R&D) and FITC 
conjugated secondary antibody. The nuclei were counter-stained blue with DAPI. 
Both immortalised benign mammary epithelial cells (MCF10A) and breast cancer 
cells (MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231) demonstrated CXCR4 
membrane expression. The fluorescence intensity of CXCR4 was measured with 
Leica software (LSCM) and expressed graphically (Figure 3-17). 
The fluorescence intensity of CXCR4 staining on TMD-MB-231, LMD-MB-231 was 
so high that the setting on Leica TCSSP2 UV confocal microscope had to be reset to 
increase the brightness threshold in order to take images and quantify the 
fluorescence intensity of these cells. There was a statistically significant (p<0.05) 
increase in CXCR4 expression on MDA-MB-231, TMD-MB-231, LMD-MB-231 breast 
cancer cells compared to MCF-10A normal breast epithelial cells (Figure 3-17). 




In order to examine surface CXCR4 expression on a range of breast cancer cells, 
flow cytometry was used. 
Lymphocytes are known to be CXCR4 expressing cells and to undergo CXCL12 
induced migration and adhesion. The Jurkat T-lymphocyte cell line was screened 
for CXCR4 expression by flow cytometry with anti-CXCR4 antibody (Mab 173) and 
showed high levels of the receptor. Jurkat cells were therefore used as a positive 
control in FACS experiments (Figure 3-18). Flow cytometric analysis revealed that 
all examined cells expressed CXCR4 on their surface (Figure 3-18). 
Microbeads with a known number of antibody binding sites per bead were used to 
compare the anti-CXCR4 antibody binding sites (proportional to CXCR4 
expression) of normal breast cells MCF-10A with breast cancer cells: MCF-7, MDA-
MB-231, TMD-MB-231, LMD-MB-231. Each cell line was also analysed with isotype 
control antibodies. By analysing the Quantum Simply Cellular microbeads with a 
known number of anti-CXCR4 antibody binding complexes per bead at the same 
time, it was possible to calculate the number of anti-CXCR4 antibody binding sites 
on each cell line. The number of anti-CXCR4 antibody binding sites is directly 
proportional to the CXCR4 expression on the cell surface. Flow cytometric analysis 
demonstrated that MCF-10A, MCF-7 and MDA-MB-231 cells had little surface 
CXCR4 expression and it was not significantly different to the isotype control. 
TMD-231 and LMD-231 breast cancer cells expressed significantly more CXCR4 
compared with MCF-10A normal breast cells and than the isotype control (p<0.05) 
(Figure 3-20). 





Figure 3-17: CXCR4 immunofluorescence staining of breast cell lines.  
Cells were stained with primary monoclonal anti-CXCR4 antibody (1:250 in 20% of NRS, Abcam) 
and FITC conjugated secondary antibody. Images in the right upper corner represent addition of 
DAPI (blue) counter-stain to visualize nuclei. Leica TCSSP2 UV confocal microscope x20 
magnification was used. CXCR4 expression was quantified by measuring fluorescence intensity (0-
255) and dividing it by area. Quantified CXCR4 expression was plotted (graph). Error bars 
represent SD. P value indicates the significance of the change from benign MCF-10A cells (*P<0.05). 





Figure 3-18: Surface CXCR4 expression of Jurkat T-cells by Flow Cytometry.  
CXCR4 expression (FL1-H) is confirmed to be high on the population of Jurkat cells. Black plot – 
Isotype control antibody, red plot – Anti-CXCR4 antibody (Mab173), n=3. 
 
 
Figure 3-19: Representative histograms of surface expression of CXCR4 on breast 
cancer cells by flow cytometry.  
MDA-231, MCF-7, TMD-231 and LMD-231 demonstrated CXCR4 expression (FL1-H) as analysed by 
flow cytometry using an anti-CXCR4 antibody (Mab173). For all histograms, Black plot – Isotype 
control, Red plot – Anti-CXCR4 antibody, n=3. 
 
 







Figure 3-20: The relative number of anti-CXCR4 binding complexes on breast 
cancer cell lines.  
MCF-10A and MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231 were analysed by flow cytometry 
using an anti-CXCR4 antibody (Mab173) and FITC-conjugated secondary antibody. Each cell line is 
also analysed with isotype control antibodies. By analysing the Quantum Simply Cellular 
microbeads with a known number of anti-CXCR4 antibody binding complexes per bead at the same 
time, it was possible to calculate the number of anti-CXCR4 antibody binding sites on each cell line. 
The number of anti-CXCR4 antibody binding sites is proportional to the CXCR4 expression on the 
cell surface. The histogram is representative data from 2 similar experiments; bars show SD of 
triplicate data points. MCF-10A, MCF-7 and MDA-MB-231 cells had little surface CXCR4 expression 
and it was not significantly different to the isotype control. TMD-231 and LMD-231 breast cancer 
cells expressed significantly more CXCR4 compared with MCF-10A normal breast cells and than 
isotype control (p<0.05). 




3.4.5 FOXP3 and CXCR4 mRNA expression 
In order to examine FOXP3 expression in breast cancer cells at the mRNA level, 
further experiments were carried out using conventional and qPCR.   
RNA was isolated from each cell line and its integrity was verified by agarose gel 
electrophoresis (Figure 3-21). Following cDNA synthesis, a panel of breast cancer 
cell lines (MCF-10A, MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231) were 
subjected to standard PCR and FOXP3 expression was compared to positive 
control, which was FOXP3 cDNA and as expected gave significant FOXP3 
expression (Figure 3-22). FOXP3 expression was detected in all breast cancer cell 
lines examined.  
To verify the specificity of manually designed FOXP3 primers, 100 µl conventional 
PCR reaction was performed using MCF-7 and MDA-MB-231 cDNA amplified using 
FOXP3 primers. The PCR products were excised from the agarose gel and 
sequenced by GeneService confirming 89% homology of the amplified product 
with the FOXP3 sequence (Figure 3-23). 






















Figure 3-21: Confirmation of RNA integrity 
After extraction from breast cancer cells using the Trizol Reagent (Invitrogen), RNA was quantified 
with nanodrop software and its quality was confirmed by electrophoresis on a 1.5% agarose gel, 
with a DNA ladder to determine the size of bands. Sharp 28S and 18S bands with minimal smearing 
indicate good integrity of the RNA. 
 





Figure 3-22: Detection of FOXP3 mRNA expression in breast cancer cell lines  
MCF-10A, MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231 cell lines were tested for FOXP3 
mRNA expression. First, mRNA was extracted and reverse transcribed to cDNA. Then, PCR 
performed using GAPDH specific primers as positive controls confirmed GAPDH size of about 
550bp (A).  The reaction performed using specific FOXP3 forward and reverse primers revealed (B) 
FOXP3 mRNA expression in all cancer cell lines studied. Primers used (VH Bio Ltd Gateshead): 
forward primer: 5‘-CAAATGGTGTCTGCAAGTGG-3’, reverse primer: 5’- ATTGAGTGTCCGCTGCTTCT 
3’ (product length 500bp, product region 772-1271). A reaction without cDNA template was 
performed as a negative control (NTC). The reaction with FOXP3 cDNA (positive control) confirmed 











Figure 3-23: Determination of FOXP3 primers specificity  
Normal PCR reaction was performed in 100 µl volume, using MCF-7 and MDA-MB-231 cDNA 
amplified using FOXP3 primers with tested FOXP3 primers. PCR products were excised from the 
agarose gel and sequenced by GeneService confirming 89% homology of amplified product with 
FOXP3 sequence. 




3.4.5.1 Validation of the real-time PCR reaction for FOXP3 and CXCR4 assays 
Having detected FOXP3 mRNA in breast cancer cell lines using normal PCR, further 
experiments to quantify the amount of FOXP3 and CXCR4 mRNA were performed 
using real-time PCR. FOXP3 and CXCR4 TaqMan assays were purchased from 
Applied Biosystems. GAPDH assay was used as internal control. It was first 
necessary to determine whether the pair of assays could be used together in the 
experiments. In order to establish that, a validation experiment was performed 
based on serial dilutions of the DNA template (Figure 3-24 A, B). The efficiency of 
qPCR reaction was determined from the equation: Eff=10(-1/slope)–1 
The qPCR efficiency should be between 90 and 100%, which means that the slope 
between linear phases of amplification graphs should be between -3.6 and -3.1. 
Slopes of -3.56, -3.27 and -3.41 indicated that efficiency of real-time PCR reaction 
was higher then 90%. The qPCR provided evidence that the chosen pair of assays 
(FOXP3 + GAPDH or CXCR4 + GAPDH), performed with almost the same efficiency 
during qPCR could be used for screening of breast cell lines for FOXP3 and CXCR4 
mRNA expression.  







Figure 3-24: Representative amplification plots and a standard curve for real-time 
PCR detection of FOXP3 and CXCR4 in diluted samples. 
Graph demonstrates how template cDNA concentration proportionally affects cycle threshold (CT). 
The gradients obtained from the optimisation experiments were acceptable for calculating ∆∆CT 
values. The standard curve was graphically represented as a semi-log regression line plot of CT 
value versus log of input nucleic acid.  Slopes of -3.56, -3.27 and -3.41 indicated a qPCR reaction 








3.4.5.2  FOXP3 and CXCR4 mRNA expression in breast cells 
Following the validation experiment, real-time PCR was performed to determine 
expression of FOXP3 and CXCR4 mRNA on a range of breast cancer cell lines. The 
housekeeping gene GAPDH was used as a control throughout this experiment. The 
pairs of verified primer/probe specific for FOXP3 and CXCR4 (TaqMan, Applied 
Biosystems) were used to perform absolute quantification of FOXP3 and CXCR4 
mRNA expression. Expression of FOXP3 and CXCR4 mRNA was revealed in all 
tumour cell lines studied. FOXP3 expression in all cancer cell lines analysed was 
increased but not significantly different with reference to MCF10, an immortalised 
human mammary epithelial cell line. CXCR4 expression was significantly increased 
in all cancer cell lines analysed with reference to MCF10A (Figure 3-25). The 
results of qPCR FOXP3 mRNA expression were inconsistent with FOXP3 protein 
expression. FOXP3 protein expression, which was studied using 
immunofluorescence and immunohistochemistry, showed that cancer cell lines 
expressed less FOXP3 protein than normal mammary cells. 
 






Figure 3-25: FOXP3 and CXCR4 mRNA expression in breast cells 
FOXP3 (A) and CXCR4 (B) mRNA expressions in a range of breast cell lines quantified by qPCR. 
Results were normalised to GAPDH in relation to MCF10A as an immortalised human mammary 
epithelial cells. Rest 2008 and Prism 3 software was used for statistical analysis. Graph bars 
represent average fold expression obtained from four independent experiments. Error bars 
represent SD; P values indicate significant change from control cells.  





3.5.1 Expression of FOXP3 and CXCR4 in human breast tissue  
The existence of FOXP3 expression in epithelial tissues remains controversial. The 
majority of authors describe FOXP3 expression in normal human breast tissue. 
However, considerable confusion persists in literature regarding FOXP3 
expression in human cancers. Some describe increased FOXP3 expression in 
cancers (Merlo A, 2009, 2005, Gupta et al., 2007), others state the opposite (Zuo et 
al., 2007b, Zuo et al., 2007d). There are reports describing only negligible FOXP3 
expression in breast tissue (Wolf D, 2010) and studies, based on genetic animal 
model, excluding expression of FOXP3 in nonhematopoietic tissues, like breast 
(Kim et al., 2009a).  
There are at least three reasons for the contradictory evidence on FOXP3 
expression in cancer tissue.  
The first is whether cytoplasmic or nuclear FOXP3 is analysed. FOXP3 is a 
transcription factor and its functional expression is nuclear whereas role of the 
cytoplasmic FOXP3 remains unknown. Those who observed decreased FOXP3 
expression in breast cancer (Zuo et al., 2007d, Zuo et al., 2007b) analysed only its 
nuclear expression; those who demonstrated equal or increased expression of 
FOXP3 in cancer (Wolf D, 2010, Andrea Merlo and Elda Tagliabue, 2009) examined 
its total expression: nuclear and cytoplasmic. To overcome this problem in this 
study, nuclear and cytoplasmic were analysed separately using both manual and 
digital microscopy. Aperio ScanScope digital microscopy system not only increased 
reproducibility, accuracy and objectivity, but also allowed it on precise separate 
analysis of FOXP3 expression in cytoplasm, nuclei and inflammatory infiltrate. 
Overall, 90% of benign and 78% of malignant breast tissue samples expressed 
FOXP3. Out of those, about 70% of cancers and 100% of benign specimens 
expressed FOXP3 in the nuclei and all samples expressed FOXP3 in the cytoplasm. 
In malignant sections with nuclear FOXP3 expression, it was weak and in limited 
areas of the epithelium. It may indicate a mutation of specific cells within the 
cancer epithelium. Total FOXP3 expression (nuclear and cytoplasmic) was no 




significantly different between cancer and benign breast tissue. However, when 
nuclear staining was compared, benign breast epithelial cells had significantly 
more nuclear FOXP3 expression than invasive ductal carcinoma.  
The second reason for the confusion is the use of different anti-FOXP3 antibodies 
in immunohistochemical staining. A recent study showed that FOXP3 
immunohistochemistry on formalin-fixed paraffin-embedded tissue has poor 
correlation between monoclonal antibodies 236A/E7 and Abcam 22510 used for 
staining sections of different organs (Woo et al., 2008). An assessment of 
specificity and sensitivity of several anti-FOXP3 monoclonal antibodies, including 
236A/E7, hFOXY, eBio7979, and FJK-16s for immunohistochemistry staining in 
both human normal epithelial cells and cancer cells confirmed the specificity of 
236A/E7 for FOXP3 using cells with silenced FOXP3 (Wang L, 2009). 
The third reason for the controversy is the presence of FOXP3 positive T cells in 
the cancer inflammatory infiltrate. As a result, the increased expression of FOXP3 
in breast cancer (Merlo A, 2009, Ohara et al., 2009, Bates et al., 2006) may be 
related to the strong FOXP3 expression of the inflammatory cells around tumours 
rather than FOXP3 expression on the epithelial cells. This finding makes the 
interpretation of the gene expression data of FOXP3 expression in tumours 
difficult. A FOXP3 mRNA variant lacking exons 3 and 4 has been identified in 
tumour cell lines but not in CD4 positive FOXP3 positive T cells (Chen C, 2006). In 
contrary to the previously published work (Merlo A, 2009), in this study there was 
not statistically significant difference between total numbers or percentages of 
FOXP3 positively stained cells within the inflammatory infiltrate surrounding 
normal duct and ductal cancer. However, it may be related to the local 
inflammatory response, which is a physiological reaction to the biopsy in the 
breast clinic.  
3.5.2 CXCR4 protein expression in breast cancer cells  
Cytoplasmic and nuclear CXCR4 expression in cancer cells has been observed in 
various cancers (Cabioglu et al., 2005a, Cabioglu et al., 2005c, Na et al., 2008, 




Yoshitake et al., 2008). As expected, we observed strong membrane and 
cytoplasmic CXCR4 expression in cancer cells. The opposite was true for normal 
breast cells. Nevertheless, cytoplasmic CXCR4 expression was thought to be critical 
for lymph node metastasis and the patients' poor prognosis compared to nuclear 
expression of the receptor. CXCR4 localization at the plasma membrane and 
intracellular vesicle (cytoplasm) were observed in leukocyte cell lines with 
enforced CXCR4 expression and CXCL12 induced polarization of CXCR4 to the edge 
of migrating leukocyte cells (van Buul et al., 2003). Therefore, cytoplasmic CXCR4 
expression may be more important for migration of cancer cells contributing to 
lymph node metastasis and unfavourable prognosis. While nuclear CXCR4 
expression occurs in normal and cancer tissues (Salvucci et al., 2006), its function 
is unknown. The splice variants of chemokines without a signal peptide 
translocating into the nucleus have been identified (Gortz et al., 2002). Similarly, 
the nuclear CXCR4 accumulation may lack a signal peptide and may not be 
functional. There are several identified factors which may induce CXCR4 
expression: NF-kappa B (Helbig et al., 2003), c-erbB-2 (Li et al., 2004), hypoxia-
inducible factor 1 (Schioppa et al., 2003) nitric oxide (Yasuoka et al., 2008). In this 
study nuclear CXCR4 expression was also observed but it was not analysed.  
3.5.3 Relationship between FOXP3 and CXCR4 expression and clinico-pathological 
factors of breast cancer 
This study confirmed that normal breast epithelial cells had significantly greater 
FOXP3 nuclear expression than invasive cancers and the opposite was true for 
CXCR4 membrane expression. Correlation of FOXP3 and CXCR4 quick scores 
(MQS) were done for nuclear and membrane staining respectively and results 
demonstrated statistically significant inverse correlation between MQS for nuclear 
FOXP3 and membrane CXCR4 staining.  
Recently it has been proposed that overall FOXP3 expression in breast cancer 
tissue is associated with worse prognosis and spread of cancer to lymph nodes 
(Andrea Merlo and Elda Tagliabue, 2009).  However, this work suggested that 




nuclear FOXP3 expression was significantly decreased in cancers showing early 
signs of metastasis (vascular and perineural invasion) when compared to tumours 
where vascular and perineural invasion were not observed. In addition, the 
prognostic indicators of breast carcinoma like lymph node status and distant 
metastasis were associated with decreased nuclear FOXP3 expression and 
increased cytoplasmic CXCR4 expression.  
3.5.4 FOXP3 and CXCR4 expression at the mRNA level 
We observed FOXP3 and CXCR4 mRNA expression in all tumour cells studied. 
FOXP3 expression was elevated in all cancer cell lines analysed, with reference to 
MCF10A as an immortalised benign human mammary epithelial cells, but it was 
not significant. This finding was contradictory to decreased FOXP3 expression at 
protein level. It may be that in cancer the production of FOXP3 is increased 
because of dysfunctional nature of this protein.  
Recent data showed that quantification of Foxp3 mRNA in tissues represented an 
independent prognostic variable in terms of overall survival and progression-free 
survival. However, those data were mostly focused on the expression of Foxp3 in 
Tregs (Wolf et al., 2005). The large number of Tregs infiltrated in cancerous tissues 
was associated with a dismal prognosis in ovarian cancer. Quantification of Foxp3 
mRNA serve as a surrogate marker for the ovarian cancer tissue infiltration grade 
by Tregs, and immunohistochemical staining of Foxp3 on a tissue microarray 
corroborated Foxp3 mRNA data in terms of the identification of tumours with 
Foxp3-positive Tregs (Wolf et al., 2005). 
CXCR4 expression was significantly increased in all cancer cell lines analysed with 
reference to MCF10A.  




3.6 Summary of observations 
 Normal breast tissue had significantly greater FOXP3 nuclear expression than 
cancers and the opposite was true for CXCR4 cytoplasmic expression. 
 There was an inverse correlation between nuclear FOXP3 and cytoplasmic 
CXCR4 staining in human breast tissue. 
 Local and distal metastasis were associated with decreased nuclear FOXP3 
and increased cytoplasmic CXCR4 expression. 
 There was a significant increase in CXCR4 cytoplasmic expression on breast 
cancer cell lines. 
 FOXP3 mRNA expression was not significantly elevated in cancer cells and 
the opposite was true for CXCR4 mRNA expression. 
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4 Failure of FOXP3 translocation to the nucleus in 
breast cancer  
4.1 Introduction 
4.1.1 Nuclear translocation of FOXP3 
Intracellular trafficking of FOXP3 to the nucleus is essential for expression of this 
protein in its active form and the maintenance of homeostasis. FOXP3 is 
synthesised in the cytoplasm but functions by interacting with DNA in the nucleus. 
Following expression it is rapidly translocated to the nucleus and binds to 
chromatin. There are three distinct FOXP3 domains that contribute to its nuclear 
transport (Hancock W, 2009). The first domain (Domain 1) comprises the C-
terminal 12 amino acids. The second domain (Domain 2) is located immediately N-
terminal to the forkhead domain (FHD), recently reported to be a binding site for 
the runt-related transcription factor 1/acute myeloid leukaemia 1 (Runx1/AML1). 
The third domain (Domain 3) is located within the N-terminal first 51 amino acids.  
FOXP3 mutant protein missing domains 1, 2, and 3 is found almost exclusively in 
the cytoplasm with only trace levels in the nuclei (Hancock W, 2009). Identification 
of factors which interact with these domains will not only facilitate our 
understanding of how FOXP3 achieves its nuclear transport to regulate the 
expression of target gene, but may lead to therapeutic modulation of these systems 
and provide a novel approach to cancer treatment. Indeed, it has been 
demonstrated that the disruption of nuclear localization is sufficient to abrogate 
growth inhibition by FOXP3 in prostate cancer (Wang L, 2009). 
4.1.2 Failure of nuclear FOXP3 translocation in cancer 
The nuclear expression of FOXP3 in human benign breast, respiratory and prostate 
tissue is well documented (Chen G, 2008). However, immunocytochemical staining 
of tumour cell lines revealed predominant cytoplasmic expression of breast, colon, 
pancreas, lung cancer cell lines (Karanikas et al., 2008). There is disagreement 
amongst researchers with regards to the immunohistochemistry of malignant 




breast epithelium: some describe nuclear staining only (Zuo et al., 2007b, Zuo et 
al., 2007d), others state that expression of FOXP3 in breast cancer is 
predominantly cytoplasmic (Andrea Merlo and Elda Tagliabue, 2009). 
Immunohistochemistry of other human malignancies detected nuclear FOXP3 
staining in prostate cancers (Wang L, 209),  mixed cytoplasmic and nuclear FOXP3 
staining in the pancreatic cancers (Hinz et al., 2007) and solely cytoplasmic 
staining in ovarian cancers (Zhang and Sun, 2010).  
4.1.3 Expression and sub-cellular distribution of FOXP3 isoforms 
The identification of splice variant forms of the protein suggests an additional level 
of complexity surrounding the biology of FOXP3. In contrast to mice, human Treg 
cells always display expression of at least two FOXP3 isoforms. Both are expressed 
at similar levels.  One represents the full-length isoform (FOXP3fl), while the other 
isoform lacks exon 2 (FOXP3D2). Recently, two further splice variants have been 
described: missing exon 7 (FOXP3D7) (Kaur et al.) and missing exons 2 and 7 
(FOXP3D2D7) (Mailer et al., 2009). All isoforms are effectively translocated into 
the nucleus in mammalian cells (Mailer et al., 2009). Analysis by fluorescence 
microscopy of HEK293T cells transfected with FOXP3fl, FOXP3D2, FOXP3D7 and 
FOXP3D2D7 constructs showed bright staining of the nucleus, while GFP-
FOXP3DFKH, a truncated version lacking the DNA binding domain was retained in 
the cytoplasm (Mailer et al., 2009). Splice variants FOXP3fl, FOXP3D2, FOXP3D7 
and FOXP3D2D7 bind to transcription factors, including NFAT, NF-kB and RUNX1. 
While FOXP3D2D7 lacks its suppressive functions, it is able to inhibit FOXP3fl in a 
dominant negative manner (Mailer et al., 2009). Recent data obtained by crystal 
structure analysis and co-immunoprecipitation experiments mapped the binding 
site of the NFAT RelA domain to the forkhead domain of FOXP3 (Wu et al., 2006), 
whereas RUNX1 targets a region starting at the c-terminus of exon 7. Isoforms 
FOXP3D2 and FOXP3D2D7 are overexpressed by certain malignant cells, eg. in 
Sezary Syndrome, an aggressive variant of cutaneous T cell lymphoma, the 
transformed T cells express FOXP3D2 and FOXP3D2D7. Moreover, FOXP3 also 




plays a role in breast cancer, as FOXP3fl acts as repressor of Her-2 (Zuo et al., 
2007c). Future studies have to establish, however, whether the isoform actually 
plays a role in cancer pathogenesis. 
4.1.4 Expression and sub-cellular distribution of FOXP3 following mutations  
In mice, a Foxp3 frameshift mutation in the forkhead domain results in lethality in 
hemizygous males 16 to 25 days after birth (Brunkow et al., 2001). The mutation 
in some human IPEX patients (Immunodysregulation, Polyendocrinopathy, and 
Enteropathy, X-linked) is analogous as they cause frameshift and early termination 
of translation (Brunkow et al., 2001, Chatila et al., 2000, Bennett et al., 2001b, 
Bennett et al., 2001a, Wildin et al., 2001). In breast cancer patients, a total of 27 
somatic mutations in all 11 coding exons and intron-exon boundary regions have 
been identified in 36% of 65 patients by PCR (Zuo et al., 2007d, Zuo et al., 2007b). 
In these mutations, there are 18 nonsynonymous mutations, 3 synonymous 
mutations and 6 mutations in the intron-exon junction 12 (Zuo et al., 2007b). 
Interestingly, the mutations are not randomly distributed in the FOXP3 gene and 
the overwhelming majority of them are either in the functional domains or within 
intron 11, which can affect the forkhead domain sequence (Zuo et al., 2007b). In 
prostate FOXP3 gene plays a critical role in suppressing cancerous transformation 
of this gland (Wang L, 2009). Four somatic FOXP3 mutations were identified in 
prostate cancer and three of them prevent nuclear localization of FOXP3, which is a 
major mechanism to inactivate FOXP3 tumour suppressor function (Wang L, 209, 
Wang L, 2009). The exact role of the somatic FOXP3 mutations in breast cancer 
remains unknown. The question whether, like in prostate cancer, it is responsible 
for failure of nuclear localization of FOXP3 protein, is yet to be answered.   




4.2 Specific Aims and Objectives 
 To study sub-cellular location of FOXP3 in breast cancer cells  
 To study sub-cellular location of FOXP3 on breast cancer cells following 
induction of its expression with cytokines and stable transfection 
 To analyse nuclear localization sequences of FOXP3 gene in breast cancer for 
presence of mutations and isoforms.  
 





4.3.1 Sequencing of FOXP3  
The samples of cDNA from breast cancer lines (HMEPC, MCF10A, MCF-7, MDA-MB-
231, TMD-231, LMD-231) were amplified by conventional PCR and sequenced. In 
the initial experiments Taq DNA polymerase was used. The results were 
subsequently verified using thermostable Pfu (Pyrococcus furiosus) DNA 
polymerase with 'proofreading' properties. Taq (Thermus aquaticus) polymerase 
has an error rate of about 1.3 x 10-5 and mutation frequency of 5.1 %, Therefore, it 
is possible that the mutations observed in the initial experiments were introduced 
and amplified during the course of the experiment. Thermostable Pfu (Pyrococcus 
furiosus) DNA Polymerase with 3  →5  exonuclease proofreading activity exhibits a 
higher fidelity than Taq DNA Polymerase. It has an error rate of about 1.8 x 10-5 – 8 
x 10-7 and 5.1–0.3% mutation frequency. Automated DNA sequencing was used to 
determine the sequence of DNA within cDNA encoding 3 domains of nuclear 
localization within FOXP3 gene. Sequencing was carried out by GeneService 
(www.geneservice.co.uk) and Bioscience (www.bioscience.co.uk) and 
chromatograms were produced using the Geospiza’s FinchTV v.1.4.0 freeware 
software (http://www.geospiza.com). The sequences were compared with FOXP3 
reference gene (accession number: A277993). 
4.3.2 Primer Design for sequencing of FOXP3 domains 
All FOXP3 primers were designed manually. Nucleotide search tool from 
www.ncbi.nlm.nih.gov was used to search for target sequence of nucleotides for 
FOXP3 locus (AF277993). “Perfect Primers Design” tool (Invitrogen: 
www.tools.invitrogen.com), was used to determine final primer sequence. 
Forward and reverse FOXP3 primers were designed to have approximately the 
same number of G and C components and to be 15-35 nucleotides in length. 
Primers were designed with a G-C content producing a melting temperature (Tm) 
of 60oC. Table 4-1 summarises 3 pairs of FOXP3 primers designed to sequence 
three nuclear localisation domains (NLD). 




















Reverse primer AGGCAAGACAGTGGAAACCTCACT 1 
 
Table 4-1: Primer sequences used in conventional PCR. 





Figure 4-1: Primer design for sequencing FOXP3 Nuclear Localization Domains. 
Based on the murine FOXP3 structure there are three distinct FOXP3 domains that contribute to its 
nuclear transport (Hancock W, 2009). The first domain (Domain 1 - red) comprises the C-terminal 
12 amino acids. The second domain (Domain 2 - green) is located immediately N-terminal to the 
forkhead domain (FHD) and the third (Domain 3 - blue) is located within the N-terminal first 51 
amino acids. FOXP3 mutant protein missing domains 1, 2, and 3 is found almost exclusively in the 
cytoplasm with only trace levels in the nuclei. (A) Diagram of FOXP3 protein with positions of 
domains of nuclear transport marked. ZF: zinc finger domain, LZ: leucine zipper domain, and FKH 
fork-head domain. (B) Three pairs of primers for sequencing each of three nuclear localization 
domains were designed manually. The primers’ sequences are highlighted as coloured arrows 
corresponding to the colours of the domains they amplify.  




4.3.3 Quantitative analysis of PCR electrophoresis products by densitometry  
Amplified products were electrophoresed at 120 volts for one hour on 2 % agarose 
gels, then photographed by the AlphaImager 3400 gel imaging system (Alpha 
Innotec, Santa. Clara, CA). Densitometry of FOXP3 isoform ratios (isoform 3/ 
isoform 1 or 2) were performed using the imaging analyses system (Image J 
system, NIH). The mean pixel intensity of the analysed band of the electrophoresis 
gel was presented as a band plot. The size of the band was then multiplied by a 
mean pixel intensity of that band giving an absolute intensity. The ratio of absolute 
intensities of two bands in the same sample gave a relative intensity. Relative 
intensity quantified the mRNA expression of the FOXP3. 
 




4.4 Results  
4.4.1 Sub-cellular FOXP3 localization  
Having examined the expression of FOXP3 and its distribution in breast cancer 
epithelium at the tissue level, further work was carried out on the cellular level 
using immunofluorescence, immunocytochemistry, digital microscopy and image 
analysis and transient transfection of MDA-MB-231 cells with human FOXP3 cDNA. 
FOXP3 is a transcriptional regulator that functions by interacting with DNA in the 
nuclei (Zuo et al., 2007c).  As the next step to test the hypothesis that FOXP3 fails 
to localise in the nuclei of the cancer cells, FOXP3 protein was tagged with an anti-
Foxp3 antibody conjugated with FITC giving green fluorescence and cellular nuclei 
were counter-stained with DAPI. Slides were analysed using confocal microscopy 
as shown in Figure 4-2. HEK-293 FOXP3 transfectants, used as a positive control, 
expressed the highest levels of FOXP3 and their expression was nuclear. 
Immortalised benign human breast cells (MCF-10A) expressed more FOXP3 in the 
nuclei compared to breast cancer cells. All cancer cell lines examined (MCF-7, 
MDA-MB-231, TMD-MB-231, LMD-MB-231) revealed FOXP3 expression, which 
was predominantly localised outside the nuclei in the cytoplasm (arrows point to 
cancer cells nuclei (Figure 4.3). FOXP3 nuclear expression was quantified by 
measuring fluorescence intensity (0-255) and dividing it by unit area. The more 
aggressive the cancer cell line was, the less nuclear FOXP3 it expressed (Figure 4-2 
graph). The least FOXP3 expression was found in the nuclei of MDA-MB-231, an 
invasive breast cancer cell line. 
To further validate this finding with digital microscopy and image analysis, FOXP3 
immunocytochemistry for cell lines grown on the chamber slides was carried out. 
All sections were scanned and analysed by the Aperio system using nuclear and 
positive pixel algorithms to quantify nuclear and cytoplasmic FOXP3 expression as 
described in chapter 3. Quick scores were then calculated in the same way as in 
breast tissue IHC. FOXP3 transfectants and normal primary human mammary cells 




were used as positive controls  (Figure B, F). All cell lines examined expressed 
FOXP3, with the lowest expression being observed on MDA-MB-231 cell line.  
It was noticed, however, that in some sections the Aperio system did not pick up all 
the nuclei. For example in MCF-7 Figure 4-3 panel D black arrows) some nuclei 
were not detected by the computer system as negative (blue) or positive  (yellow, 
orange, red). If all nuclei had been detected, the MCF-7 MQS would have been 
lower because smaller percentage of nuclei would have been scored as positive. 
The results indicate that all the cancer cell lines examined (MCF-7, MDA-MB-231, 
TMD-MB-231, LMD-MB-231) fail to import FOXP3 protein into the nuclei.  





Figure 4-2: FOXP3 immunofluorescence staining of breast cell lines. 
FOXP3 HEK-293 transfectants, MCF-10A, MCF-7, MDA-231, TMD-231, LMD-231 were stained with 
primary monoclonal anti-Foxp3 antibody (1:5 in 20% of normal rabbit serum) and FITC conjugated 
secondary antibody. Images in the right upper corners represent addition of DAPI (blue) staining to 
highlight the cellular nuclei. Leica TCSSP2 UV confocal microscope x40 magnification was used. 
Scale bars represent 50 µm. Arrows point to nuclei of cancer cells. FOXP3 nuclear expression was 
quantified by measuring fluorescence intensity (0-255) and dividing it by unit area. Results were 
plotted (bottom panel). Error bars represent SD; n=3. 





Figure 4-3: Immunocytochemistry and digital microscopy of FOXP3 nuclear 
expression in breast cell lines. 
Cells were stained with primary monoclonal anti-Foxp3 antibody (cell culture supernatant 1:5 in 
20% of normal rabbit serum) and biotinylated secondary antibody (DAKO). Slides were scanned 
with the Aperio scanner; digital images were analysed with IHC nuclear algorithm and staining was 
automatically quantified. The quick scores were calculated and plotted (bottom panel). Error bars 
represent SD; n=2.





4.4.2 Sub-cellular location of FOXP3 in breast cancer cells following induction of its 
expression. 
Intracellular trafficking of FOXP3 to the nucleus of the cells is required in order to 
express this protein in its active form and subsequently maintain cellular 
homeostasis. Having observed pathological cytoplasmic localisation of FOXP3 
protein in a range of breast cancer cells, the attempt to reverse this expression 
pattern was made by upregulating FOXP3 expression. Stable transfection of a 
cancer cell line with a plasmid encoding wild type FOXP3 protein was performed 
to determine whether it would reverse FOXP3 expression to the normal nuclear 
pattern. TGF-β-treated MDA-231 and stable FOXP3 transfectants of MDA-MB-231 
cells (methodology is described in the chapter 5) were stained with primary 
monoclonal anti-Foxp3 antibody (1:5 in 20% of normal rabbit serum); FITC 
conjugated secondary antibody (green) and DAPI to visualize nuclei (blue).  FOXP3 
protein in MDA-231 breast cancer cells was localised predominantly in the 
cytoplasm (Figure 4-4 top column). Following treatment with TGF-β for 6h amount 
of FOXP3 significantly (p<0,05) increased but still its localization was mainly 
cytoplasmic. Transfection of MDA-231 cells with normal FOXP3 vector significantly 
increased FOXP3 expression within cellular nuclei (Figure 4-4 bottom column). 





Figure 4-4: Sub-cellular localization of FOXP3 protein following upregulation of its 
expression.  
Wild type, TGF-β treated and FOXP3 transfected MDA-MB-231 cells were stained with primary 
monoclonal Foxp3 antibody (1:5 in 20% of normal rabbit serum), FITC conjugated secondary 
antibody (green) and DAPI to visualize nuclei (blue).  
Images in the middle column show green FITC immunofluorescence of FOXP3 within MDA-231 
cells, whereas the left column represents merged DAPI and FITC images. Right column 
demonstrates selected cells in higher magnification. Leica TCSSP2 UV confocal microscope x40 




magnification was used for left and middle columns, x60 for right column. Scale bars represent 47.6 
µm. Arrows point to cellular nuclei.  
FOXP3 nuclear and cytoplasmic expressions were quantified by measuring fluorescence intensity 
(0-255) and dividing it per unit area. Results were plotted and illustrated on the histograms 
(bottom panel). Error bars represent SD. This experiment has been repeated at least 3 times. 




4.4.3 Analysis of nuclear localization sequences of FOXP3 gene 
Having observed a failure of FOXP3 nuclear localisation in breast cancer cells, an 
attempt was made to identify possible mutations or splice variants in FOXP3 gene 
that may cause disruption of its nuclear localization (Figure 4-5).  
Samples of cDNA from MDA-MB-231 and MCF-7 cell lines were amplified by 
conventional PCR using Taq and Pfu DNA Polymerases and sequenced. Finch TV 
software was used to assemble the sequences and compare them with FOXP3 
reference gene. Figure 4-5 represent PCR electrophoresis gels of nuclear 
localization domains. Domain 1 gave at least two bands on electrophoresis gel: 
480bp and 345bp. All the bands were cut out from the gel for sequencing. All the 
analysed cells analysed showed a shorter band representing FOXP3 isoform 1 or 2 
with an expected product size of 344bp. The larger band with the insertion of 
120bp might represent isoform 3 of FOXP3. The protein sequence of isoform 3 has 
been already described and published by Swissprot (Figure 4-6), however, there 
has been no experimental confirmation of this isoform so far. Interestingly, cancer 
cells (MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231) had proportionally 
higher expression of isoform 3 compared to isoform 1 or 2 than normal cells as 
shown by electrophoresis densitometry (Figure 4-7).  
Domain 2 gave a single band of 650bp as expected. They were sequenced 
confirming 100% alignment to the FOXP3 gene (AF277993). 
Domain 3 PCR electrophoresis gel resulted in multiple bands shorter then 
expected product. Six bands for each cell line were sequenced confirming non-
specific binding to myelin transcription factor and zinc finger protein. The primers 
for domain 3 spanned a large gene area of 1.4k and had a low melting temperature 
of 53.5ºC, therefore likely to give the multiple bands due to non-specific binding. 
 






Figure 4-5: Multiple FOXP3 cDNA fragments on RT-PCR electrophoresis gel  
RNA was extracted from various cell lines (primary epithelial breast cells HMEPC, benign breast 
cells MCF10A and breast cancer cells MCF7, MDA231, TMD231, LMD231). Samples of cDNA were 
amplified by conventional PCR using Pfu DNA Polymerase and sequenced. Finch TV software was 
used to assemble the sequences and compare them with FOXP3 reference gene. Amplification of 
domain 1 gave at least two bands on electrophoresis gel: 480bp and 345bp. The expected product’s 
size was 344bp and the insertion of 120bp might represent isoform 3 of FOXP3. Domain 2 gave a 
single bands 650bp. Domain 3 resulted in multiple bands shorter then expected product. The 
experiment was performed 6-9 times in duplicates or triplicates.  












Figure 4-6: Identification of splice variant forms of the human FOXP3 gene 
There are 3 isoforms: Isoform 1 (Q9BZS1), Isoform 2 (Q9BZS1-2), and Isoform 3 (Q9BZS1-3). All 
analysed sequences corresponded to Isoform 3. (A) The published human FOXP3 sequence 
(AF277993 Isoforms 1, 2 and decoded from protein “draft DNA” sequence of isoform 3) was aligned 
with nuclear sequence localization number 1 (NSL) on forkhead domain isolated from primary 
(HMEPC), benign (MCF10A) and breast cancer cells (MCF7, MDA231, TMD231, LMD231).  (B) NSL 1 
sequence was translated into protein and aligned with FOXP3 isoforms 1,2 and 3 published protein 
sequences. The experiment was repeated 7 times in duplicates or triplicates.  








Figure 4-7: RT-PCR expression analyses and gel electrophoresis of alternatively 
spliced FOXP3 in breast cancer cells 
A) The levels of FOXP3 expression mRNA were analyzed by RT-PCR. The product underwent 
agarose electrophoresis and then photographed by the AlphaImager 3400 gel imaging system 
(Alpha Innotec, Santa. Clara, CA). Two well-defined bands were visualized using agarose gel 
electrophoresis: isoform 3 (460bp) and isoform 1 or 2 (345bp). N=7 
B) FOXP3 mRNA levels were determined by densitometry. Data ware expressed as ratios of longer 
(isoform 3) to shorter band (isoform 1 or 2) and as means ± SE of 3 independent experiments. The 
result suggests that at the mRNA cancer cells (MCF-7, MDA-MB-231, TMD-MB-231, LMD-MB-231) 
had more isoform 3 comparing to isoform 1 or 2 then HMPC. 





Intracellular trafficking of FOXP3 to the nucleus is required in order for this 
protein to function. FOXP3 physically interacts with the nuclear factor of activated 
T cells (NFAT) and forms nuclear complexes that are important to regulate the 
transcription of several target genes (Marson et al., 2007) thereby conferring 
Tregs their suppressive function (Wu et al., 2006, Rudensky et al., 2006). There are 
three regions on FOXP3 that contribute to its nuclear transport (Hancock W, 2009) 
and identification of factors which interact with these domains is crucial for 
studying FOXP3 regulation on cancer cells. It has been demonstrated that the 
failure of FOXP3 nuclear translocation is sufficient to inhibit its tumour suppressor 
function in prostate cancer (Wang L, 2009, Wang L, 2009). Somatic mutations 
detected in human prostate cancer abrogated MYC repression by preventing 
FOXP3’s nuclear localization (Wang L, 2009, Wang L, 2009). The presence of 
alternative splice variants as dominant forms of human FOXP3 isoform can also 
lead to disruption of nuclear localization by inhibition of FOXP3fl in a dominant 
negative manner (Hancock W, 2009). During initial experiments, a novel isoform 3 
was found to be highly expressed in cancer cells (MCF7, MDA-MB-231, TMD-231, 
LMD-231) and benign breast cell line MCF-10A in comparison with primary 
mammary cells (HMPC).  In contrary to previous work (Zuo et al., 2007b), this 
study did not reveal any mutations in FOXP3 gene. However, the authors who 
described FOXP3 mutations,  used genomic DNA from cancer tissue rather then cell 
lines.   
Since FOXP3 is a transcription factor, majority of authors considered the presence 
of nuclear FOXP3 as an indication of its functional expression (Liu et al., 2009, 
Wang L, 2009, Zuo et al., 2007d). Immunohistochemical staining of the cytospins of 
cancer cell lines showed cytoplasmic expression of FOXP3 predominantly in 
melanoma (GERL), colon (HCA 2.6), and breast cancer (MCF7) cell lines and both 
cytoplasmic and nuclear expression in cell lines of lung cancer (GILI) and T 
lymphoblastic leukemia (JURKAT) (Karanikas et al., 2008). In agreement with their 




findings this study demonstrated that cancer cell lines (MCF7, MDA-MB-231, TMD-
231, LMD-231) failed to import FOXP3 protein into their nuclei where it is 
required to maintain its tumour suppressor function. Following 6h TGF-β 
treatment, the amount of FOXP3 protein significantly increased but still its 
localization was mainly cytoplasmic. FOXP3 expression was increased in MDA-MB-
231 breast cancer cells transfected with FOXP3 plasmid compared to the wild type 
MDA-MB-231 cells. Importantly, there was an increase in intra-nuclear FOXP3 
expression in the FOXP3 transfectants. This may indicate that cancer cells fail to 
import FOXP3 protein into their nuclei due to the loss of FOXP3 biological function. 
However, when transfected with the normal FOXP3 plasmid, cancer cells reverse 
to their physiological non-cancerous phenotype and express FOXP3 in their nuclei. 
FOXP3 gene may be inactivated in breast cancer by excessive proportion of FOXP3 
splice variants or presence of somatic mutation, which results in disruption of 
nuclear localisation of FOXP3 protein and leads to development of malignant 
FOXP3 phenotype. A change in the subcellular localization of FOXP3 from a more 
cytoplasmic and perinuclear to a nuclear expression pattern, possibly due to 
posttranslational modifications, has recently been reported for Tregs activated 
with anti-CD3/anti-CD28 antibodies (Ebert LM, 2008). The question remains 
whether, in human breast tissue, heterogeneous subcellular FOXP3 localization 
reflects the presence of its different post-translationally modified forms and 
whether such modifications are functionally relevant.  




4.6 Summary of observations: 
 Breast cancer cell lines unlike non-cancerous cells failed to import FOXP3 
protein into nuclei. 
 TGF-β significantly increased expression of cytoplasmic FOXP3 whereas 
transfection of normal FOXP3 vector increased its nuclear expression. 
 Nuclear localization sequences of FOXP3 contained multiple bands of shorter 
then expected products what might represent various splice variants. 
 The increase of isoform 3 expression was observed in all cancer cell lines. 
Isoform 3 nucleotide sequence might provide an experimental confirmation of 
corresponding protein described by Swissprot. 
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5 Role of FOXP3 in CXCR4-induced migration of breast 
cancer cells 
5.1 Introduction  
5.1.1 CXCR4-induced migration of breast cancer cells 
Metastasis is the major cause of death associated with breast cancer (Gupta and 
Massague, 2006). Metastasis of cancer cells is a complex process including 
invasion, hemangiogenesis, lymphangiogenesis, trafficking of cancer cells through 
blood or lymph vessels, extravasations, organ-specific homing, and growth. 
Evidence suggests that CXC chemokine receptor 4 (CXCR4) plays a critical role in 
the homing of cancer cells to specific metastatic sites including lung, liver and bone 
(Muller et al., 2001).  
CXCR4 is normally expressed on various cell types, including: endothelial cells 
(Volin et al., 1998, Feil and Augustin, 1998), bronchial epithelial cells (Eddleston et 
al., 2002), lymphocytes (Bleul et al., 1996b, Bleul et al., 1996a), intestinal 
(including colonic) epithelial cells (Dwinell et al., 1999, Jordan et al., 1999), 
primitive haematopoietic progenitor cells (Aiuti et al., 1997), microglia, neurons 
and astrocytes (Bonavia et al., 2003), vascular smooth muscle cells (Schecter et al., 
2003) and fibrocytes (Phillips et al., 2004). CXCR4 is also expressed in pluripotent 
stem cells, including mammary stem cells (Dontu et al., 2003). This suggests that 
CXCR4 may define the progenitors of breast cancer (Liu et al., 2005).  
CXCR4 expression in the primary tumour has been positively correlated with the 
degree of lymph node metastasis, homogenous metastasis to the lungs, bone 
metastasis, poor patient overall survival and tumour grade (Altundag et al., 2005). 
The CXCR4 ligand, CXCL12, is expressed in bone marrow (Semerad et al., 2005), 
lung (Phillips et al., 2003, Muller et al., 2001), liver (Sun et al., 2005, Wald et al., 
2004), adrenals (Sun et al., 2005), brain (Bonavia et al., 2003) promoting migration 
of cancer cells (Fernandis et al., 2004). Reports demonstrated CXCR4/CXCL12 




inhibition in preventing breast cancer cell migration to metastatic sites (Harvey et 
al., 2007, Harvey, 2005).  
5.1.2 Regulation of CXCR4 expression by FOXP3 
There is evidence that the FOXP3 transcription factor may participate in the 
regulation of the expression and function of the CXCR4 chemokine receptor (Merlo 
et al., 2009). TGF- β, SMAD, NFAT can occupy Foxp3 enhancer and/or promoter 
loci and activate Foxp3 transcription on Tcells (Ruan et al., 2009). 
FOXP3 in T cells is known to induce or repress a number of genes, including CXCR4 
(Marson A, 2007, Zheng Y, 2007). It binds to the region upstream of the 
transcriptional start site of CXCR4 and CCR7 two chemokine receptors reported to 
play a vital role in cancer invasion and metastasis (Marson A, 2007).  
FOXP3 is a master regulator of T reg cells which are known to be present in the 
inflammatory infiltrate of breast cancer (Zheng and Rudensky, 2007). 
Inflammatory mechanisms influence tumorigenesis and metastatic progression 
even in cancers whose aetiology does not involve pre-existing inflammation or 
infection, such as breast and prostate cancers (Grivennikov et al.). For instance, 
prostate cancer metastases are associated with the infiltration of lymphocytes into 
advanced tumours and the upregulation of two tumour-necrosis-factor family 
members: receptor activator of nuclear factor-kB (RANK) ligand (RANKL) and 
lymphotoxin (Luo et al., 2007). Most recently, study of a mouse model and humans 
revealed that RANKL-producing T cells expressed FOXP3 (Tan et al.). The 
dependence of pulmonary metastasis on T cells was replaceable by exogenous 
RANKL, which also stimulated pulmonary metastasis of RANK positive human 
breast cancer cells (Tan et al.). 
Up-regulation of FOXP3 inhibits the activity of NF-kappa B. FOXP3 might inhibit 
cell migration and invasion partly through the inhibition of NF-kappa B and its 
target genes MMPs (Grant et al., 2006, Hai-Yan Zhang, 2010). NF-kappa B is known 
to induce CXCR4 expression and therefore induction of CXCR4 fails with 
upregulation of FOXP3 (Helbig et al., 2003). 




CXCR4 and CCR7 are two chemokine receptors which play a vital role in cancer 
invasion and metastasis (Marson A, 2007). The expression of CXCR4 in breast 
cancer is linked to the expression of HER-2 (Merlo A, 2009) and it has been proven 
that FOXP3 is an important regulator of this oncogene (Zuo et al., 2007c). Hence, it 
is also possible that FOXP3 can regulate CXCR4 expression indirectly through its 
action on HER-2. Foxc transcription factors are important regulators of the 
chemotactic motility of endothelial cells through the induction of CXCR4 
expression (Hayashia H, 2008). Some members of the forkhead family of 
transcription factors (Foxc1 and Foxc2) are able to directly induce CXCR4 
expression by activating its promoter on endothelial cells. Furthermore, Foxc1-
deficient endothelial cells show a significant reduction in CXCR4 expression as well 
as CXCL12-stimulated migration (Hayashia H, 2008).  




5.2 Specific aims and objectives 
 To examine FOXP3 expression in breast cancer cells following stimulation 
with TGF- β1 
 Construction of FOXP3 overexpressing breast cancer stable transfectants  
 To study the chemokine responsiveness of breast cancer cells following 
induction of FOXP3 expression  
 To analyse the functional significance of FOXP3 nuclear localisation on 
CXCR4-induced migration of breast cancer cells 





5.3.1 Induction of FOXP3 expression with TGF-1 
Cells were incubated in their normal growing conditions with or without TGF-1 
(R&D Systems) at final concentration of 10 ng/ml for 6h, 12h, 24h, 48h and 72h. At 
the protein level FOXP3 expression was measured using immunofluorescence 
staining and Leica TCSSP2 UV confocal microscope by quantifying the fluorescence 
intensity (0-255). At mRNA level, FOXP3 expression was measured by real-time 
PCR. 
5.3.2 Transient transfection of MDA-MB-231 cells with a reporter gene construct 
In order to establish the optimum conditions for stable transfection, a plasmid 
encoding a green fluorescence protein (GFP) was used to transiently transfect 
MDA-MB-231. Cells were transiently transfected with EGFP reporter plasmid 
(encodes enhanced green fluorescent protein) for 24, 48 or 72 hours using 
Effectene Transfection Kit (Qiagen). The day before transfection, 0.9–4.0 x 105 cells 
were seeded into each 6-well plate and 1600 µl of standard growth medium 
containing serum and antibiotics was added. The cells were incubated under their 
normal growth conditions (37°C and 5% CO2) until 70-80% confluent on the day 
of transfection. Various amounts of EGFP plasmid were dissolved in TE buffer, pH 
7 (DNA concentration: 325 ng/µl) with the DNA-condensation buffer, Buffer EC, to 
a total volume of 100 µl; enhancer and effectene reagent were added keeping the 
ratio of DNA to enhancer constant (1:25 and 1:50). Cells in 6-well plates were 
washed once with 4 ml of PBS, 1600 µl of standard growth medium containing 
serum and antibiotics was added and after 15 minutes of incubation, transfection-
complexes were added. To avoid cytotoxicity, after 10 hours the medium 
containing effectene–DNA complexes was replaced by 5 ml of standard growth 
medium.   




5.3.3 Construction of FOXP3 overexpressing breast cancer stable transfectants  
Human FOXP3 vector was cloned within a pcDNA3 backbone (Invitrogen). It was a 
kind gift from Prof S Sakaguckhi from Kyoto University, Japan. The sequence was 
confirmed using T7 forward and bGHR reverse primers by GeneService 
(www.geneservice.co.uk). Once the sequence was verified, plasmid DNA was 
isolated following initial transformation into Escherichia coli. Cells were selectively 
isolated based upon their Ampicillin resistance. The target plasmid was eluted 
using Qiagen Mini-Prep kit, and this was sequenced again to ensure the plasmid 
expressed the target FOXP3 sequence. 1µg of the plasmid was linearised using the 
restriction enzymes Xho1 and Not1 and run on a 1% agarose gel to confirm the 
plasmid size of 6.9 kbp containing FOXP3 sequence 1.4 kbp + plasmid sequence 5.5 
Kbp. Large quantities of FOXP3 plasmid DNA were isolated using plasmid DNA 
isolation kit Maxi-Prep (Sigma).  
Two different methods of transfection depending on cell type were used to obtain 
stably transfected cell lines.  
5.3.3.1  Effectene Reagent 
Based on the results of the transient transfection with the EGFP reporter plasmid, 
the optimum DNA/effectene/enhancer combination was determined. The day 
before transfection, 2.0–8.0 x 105 cells were seeded into 60 mm dish and 4000 µl of 
standard growth medium containing serum and antibiotics was added. The cells 
were incubated under their normal growth conditions (37°C and 5% CO2) until 
70-80% confluent on the day of transfection. The transfection was performed as 
per Qiagen Effectene reagent protocol. The DNA/effectene/enhancer combinations 
used are shown in Table 5-1. To avoid cytotoxicity effectene–DNA complexes were 
removed after 10 hours, cells were washed once with PBS and 5 ml of fresh growth 
medium was added to each well. After 48h the cells were trypsinised and 
transferred to 25 mm3 flasks. Previously optimised G418 concentration was added 
to the flasks (1200 g/ml) for generation of stable transfectants.  


























Dish 1 2.0 16.0 100 50 4000 1000 
Dish 2 2.0 16.0 100 100 4000 1000 
Table 5-1: Transfection of MDA-MB-231 with FOXP3 plasmid 




5.3.3.2  Amaxa system  
Jurkat cells were transfected with the pcDNA 3.1(+)-FOXP3 vector using the Amaxa 
nucleofection system (Amaxa Biosystems, Germany). Prior to poration, cells were 
were grown in the 75cm2 flasks. For each sample, 5 µg DNA (in 1-5 µl H2O) was 
prepared. Six-well plates were prepared by filling the appropriate number of wells 
with 1 ml of complete medium. Cells were harvested with trypsin-EDTA, counted 
and centrifuged (1x106 cells per nucleofection sample), at 200×g for 10 min. The 
supernatant was completely removed and the cell pellet was resuspended. 
Nucleofector Solution V (Amaxa) was added to make a suspension of 1x106 
cells/100 µl. 5 µg DNA was added to prepared 100 µl of cell suspension and then 
transferred into an Amaxa cuvette. The Cuvette was inserted into the cuvette 
holder of the Amaxa machine and the program Q-01 was used. The sample was 
removed from the cuvette immediately after the program was finished. 
Subsequently, 500 µl of the pre-warmed culture medium was added and the 
sample was transferred into 6-well culture plates. Cells were then incubated as 
required. 
5.3.3.3  Generation of antibiotic resistant clones 
It is necessary to determine the lowest concentration of antibiotic required to kill 
untransfected cells in order to generate a stable line containing integrated plasmid 
DNA. MDA-MB-231 cells were plated in 6-well plates. At 60-70% confluence 
Neomycin (G418 Calbiochem) selection media were added to the plates at 
following concentrations: 500 g/ml, 800 g/ml, 1000 g/ml, 1200 g/ml, 1500 
g/ml, 2000 g/ml, 3000 g/ml. Media replaced every 3-4 days and cells were 
examined. 800 g/ml G418 was chosen as optimal concentration for selection of 
MDA-MB-231 transfected cells (Figure 5-7).  
To select stable cell lines of MDA-MB-231 transfectants, 48 hours after transfection 
the cells were split into 24-well plates at 1/10 dilution in fresh medium containing 
an appropriate concentration of antibiotic required for this cell line. Antibiotic-




resistant clones were generally visible after 14 days culture in the presence of 
antibiotic. Clones were then isolated and cultured in selective medium.   
5.3.4 Functional studies 
5.3.4.1 Proliferation assay  
The proliferation assay allows measurement of the number of cells growing in the 
absence or presence of proliferation-affecting agents. 10000 cells were seeded in 
the wells of a 12 well plate. At the same time TGF-β1 was added to half of the wells. 
The cells were incubated in their normal growing conditions for 24, 48 and 72h, 
after which time cells were detached from the flask, resuspended in PBS and 
counted. 
5.3.4.2 Chemotaxis Assays 
The chemotactic potential of cells was assessed using a transwell filter system 
developed using 8μm pore polyethylene terepthalate chemotaxis filters (Falcon, 
Fahrenheit Laboratory Supplies, Rotherham) and 24-well companion plates 
(Falcon). Human breast cancer cells require a Fibronectin matrix on the filter 
insert upon which to migrate. The underside of filter was coated with 150μl of 
2.5μg/ml of Fibronectin (Sigma) at room temperature for 60 minutes prior to the 
assay. After removal of excess fibronectin, filters were allowed to dry for a further 
30 minutes at room temperature before use. 1ml of 0.1% BSA-containing media 
was added to the lower well along with CXCL12 (0-200 nM), which was assessed 
for its chemotactic potential. Mammalian cells were resuspended in media 
containing 0.1% BSA at a concentration of 1x106 cells/ml. 300μl of the cell 
suspension was then added to the filter before carefully placing the filter into the 
well. Chemotaxis assays were then incubated at 37oC, 5% CO2 for a period of time 
optimised for the individual cell line used. 
Filters were removed and fixed in methanol overnight at -20oC, dehydrated 
through increasing ethanol concentrations and then stained with haematoxylin 
(Sigma). Filters were mounted on glass microscope slides prior to counting. 
Migrant cells on the undersurface of the filter were assessed by counting 9 high 




power fields per filter. Triplicates of each assay were counted with the identity of 
each filter being blinded to the assessor. 





5.4.1 Analysis of FOXP3 expression following TGF-β1 stimulation 
TGF-β1 is able to stimulate FOXP3 expression on activated T-cells (Pekalski, 2009). 
A series of experiments was performed to examine the possibility of induction of 
the expression of FOPX3 transcription factor in a range of breast cancer cell lines. 
Real-time PCR and immunofluorescence were used to examine regulation of the 
expression of FOPX3 transcription factor by TGF-β1.  
5.4.1.1  Real-time PCR examination  
To examine regulation of FOXP3 expression by TGF-β1 at RNA level a real-time 
PCR was performed. A range of breast cancer cell lines was screened for up-
regulation of FOXP3 mRNA expression following treatment with TGF-β1. T-cells 
activated with CD3/CD28 Dynabeads were used as positive control (Figure 5-1 A) 
and 18s RNA as a housekeeping gene. TGF-β1 significantly induced FOXP3 
expression after 6 hours in all cancer cell lines analysed (MCF-7, MDA-MB-231, 
LMD-MB-231). Longer periods (24 hours, 48 hours- data not shown) of incubation 
with TGF-β1 did not lead to a further increase of FOXP3 expression (Figure 5-1 B). 
However, the large standard deviation indicated that the data were spread over a 
large range of values. Therefore, the MDA-MB-231 cell line, which gave the highest 
FOXP3 up-regulation, was nominated to verify the initial results. In order to 
improve the results further experiments were performed with two housekeeping 
genes: GAPDH (Figure 5-1C) and 18S RNA (Figure 5-1 D) and repeated four times 
in triplicates. TGF-β1 significantly increased FOXP3 expression after 6 hours in 
MDA-MB-231 and did not change FOXP3 expression after 24 hours. 
 






Figure 5-1: Real-time PCR analysis of FOXP3 expression in breast cancer cells 
following treatment with TGF-β 
Positive control: A.) FOXP3 expression on T cells activated using CD3/CD28 Dynabeads after TGF-
β1 treatment (housekeeping gene: 18s RNA, n=2). B) FOXP3 expression on breast cancer cell lines 
after TGF-β1 treatment (housekeeping gene: GAPDH, n=2), C) FOXP3 expression on MDA-MB-231 
after TGF-β1 treatment (housekeeping gene: GAPDH, n=4), D) FOXP3 expression on MDA-MB-231 
after TGF-β1 treatment (housekeeping gene: 18s RNA, n=4); *P<0.05, error bars indicate SD, Rest 
2008 and Prism 3 software was used for statistical analysis. E) Representative real-time PCR graph 
showing amplifications of FOXP3 mRNA.  




5.4.1.2  FOXP3 Immunofluorescence 
Expression of FOXP3 by activated T cells and breast cancer cells stimulated with 
TGF-β1 was also examined at the protein level using primary monoclonal anti-
Foxp3 antibody (1:5 in 20% of normal rabbit serum) and FITC conjugated 
secondary antibody. The 6-hour incubation with TGF-β1 was used in this 
experiment as it gave the highest FOXP3 upregulation at RNA level. FOXP3 
expression was induced after 6-hour incubation with TGF-β1 in the cellular nuclei 
of T-cells (Figure 5-2 B) and cytoplasm of MCF-10A, MCF-7 and MDA-MB-231 cells 
(Figure 5-2 C).  





Figure 5-2: Immunofluorescence analysis of FOXP3 expression in breast cells 
following treatment with TGF- β. 
A) Cells were stained with primary monoclonal Foxp3 antibody (1:5 in 20% of normal rabbit 
serum) and FITC conjugated secondary antibody. Images in the right upper corners represent 
addition of DAPI (blue) staining to highlight the cellular nuclei. Leica TCSSP2 UV confocal 
microscope x40. FOXP3 nuclear expression was quantified by measuring fluorescence intensity (0-
255) and dividing it by unit area. B) Expression of FOXP3 in nuclei was quantified and plotted, C) 
Expression of FOXP3 in cytoplasm was quantified and plotted. *p<5 values indicate significant 
change from control cells.  
 




5.4.2 Generation of FOXP3 breast cancer stable transfectants   
Following observation of reduced FOXP3 nuclear expression in breast cancer cells, 
stable transfection of a cancer cell line with plasmid encoding wild type FOXP3 
protein was performed to determine whether this would increase nuclear FOXP3. 
Along with FOXP3 stable transfectants, MDA-MB-231 were transfected with the 
empty vector pcDNA3.1+/Zeo to generate mock stable transfectants for 
subsequent experiments and controls including mock transfectants.  
A human FOXP3 sequence was cloned within a pcDNA3.1+/Zeo (Invitrogen) 
(Figure 5-3). Escherichia coli colonies were used to expand the DNA plasmid. 
Plasmid was isolated using a Mini-Prep kit (Qiagen). The mammalian expression 
vector was a kind gift from Prof S. Sakaguckhi from Kyoto University, Japan. The 
plasmid DNA was sequenced, confirming 100% homology with target FOXP3 
sequence (AF299773 Genebank FOXP3 cDNA). To generate stable transfectants 
with DNA integrated into the chromosomes, use of linearised plasmid is 
recommended. Hence, the plasmid was linearised using Xho1 restriction enzyme 
and its size was determined by agarose gel electrophoresis to confirm correct 
product size of 6.9kbp (FOXP3 sequence 1.4 kbp + plasmid sequence 5.5 Kbp) 
(Figure 5-4).  





Figure 5-3: pcDNA3.1+/Zeo eukaryotic plasmid map. 
This vector is designed for high-level stable and transient expression in mammalian hosts using the 
human cytomegalovirus (CMV) promoter. The unique restriction endonuclease recognition sites on 
either side of the cloning site are listed. The vector also contains resistance genes for both 
Ampicillin and Zeocin. 






Figure 5-4: Agarose gel demonstrating restriction enzyme digestion of plasmid 
containing FOXP3 cDNA 
Four Escherichia coli colonies were used to expand the DNA plasmid. Plasmid was isolated using a 
Mini-Prep kit (Qiagen). To produce transfectants that express FOXP3 DNA, the plasmid containing 
FOXP3 was sequenced and results confirmed 100% homology with AF299773 Genebank FOXP3 
cDNA. DNA underwent enzyme digestion with Xho1 and Not1. Plasmid was linearised with Xho1 
and its size was determined by agarose gel electrophoresis to confirm correct product size of 
6.9kbp (FOXP3 sequence 1.4 kbp + plasmid sequence 5.5 Kbp). 
 
 




5.4.2.1 Transient transfection of MDA-MB-231 cells  
Prior to stable transfection, transient transfection was carried out. To determine 
optimum transient transfection efficiency a control study was performed with the 
reporter plasmid EGFP (Figure 5-5). The greatest transfection efficiency of around 
65% of MDA-MB-231 cells was demonstrated after 48 hours.  Based on these 
results, 48-hour transfection was done to produce MDA-MB-231 transient 
transfectants that expressed FOXP3. 
Slides with transfectants were scanned and analysed with digital microscopy 
(Figure 5-6). The Quick Scores were calculated for nuclear FOXP3 expression. 
FOXP3 nuclear expression increased in FOXP3 transfected MDA-MB-231 cells 
(Median Quick Score = MQS=7) compared to the wild type MDA-MB-231 cells 
(MQS=4). Importantly, there was an increase in intra-nuclear FOXP3 expression in 
FOXP3 transfectants (Figure 5-6 D, arrows). 
Following successful transient transfection, stable MDA-MB-231 FOXP3 
transfectants were generated. MDA-MB-231 cell line was used for the stable 
transfection because it revealed low nuclear FOXP3 expression on 
immunofluorescence and immunocytochemistry (Figure 4-2, Figure 4-3) as well as 
high CXCR4 expression, which was mentained with passaging the cells (Harvey et 
al., 2007). A dose response curve for antibiotic selection was performed. 850 
g/ml of G418 was chosen as optimal concentration for selection of colonies 
(Figure 5-7). Empty vector pcDNA3.1+/Zeo was used as a negative control for 
stable transfection. HEK293 were transfected along with MDA-MB-231 as a 
positive control. 






Figure 5-5: Optimization of transient transfection for MDA-MB-231 cells using the 
reporter plasmid encoding EGFP  
MDA-MB-231 cells were transfected with EGFP plasmid over and expression analysed over a range 
of time points. A) Untransfected cells analysed by light microscopy; B) 24-hour transfection; C, 48-
hour transfection.  Optimum transfection efficiency was observed at 48 hours. 






Figure 5-6: Transient transfection of MDA-MB-231 with FOXP3  
A: WT MDA-MB-231 cells growing on the chabber slides were fixed, permeabilized, and stained 
with primary monoclonal Foxp3 antibody (cell culture supernatant) at the optimum concentration 
of 1:5 in 20% of normal rabbit serum and biotinylated secondary antibody (DAKO). The images 
were acquired and generated by Aperio digital scanner.  
C: Transient transfection of cells growing on chamber slides was performed. Effectene (Qiagen) was 
used to transiently transfect MDA-MB-231 with FOXP3 plasmid. Again, cells were fixed, 
permeabilized, and stained with primary monoclonal Foxp3 antibody (cell culture supernatant) at 
the optimum concentration of 1:5 in 20% of normal rabbit serum and biotinylated secondary 
antibody (DAKO). The images were acquired and generated by Aperio digital scanner.  
The digital images of WT (B) and stable transfectants (D) were analysed with IHC nuclear and 
positive pixel count algorithms and staining was automatically quantified. Each section was 
manually or digitally scored for the percentage of positively stained cells (0: no staining, 1: <1%, 2: 











5.4.2.2 Real-time PCR analysis of stable FOXP3 transfectants 
Individual stable clones were expanded: out of 9 isolated colonies, 3 were further 
cultured and examined for FOXP3 expression. Using real-time PCR, FOXP3 
expression was significantly increased in all 3 colonies analysed (P<0.05). The 
maximal FOXP3 upregulation was observed in colony 3 (Figure 5-8). 
5.4.2.3 Immunofluorescence analysis of FOXP3 transfectants 
HEK-293 FOXP3 transfectants, wild type (WT) MDA-MB-231, MDA-231 FOXP3 
transfectants and MDA-MB-231 transfected with empty vector pcDNA3.1+/Zeo 
grown on the chamber slides were stained with primary monoclonal Foxp3 
antibody (1:5 in 20% of normal rabbit serum), FITC conjugated secondary 
antibody (green), and DAPI to visualize nuclei (blue).  FOXP3 protein in FOXP3 
transfected HEK-293 and MDA-MB-231 cells was localised predominantly in the 
nuclei. HEK-293s, as a type of T-cells, don't have the cytoplasm so the FOXP3 
localizes only in the nuclei. Transfection of MDA-MB-231 cells with the FOXP3 
vector significantly increased FOXP3 expression within cellular nuclei compared to 
negative control (transfectants with the empty vector) and WT cells (Figure 5-9 E). 
However, there was no significant difference in cytoplasmic FOXP3 expression 
between WT MDA-MB-231, MDA-231 FOXP3 transfectants and MDA-MB-231 
transfected with empty vector pcDNA3.1+/Zeo (Figure 5-9 F). 









Figure 5-7: G418 killing curve for MDA-MB-231 cells. 
MDA-MB-231 cells were seeded onto 6-well plates and cultured with different concentrations of the 
antibiotic. Daily assessment of confluence was made by visual inspection of the growth area and the 
antibiotic reapplied every 4 days. 850 µg/ml of G418 was determined as the optimum 
concentration for selection of colonies 








Figure 5-8: RT-PCR analysis of FOXP3 expression in MDA-MB-231 FOXP3 stable 
transfectants 
Representative real-time PCR graph showing amplification of FOXP3 mRNA in relation to wild type 
MDA-MD-231. FOXP3 expression was significantly induced in all 3 colonies analysed (P<0.05). The 
maximal FOXP3 upregulation was observed in colony 3.  
Boxes represent the interquartile range, or the middle 50% of observations. The line in the boxes 
represents the median gene expression. Whiskers represent the minimum and maximum 
observations. Housekeeping gene was GAPDH. The  experiment was repeated 3 times in triplicates. 






Figure 5-9: Immunofluorescence analysis of FOXP3 expression in MDA-MB-231 
FOXP3 transfectants 
HEK-293 FOXP3 transfectants (A), MDA-MB-231 transfected with empty vector pcDNA3.1+/Zeo 
(B), wild type MDA-MB-231 (C), MDA-231 FOXP3 transfectants (D) were stained with primary 
monoclonal Foxp3 antibody (1:5 in 20% of normal rabbit serum), FITC conjugated secondary 
antibody (green) and DAPI to visualize nuclei (blue). Expression of FOXP3 in nuclei (E) and 
cytoplasm (F) was quantified (fluorescence intensity/ unit area) and plotted. Images in the right 
column show green FITC IF of FOXP3, whereas the left column represents merged DAPI and FITC 
images. Leica TCSSP2 UV confocal microscope at x40 magnification was used. Scale bars represent 
47,6 µm. Error bars represent SD. This experiment has been repeated at least 3 times. 




5.4.3 CXCR4 expression of breast cancer cells following induction of FOXP3 
expression. 
Following validation of stable transfection of cells with FOXP3 vector, changes of 
CXCR4 expression were investigated. 
Six weeks after transfection of MDA-MB-231 levels of the FOXP3 and CXCR4 
transcripts were quantitated by real-time PCR. For comparison, results for MDA-
MB-231 stimulated with TGF-β (10 ng/mL) for 6h were added to the graph. There 
was significant downregulation of CXCR4 in FOXP3 transfected breast cancer cells. 
Stimulation of FOXP3 expression with TGF-β did not have a significant effect on 
CXCR4 expression levels (Figure 5-10 A, arrows).  
Immunofluorescence of cells transfected with FOXP3 vector decreased CXCR4 
expression within cellular membrane (Figure 5-10 B arrows) comparing to 
negative control transfectants with the empty vector. Stimulation of MDA-MB-231 
with TGF-β did not influence the CXCR4 expression. 






Figure 5-10: Analysis of CXCR4 expression in breast cancer cells following FOXP3 
transfection 
A) Overexpression of FOXP3 resulted in downregulation of CXCR4 in MDA-MB-231 breast cancer 
cells. MDA-MB-231 were transfected with either normal FOXP3 vector or control vector. Six weeks 
after transfection levels of the FOXP3 and CXCR4 transcripts were quantitated by real-time PCR 
(GAPDH was used as a house-keeping gene; error bars represent SD, *p<0.05); representative 
results of 3 similar experiments. For comparison, MDA-MB-231 stimulated with TGF-β (10 ng/mL) 
for 6h were added to the graph. 
B) CXCR4 immunofluorescence staining: FOXP3 Tx - MDA-MB-231 FOXP3 transfectants, Vec Ctrl - 
MDA-MB-231 transfected with empty vector pcDNA3.1+/Zeo (control vector transfectants), TGF-β 
6h – cells treated with TGF-β (10 ng/mL) for 6h. Cells were stained using primary monoclonal 
CXCR4 antibody (1:250 in 20% of NRS) and FITC conjugated secondary antibody. The top panel 
Images represent addition of DAPI (blue) counter-stain to visualise nuclei. Leica TCSSP2 UV 
confocal microscope x20 magnification was used. Arrows poin to cellular membrane.  




5.4.4 Chemokine responsiveness of breast cancer cells following induction of 
FOXP3 expression  
5.4.4.1  Validation of chemotaxis assay  
Following confirmation that MDA-MB-231, TMD-MB-231 and LMD-MB-231 
demonstrated surface CXCR4 expression (chapter 3), it was necessary to 
investigate whether this resulted in functional difference between the cell lines. In 
order to optomise chemotaxis assay MDA-MB-231, and cell lines dervived from 
MDA-MB-231 (TMD-MB-231, LMD-MB-231) were used alomng T-cells for positive 
controls. 
The chemotaxis assay was optimised for incubation time and both the presence 
and absence of fibronectin prior to definitive assays. Cells were incubated with 
varying concentrations of chemokine at 37oC for 24 hours in 0.1% BSA medium. 
Migration of cells through the 8μm filter was assessed after 12 and 24 hours. After 
24h MDA-MB-231, TMD-MB-231 and LMD-MB-231 cells demonstrated significant 
chemotaxis towards 6-50nM CXCL12 compared to the “No CXCL12” control. TMD-
MB-231 and LMD-MB-231 cells demonstrated significant chemotaxis towards 
12.5-50nM CXCL12 compared to the “No CXCL12” control after 24h, whereas MDA-
MB-231 cells failed to demonstrate consistent and significant chemotaxis towards 
CXCL12 after 12h (Figure 5-11). A concentration of 12.5 nM CXCL12 was 
considered optimal and was used in further experiments.  
Despite significant chemotaxis towards CXCL12, TMD-MB-231 and LMD-MB-231 
were not used earlier for the transfection experiments because previous studioes 
in our group demonstrated reduction of CXCR4 expression following culture 
(Harvey et al., 2007).  





Figure 5-11: Chemotaxis of breast cancer cells following FOXP3 transfection 
T-cells, MDA-MB-231, TMD-MB-231 and LMD-MB-231 cells underwent chemotaxis in an 8μm 
transwell filter assay coated with fibronectin, in presence of increasing concentrations of CXCL12.   








5.4.4.2  Chemotaxis of breast cancer cells following FOXP3 transfection 
MDA-MB-231 cells were able to migrate in response to CXCL12. Following 
successful transfection of MDA-MB-231 cells with vector encoding FOXP3 cDNA 
and demonstration of nuclear expression of FOXP3 proteins; the stable 
transfectants were used to investigate the potential of FOXP3 to reduce chemotaxis 
of MDA-MB-231 breast cancer cells in vitro in relation to stable mock 
transfectants. Chemotaxis was reduced in transfected colony 1, 2 and 3 after 24h of 
incubation with 12.5 nM CXCL12. Migration of colony 1 was reduced by 30% 
(p<0.05), colony 2 by 38% (p<0.05) and colony 3 by 76% (p<0.01) (Figure 5-12).  






















Figure 5-12: Effect of FOXP3 transfection upon chemotaxis of breast cancer cells 
towards CXCL12 
Over 24h of incubation WT MDA-MB-231 cells and three colonies of MDA-MB-231 stable 
transfectants underwent chemotaxis in an 8μm transwell filter assay coated with fibronectin, in 
presence of 12.5 nM CXCL12. “No CXCL12” represents the negative control. The histograms are 
representative of data from 2 similar experiments; bars show Mean ± SE of duplicate data points. * 
p<0.05, **p<0.01. 




5.4.5 Functional significance of FOXP3 subcellular localization on migration and 
proliferation  
Nuclear expression of FOXP3 is required in order to express this protein in its 
active form and subsequently maintain homeostasis. The results of this study have 
already demonstrated that TGF-β treatment significantly increased expression of 
cytoplasmic FOXP3 whereas transfection of normal FOXP3 encoding vector 
increases its nuclear expression in MDA-MB-231 cells. In order to investigate 
whether subcellular localization of FOXP3 protein mediates a functional difference 
chemotaxis assay was performed using FOXP3 MDA-MB-231 colony 3 
transfectants and TGF-β1 (6 h, 10 ng/mL) treated MDA-MB-231 cells.  
5.4.5.1  Effect of FOXP3 subcellular localization on migration 
As shown in Figure 5-12 and Figure 5-13, MDA-MB-231 showed significant 
chemotactic response to CXCL12. Furthermore, the chemotactic responses of MDA-
MB-231 cells were significantly blocked in cells overexpressing FOXP3 in the 
nuclei (MDA-MB-231 FOXP3 transfectants colony 3) (p<0.05). Treatment of MDA-
MB-231 with TGF-β1 had no effect on migration of cells towards CXCL12. 








Figure 5-13: Effect of FOXP3 cellular localization upon chemotaxis of breast cancer 
cells towards CXCL12.  
WT MDA-MB-231, TGF-β1 (10 ng/mL) treated (6h) MDA-MB-231 and FOXP3 transfected MDA-MB-
231 cells underwent chemotaxis over 24h in an 8μm transwell filter assay coated with fibronectin, 
towards 12.5 nM CXCL12.   
The histogram is representative of data from 2 similar experiments; bars show Mean ± SE of 
triplicate data points. * p<0.05 
  





Metastasis is facilitated by up-regulation of particular chemokine receptors (such 
as CXCR4) on the tumour cells, which enables them to migrate to secondary tissues 
where the ligands are expressed (such as CXCL12) (Balkwill and Mantovani, 2001).  
There are several ways in which FOXP3 may be involved in regulation of CXCR4. 
First of all, FOXP3 on T cells induces or represses a number of genes, including 
CXCR4 (Marson A, 2007, Zheng Y, 2007). FOXP3 binds to the region upstream of 
the transcriptional start site of CXCR4 and CCR7 two chemokine receptors 
reported to play a vital role in cancer invasion and metastasis (Marson A, 2007). 
FOXP transcription factors can directly induce CXCR4 expression by activating its 
promoter on endothelial cells. (Hayashia H, 2008).  
At the post-transcriptional level, changes in receptor translation and 
desensitization by internalization and degradation provide mechanisms for 
regulating chemokine- receptor expression. Enhanced CXCR4 translation in breast 
cancer cells is associated with the oncogene HER2, which may help to protect 
CXCR4 from ligand-induced ubiquitination and degradation (Li et al., 2004). 
In this study, the effects of FOXP3 up-regulation and the implications of its cellular 
location on the migration and proliferation of MDA-MB-231 cells were examined. 
Cytokine TGF-β1 was used to induce FOXP3 expression in cancer cells. It has been 
previously demonstrated in Tregs. FOXP3 might prolong nuclear retention on 
Tregs rather than influx of Smad2 and 3. Thus, FOXP3 can directly influence TGF-
β1 signalling, even in non-T cells. In this study, significant induction of FOXP3 
expression on the epithelial breast cancer cells following short period (6h) of 
incubation with TGF-β1 was demonstrated. However, longer TGF-β1 stimulation 
(24h, 48h) decreased FOXP3 expression. Stimulation for up to 72h with TGF-β1 
had no significant effect on proliferation of MDA-MB-231 cells. Results of TGF-β1 
stimulation beyond 12 hours are not presented. 




Up-regulation of nuclear FOXP3 reduced CXCR4 expression on the cancer cells. 
Furthermore, the clone with the highest FOXP3 nuclear expression (clone 3) 
demonstrated the most significant inhibition of chemotaxis of cancer cells. 
The above chemotaxis results are provisional and should be validated by futher 
experiments. The limitations of chemotaxis experiments are only 3 colonies of 
MDA-MB-231 stable transfectants, which only increased FOXP3 expression 3-4 
fold. Multiple attempts of producing more stable transfectants resulted very slow 
growing colonies (at least 6 weeks). It has been previously observed that FOXP3 
inhibits proliferation in ovarian cancer and subsequently generated slowly 
growing transfected colonies (Zhang and Sun). In futher studiues the transfectants 
of MDA-MB-231 with inducible FOXP3 vector could be used. It would be easier to 
generate these transfectants, as the proliferation of their colonies would not be 
inhibited.   
It is known that MMPs were critically involved in the processes of tumour cell 
invasion and metastasis (Sillanpaa et al., 2007), and MMP-9 and MMP-2 were 
directly associated with metastatic processes in ovarian and colorectal cancers 
(Curran et al., 2004, Belotti et al., 2003, Manenti et al., 2003). In addition, 
upregulation of FOXP3 inhibits the activity of NF-kappa B, which confirms that 
FOXP3 might inhibit cell migration and invasion partly through the inhibition of 
NF-kappa B and its target genes MMPs (Ogawa et al., 2004, Fujioka et al., 2003).  
Up-regulation of FOXP3 on the epithelial cells has been previously described on 
ovarian cancer, and demonstrated that it inhibited cell proliferation, decreased cell 
migration, and reduced cell invasion (Hai-Yan Zhang, 2010). These and our 
findings suggest that up-regulation of the nuclear FOXP3 could be a novel 
approach for inhibiting cancer progression. 




5.6 Summary of observations 
 TGF-β stimulated FOXP3 cytoplasmic expression in breast cancer cells 
 FOXP3 overexpressing breast cancer stable transfectants had normal 
(predominantly nuclear) FOXP3 expression 
 Nuclear FOXP3 expression significantly reduced migration of breast cancer 
cells in vitro  
 Cytoplasmic FOXP3 expression had no effect on migration of breast cancer 
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6  Discussion 
This general discussion is designed to address the extent to which the generated 
data has met the initial aims, which were set out at the beginning of this thesis. The 
results of this project have explored and partially answered the research question. 
Therefore, I have set out to discuss the salient points, and the future directions that 
this work may require to further our understanding. Finally, after addressing each 
aim, I have set out a simplified model to summarise our up to date understanding 
and outline the limitation of this project. 
Evidence suggests that the CXCR4 chemokine receptor is critical for the formation 
of metastases in breast cancer (Balkwill and Mantovani, 2001, Muller et al., 2001). 
Its multifunctional implications in breast tumor biology make it an optimal 
candidate as a diagnostic marker and as a therapeutic target (Muller et al., 2001). 
Mechanism of CXCR4 regulation in normal and cancerous epithelial cells may hold 
the keys to the molecular mechanism of mutagenesis.  
FOXP3 can have conflicting function in breast cancer depending if it is expressed 
on Treg cells or on epithelial breast cells. In breast cancers the percentage of Treg 
cells, which are assessed by FOXP3 positivity, increases in parallel with the disease 
stage, from normal to DCIS and from DCIS to invasive carcinoma (Bates et al., 
2006). The opposite is true for the epithelial cells, where the expression of a 
functional FOXP3 is decreased proportionally to the breast cancer stage. On the 
epithelial cells, FOXP3 transcription factor plays important role in molecular 
pathogenesis of breast cancer development, including both upregulation of 
oncogenes, such as ERBB2/HER2 (Zuo et al., 2007c), MYC (Wang L, 2009), SPK2 
(Zuo et al., 2007b), and inactivation of tumor suppressor genes, such as p21 (Liu et 
al., 2009). It is likely that Foxp3 may affect other pathways involved in breast 
cancer (Zuo et al., 2007b, Zuo et al., 2007c). 
This study was an attempt to provide experimental evidence of CXCR4 as a 





indicate that defect of FOXP3 nuclear expression is a potential mechanism for 
CXCR4 upregulation in breast cancer and mutagenesis. 
6.1 To characterize relationship between FOXP3 and CXCR4 expression 
in breast cancer 
CXCR4 is the physiological receptor for CXCL12 with potent chemotactic activity 
for lymphocytes. It has been established that peripheral lymphocytes 
preferentially localize to peripheral lymphoid tissues, such as lymph nodes, which 
is known as the homing phenomenon (Cabioglu et al., 2005c). The evidence 
suggests that metastatic breast cancer cells overexpress CXCR4 chemokine 
receptor protein and that this receptor plays a critical role in homing of cancer 
cells at specific metastatic sites (Muller et al., 2001). Despite vast evidence of the 
importance of CXCR4 in breast cancer, we aimed to confirm the CXCR4 expression 
in human primary breast cancers and its relation to clinico-pathological factors. 
The CXCR4 expression in primary breast cancers is based on CXCR4 mRNA 
expression levels (Muller et al., 2001) and immunohistochemical studies of 
tumours (Cabioglu et al., 2005c, Muller et al., 2001). As verified by our CXCR4 
immunostaining of CXCR4 transfected cells, CXCR4 is predominantly localised on a 
cell-surface. A small degree of cytoplasmic staining is likely, due to the recycling of 
the receptor within the cell. In contrary to this view, there are reports describing 
immunohistochemistry of CXCR4 on paraffin embedded tissues demonstrating 
little cell surface expression, with predominantly cytoplasmic and nuclear staining 
(Cabioglu et al., 2005c, Muller et al., 2001). In this study, a similar pattern of 
membrane and cytoplasmic CXCR4 staining of paraffin embedded primary 
tumours to those already published has been demonstrated. However, non-specific 
staining was also demonstrated. Our work demonstrated that cytoplasmic CXCR4 
expression, lymph node metastasis, and distant organ metastasis were 
significantly inversely correlated with FOXP3 transcription factor expression in 





The next aim was to examine the existence of FOXP3 expression in breast 
epithelial tissues and cancer, which have been hotly debated in the recent 
literature. Majority of studies describe FOXP3 expression in human breast tissue. 
However, their reports are opposing stating that it is increased (Merlo A, 2009, 
2005, Gupta et al., 2007) or decreased (Zuo et al., 2007b, Zuo et al., 2007d). 
Controversially, there is also evidence from a genetic animal model excluding 
expression of FOXP3 in non-haematopoietic tissues, like breast tissue (Kim et al., 
2009a). Additionally, negligible FOXP3 expression in benign and malignant human 
breast tissue has been described (Wolf D, 2010). Those who observed decreased 
FOXP3 expression in breast cancer (Zuo et al., 2007d, Zuo et al., 2007b) analysed 
only its nuclear expression; whereas those who demonstrated equal or increased 
expression of FOXP3 in cancer (Wolf D, 2010, Andrea Merlo and Elda Tagliabue, 
2009) examined its total expression: nuclear and cytoplasmic. In this study instead 
of examining overall FOXP3 expression, we separately analysed nuclear, 
cytoplasmic and Tcells FOXP3 expression in human breast tissues. Significant 
majority of malignant and benign breast tissue samples expressed FOXP3. 
Although, all benign and significant majorities of malignant specimens expressed 
FOXP3 in the cellular nuclei, all samples expressed FOXP3 in the cytoplasm. In 
malignant sections where nuclear FOXP3 expression was observed, it was weak, 
and it was confined to certain areas of the malignant epithelium. It may indicate a 
mutation of specific areas within cancer epithelium. Total nuclear and cytoplasmic 
FOXP3 expression was not significantly different between cancer and benign 
breast tissue. However, when nuclear staining was compared, benign breast 
epithelial cells had significantly greater nuclear FOXP3 expression than invasive 
ductal carcinoma. Heterogeneous subcellular localization of FOXP3 transcription 
factor may be an explanation for confusing reports in the literature regarding 
expression of this protein in human breast tissue. 
Increased expression of FOXP3 in breast cancer is thought to be related not only to 
the tumour cells but also the strong FOXP3 expression on the Tregs cells in 





et al., 2006). FOXP3 expressed in tumours might be a different transcript than 
FOXP3 expressed in Tregs. FOXP3 mRNA variant lacking exons 3 and 4 has been 
identified in tumour cell lines but not in CD4+FOXP3+ T cells (Chen C, 2006). The 
fact that both tumour cells and tumour-infiltrating Tregs can express FOXP3, 
makes the interpretation of the gene expression data of FOXP3 expression in 
tumours complicated as the increased levels of FOXP3 mRNA expression in cancer 
may be a result of increased expression of FOXP3 in tumour cells and an influx of 
Tregs which is amplified in cancer tissue. In contrast to the previously published 
work (Merlo A, 2009), in this study there was not statistically significant difference 
between total numbers or percentages of FOXP3 positively stained cells within the 
inflammatory infiltrate surrounding normal duct and ductal cancer. We suspect 
that it may be due to increased local inflammatory response and influx of Tregs to 
the tissue around the biopsy site of both benign and malignant specimens.  
Additionally, we observed that the nuclei of ductal carcinoma in situ (DCIS) cells 
expressed FOXP3 similar to invasive cancer cells even though DSIC is a non-
invasive breast cancer. However, it has a potential for aggressive progression to 
invasive breast cancer. It may indicate that FOXP3 downregulation is widespread 
in breast cancer and that such downregulation may have occurred at an early stage 
of breast cancer (DCIS). Similarly, the development of prostate intraepithelial 
neoplasia, a probable precancerious condition, demonstrates clearly that 
inactivation of FOXP3 in prostate cancer patients contributes to prostate cancer 
development (Wang L, 2009). Interestingly, statistically significant downregulation 
of FOXP3 occurred in the prostate epithelial neoplasia (PIN) of human samples 
(Wang L, 2009). Moreover, somatic mutations of FOXP3 were found in both PIN 
and cancerous lesions which suggests that FOXP3 inactivation is an early event in 
prostate carcinogenesis.  
Recently, it has been proposed that overall FOXP3 expression in breast cancer 
tissue (infiltrate and epithelium) is associated with worse prognosis and spread of 
cancer to lymph nodes (Andrea Merlo and Elda Tagliabue, 2009).  However, our 





cancers showing early signs of metastasis, namely vascular and perineural 
invasion, when compared to tumours where vascular and perineural invasion 
were not observed. Furthermore, the prognostic indicators of breast carcinoma 
like lymph node status and distant metastasis were associated with decreased 
nuclear FOXP3 expression and increased cytoplasmic CXCR4 expression.  
Expression of FOXP3 and CXCR4 was also compared on mRNA level. FOXP3 
expression was detected in all cancer cell lines analysed but it was not significantly 
different with reference to MCF10A as a benign human mammary epithelial cell 
line. This result was contradictory to FOXP3 protein expression on 
immunostaining. It may be that FOXP3 mRNA is overproduced as a response to the 
functionally inactive FOXP3 protein in breast cancer.  CXCR4 mRNA expression on 
all cancer cell lines analysed was significantly elevated with reference to MCF10A. 
In summary, in this study normal breast epithelial cells had significantly greater 
FOXP3 nuclear expression than invasive cancers and the opposite was true for 
CXCR4 membrane expression. Correlation of FOXP3 and CXCR4 demonstrated 
significant inverse correlation between nuclear FOXP3 and membrane CXCR4 
staining.  
6.2 To investigate FOXP3 translocation to the nucleus in breast cancer 
The functionally active FOXP3 is expressed in the nucleus of normal epithelial cells 
of breast, colon, pancreas, prostate and bronchus (Chen G, 2008). The expression 
of this molecule in the tumour cells revealed predominant cytoplasmic expression 
(Karanikas et al., 2008). There is disagreement amongst the authors with regards 
to the immunohistochemistry of malignant mammary epithelium: some describe 
nuclear staining only (Zuo et al., 2007b, Zuo et al., 2007d), others state that 
expression of FOXP3 in breast cancer is predominantly cytoplasmic (Andrea Merlo 
and Elda Tagliabue, 2009). In this study all cancer cell lines studied fail to express 
FOXP3 protein in the cellular nuclei where it is required to maintain its tumour 
suppressor function. The expression of FOXP3 in the cancer cells was cytoplasmic 





The human cancer cells exhibit distinct FOXP3 staining profile, e.g. nuclear 
expression in prostate cancer (Wang L, 2009), mixed cytoplasmic and nuclear in 
the pancreatic cancer (Hinz et al., 2007) and solely cytoplasmic staining in ovarian 
cancer (Zhang and Sun). FOXP3 protein expression was recently described in 
hepatoma cell lines (SMMC-7721 and Hepa-G2) (Wang et al.). In addition, the 
authors found that FOXP3 was mainly expressed in the nucleus in well-
differentiated hapatocellular carcinoma (HCC) tissues (less aggressive) and 
cytoplasm in moderately and poorly differentiated HCC tissues (more aggressive). 
In agreement with these findings, our study also indicated a relationship between 
aggressiveness of the cancer and FOXP3 staining at the tissue and cell level. 
Lobular breast cancer, which is known to be one of the most aggressive, invariably 
had no nuclear FOXP3 expression. It may implicate that the factors coming from 
microenvironment and differentiation of tumour might induce a change in the 
subcellular localization of FOXP3 between cytoplasmic and nuclear expression 
patterns, which would result from post-translational modifications (Chen C, 2006). 
As a result, the heterogeneous subcellular localization of FOXP3 in breast cancer 
cell lines and tissues may be a sign of the different post-translationally modified 
forms of FOXP3.  
It is difficult to interpret the significance of FOXP3 cytoplasmic localization, which 
could be due to a mutation or a deletion of the nuclear localization signals 
surrounding its forkhead domain. For example, three of the four FOXP3 mutants 
obtained from human prostate carcinomas disrupted their translocation into 
nuclei but localized in the cytoplasm (Wang L, 2009). Our study hasn’t 
demonstrated any FOXP3 mutations within its three domains of nuclear 
localisation, leucine zipper and forkhead domains which were previously 
described on prostate cancer (Wang L, 2009) and breast cancer (Zuo et al., 2007d).  
In the course of this work, breast cancer cells, which were transfected with wild-
type FOXP3 expressing vector, recovered their physiological nuclear FOXP3 
expression, whereas following TGF-β treatment; FOXP3 expression was induced 





into their nuclei due to dysfunctional FOXP3 protein. Similarly, the baseline FOXP3 
mRNA level was increased in four cancer cells compared to the normal cells 
possibly due to increased demand on functioning FOXP3 protein or due to a 
modulation exerted mainly at post-transcriptional level. These results were 
opposing to the previous observations where cancer cell lines had a different 
degree of reduction in FOXP3 mRNA levels in comparison to HMEC and MCF-10A 
(Zuo et al., 2007c). On the other hand, a similar change in the subcellular 
localization of FOXP3 possibly due to posttranslational modifications, has recently 
been reported for Tregs activated with anti-CD3/anti-CD28 antibodies (Ebert LM, 
2008). 
Finally, the heterogeneous subcellular FOXP3 localization has been thought to be 
due to the alternatively spliced transcript variants encoding different FOXP3 
isoforms. At least five FOXP3 splice variants: Foxp3FL, Foxp3∆2, Foxp3∆7 (Kaur et 
al.), Foxp3∆2∆7 (Mailer et al., 2009), Foxp3∆3∆4 (Zuo et al., 2007c) have been 
identified on the normal mammalian T-cells (Kaur et al., Mailer et al., 2009). They 
are expressed simultaneously (Mailer et al., 2009) and no functional difference 
between them has been demonstrated. These splice variants were all effectively 
translocated into the nucleus (Mailer et al., 2009). A change in the proportions of 
alternatively spliced Foxp3 transcripts might affect the ability of Foxp3 to interact 
with other transcriptional regulators and hence influence cell function. In line with 
this, the E251 mutant Foxp3 protein lost its ability to homo-associate or hetero-
associate with Foxp1, although it still assembled as part of a large protein complex 
(Li et al., 2007b, Lopes et al., 2006, Carson et al., 2006). During the course of this 
study, nuclear localization sequences of FOXP3 contained multiple bands of 
shorter then expected products which might represent various splice variants. 
It has been previously reported that the primary mammary cells (HMEC) 
expressed the same two isoforms as observed in the T cells, while MCF-10A 
expressed the exon 3-lacking isoforms (Zuo et al., 2007c). The same isoform was 
also found in four tumour cell lines at much lower levels (Zuo et al., 2007c). In 





and 4 .We could not confirm these findings in our experiments as our sequences 
predominantly included domains of nuclear localisation. However, our results 
were contradictory to the previously described that some tumour cell lines (MCF-
7) expressed a FOXP3 isoform lacking exon 8 which encodes the leucine-zipper 
domain that is frequently mutated in IPEX patients (Ziegler, 2006, Ziegler and 
Buckner, 2006). All our sequences demonstrated exon 8 identical to full length 
FOXP3.  
We identified a possible novel isoform 3 as a predominant form in cancer cells 
compared to primary mammary cells. The protein sequence of isoform 3 has been 
previously described and published by Swissprot (http://expasy.org); however, 
there has been no experimental confirmation and no scientific references of that 
isoform so far. Although functional differences between isoforms 1, 2 and 3 could 
not be identified in this study, identification and quantification of these alternative 
transcripts in future studies may shed light on their physiological significance. 
Interestingly, cancer cells in our study had proportionally more isoform 3 
compared to isoform 1 or 2 what may suggest inactive FOXP3 in breast cancer due 
to pathological proportion of splice variants.  
The question remains whether, in human breast tissue, heterogeneous subcellular 
FOXP3 localization reflects the presence of abnormal proportion of splice variants, 
somatic mutations or different post-translationally modified forms.  
6.3 To access the role of FOXP3 in CXCR4-induced migration of breast 
cancer cells 
Little is known about CXCR4 regulation by FOXP3. Metastatic breast cancer cells 
overexpress CXCR4 and this receptor plays a critical role in homing of cancer cells 
at specific metastatic sites (Muller et al., 2001). There are several factors 
regulating the expression of CXCR4 receptor. According to the previous reports 
NF-kappa B (Helbig et al., 2003), HER2/ERBB2 (Li et al., 2004),  hypoxia (Schioppa 
et al., 2003) and nitric oxide (Yasuoka et al., 2008), vascular endothelial growth 





induce functional CXCR4 expression. Thus, inhibitors of above factors should 
reduce breast cancer metastasis by reducing the expression of a number of 
prometastatic genes including CXCR4. NF-kappa B inhibitors reduce metastasis of 
several cancers including melanoma, ovarian, prostate, brain, and pancreatic 
cancers and are dependent on CXCR4 for migration, survival, and metastasis 
(Edwards and Murphy, 1998, Chambers and Matrisian, 1997, Koshiba et al., 2000, 
Sehgal et al., 1998, Murakami et al., 2002, Scotton et al., 2002). Indeed, receptor 
activator of nuclear factor-kB (RANK) signalling in mammary carcinoma cells that 
overexpress the proto-oncogene Erbb2, which is frequently amplified in metastatic 
human breast cancers (Tiwari et al., 1992) was important for pulmonary 
metastasis (Tan et al., 2011). Recent evidence demonstrates that Foxp3 can block 
retroviral transcription by targeting key inducible proteins such as NF-kappa B 
and cAMP-responsive element binding protein (CREB) (Grant et al., 2006) and 
therefore it may inhibit CXCR4 by inhibiting NF-kappa B. FOXP3 has been 
identified as a transcriptional repressor of the HER2/ERBB2 oncogene (Zuo et al., 
2007d), hence indirectly represses the expression of CXCR4. Additionally, FOXP3 
suppressed growth and induced the cell death of MCF-7, a breast cancer line 
without HER2/ERBB2 overexpression (Zuo et al., 2007d). Therefore, it is likely 
that Foxp3 may affect other pathways involved in breast cancer.  
Evidence suggests that expression of FOXP3 is associated with survival but not 
with local relapse suggesting that this molecule might be related to metastatic 
potential of breast cancer (Merlo et al., 2009). FOXP3-induced downregulation of 
genes such as PDE3B (cyclic nucleotide phosphodiesterase 3B, cGMP inhibited) 
has been shown to confer a survival advantage and a better resistance to apoptosis 
in T cell (Gavin et al., 2007). Furthermore, in T-cells FOXP3 binds to the gene 
region upstream of the transcriptional start site of CCR7 and CXCR4 (Zheng and 
Rudensky, 2007), two chemokine receptors recently reported to play an important 
role in cancer invasion and metastasis (Kodama et al., 2007b, Kodama et al., 2007a, 
Pitkin et al., 2007). Thus, FOXP3 expressed in breast cancer cells might influence 





receptors or of other genes encoding cell surface or secreted molecules that alter 
tumour cell response to the environment.  
Very recently, FOXP3 positive Treg cells showed similar distribution to cytokine 
RANKL (receptor activator of NF-kappaB ligand) positive cells in breast tumours 
(Tan et al.). Notably, Treg cells in breast tumours are associated with an invasive 
phenotype and poor prognosis. CD41CD25 tumoral T cells, which are FOXP3 
enriched (Fontenot et al., 2003), expressed fourfold more Rankl mRNA than 
CD41CD252 T cells. Furthermore, FOXP3 and RANKL were co-localized in tumours 
inflammatory cells in humans and mice (Tan et al., 2011). These results suggest 
that tumour-infiltrating CD4 positive FOXP3 positive Treg cells are the most 
critical cells for maintaining RANKL expression in the micro-environment of 
metastatic mammary tumours (Tan et al., 2011). On the other hand, expression of 
RANKL was found in human breast cancer cells and tissues and was found to 
trigger migration of human epithelial cancer cells and melanoma cells that express 
the receptor RANK (Jones et al., 2006).  Previously, loss of expression of RANKL in 
86% of breast cancers was found to be associated with oestrogen receptor 
negative cancers (Cross et al., 2006). Those cancers are known to have high 
histological grade, poor prognosis and potential for metastasis (Cross et al., 2006).  
In this study, significant expression of FOXP3 expression on cancer cells was 
achieved by stable transfection and TGF-β1 stimulation as previously 
demonstrated on Tregs. It has been suggested that in Tregs FOXP3 might prolong 
nuclear retention rather than influx of Smad2 and 3. Thus, FOXP3 can directly 
influence TGF- β signalling, even in non-T cells.  
Up-regulation of nuclear FOXP3 by transfection reduced CXCR4 cellular expression 
as well as inhibited migration rate of breast cancer cells. FOXP3 nuclear expression 
levels were correlated with degree of chemotaxis inhibition. Conversely, the 
expression of cytoplasmic FOXP3 had no effect on CXCR4 expression, growth and 





Our findings suggest that up-regulation of the nuclear FOXP3 could be a novel 
approach for inhibiting cancer progression.  
In summary, this study presented experimental evidence that supported the role of 
FOXP3 up-regulation as anti-tumour and anti-metastatic mechanisms in breast 
cancer. From these data, we could expect that up-regulation of FOXP3 might 
potentially be an effective therapeutic approach for the inhibition of cell growth 
and migration in breast cancer. However, further detail studies are needed to 
ascertain the precise molecular regulation of FOXP3 and the role of FOXP3 in cell 
growth, and migration in animal models of human breast cancer. 
6.4 Clinical implications 
6.4.1 Gene therapy  
Unlike autosomal tumor suppressor genes that are usually inactivated by 
mutations in both alleles, X-linked FOXP3 mutations in cancer samples are usually 
heterozygous, with the wildtype allele selectively inactivated in cancer. This 
skewed X-inactivation suggests a new approach to reactivation of FOXP3 for 
cancer therapy. One of the most difficult challenges in cancer therapy is to restore 
the function of inactivated tumor suppressors. Mutation of X-linked tumor 
suppressor genes, such as FOXP3 may be heterozygous in female cancer cells (Zuo 
et al., 2007c). Since one allele of an X-linked tumor suppressor gene has not 
undergone selection during carcinogenesis, it may be possible to restore the wild 
type allele for cancer therapy. Indeed, anisomycin treatment induced FOXP3 
expression in both mouse and human breast cancer cell lines (Zhang et al., 2009) 
resulting in increased apoptosis of cancer cells and reduced growth of established 
mouse mammary tumors (Zhang et al., 2009). It raises the intriguing question 
whether functional FOXP3 can be restored in cancer cells.  Global reactivation of X-
linked genes could potentially have serious side effects. About 10% of X-linked 
genes show variable patterns of inactivation and are expressed from some inactive 
X chromosomes in humans (Carrel and Willard, 2005). Therefore, less than precise 





specific transcript (XIST), and histone hypoacetylation maintain inactivation of X-
linked genes (Pageau et al., 2007, Plath et al., 2002). In the breast cancer samples 
loss of DNA methylation and XIST on the chromosome X reinforces the need for 
selective reactivation of X-linked tumor suppressor genes (Richardson et al., 
2006).  
6.4.2 Transduction of mammary epithelium with FOXP3 
The other potential way to restore physiological FOXP3 phenotype on the cancer 
cells is to transfect them with normal FOXP3 vector using e.g. intraductal 
microinjection of adenovirus vectors (Russell et al., 2003). Since adenovirus 
transduction appears to be confined to the mammary epithelium, this method 
provides a technique to target genes of interest to this tissue compartment.  
6.4.3 FOXP3 as a molecular marker  
Increasingly, molecular-based cancer diagnostics are supporting standard clinical 
diagnosis. Molecular markers are used for confirming diagnosis, monitoring 
patient prognosis, pre-symptomatic screening, guiding treatment options, 
monitoring treatment efficacy and disease progression, and identifying disease 
recurrence after treatment. In one study, FOXP3 expression was found to 
discriminate the prognostic risk of patients within node-negative patients: overall 
survival of FOXP3-positive patients was found to be significantly poorer than that 
of FOXP3-negative patients (Merlo et al., 2009). These findings might aid in 
identifying subgroups of patients who are more likely to have a poor outcome and 
to whom specific therapies might be directed. 
6.5 Limitations of the study 
6.5.1 Immunostaining and its interpretation difficulties 
Because FOXP3 is expressed at lower levels in epithelial cells than in the 
regulatory T cells, the conditions typically used for detecting Treg cells in tumor 
samples do not give reproducible staining in the epithelial cells. Higher 





Immunostaining of CXCR4 on breast cancer tissues had significant cytoplasmic 
staining and background or nonspecific DAB staining. Therefore, Aperio digital 
image analysis was used to subtract the background. However, some sections were 
not possible to be scanned on the Aperio scanner due to their uneven surface, dirt, 
and excessive thickness of the sections. Early signs of metastasis (vascular and 
perineural invasion) were only assessed manually. In some sections Aperio system 
did not pick up all the nuclei. For example in MCF-7 some nuclei were not detected 
by the computer system as negative (blue) or positive  (yellow, orange, red). If all 
nuclei had been detected, the MCF-7 score would have been lower because smaller 
percentage of nuclei would have been scored as positive. 
6.5.2 Real-time PCR results 
During initial phase of experiments, the real-time PCR of FOXP3 expression 
following TGF-β1 stimulation gave very unpredictable and unreproducible results. 
The high standard deviations indicated that the data were spread out over a large 
range of values. Therefore, MDA-MB-231 cell line, which gave the highest FOXP3 
up-regulation, was nominated to verify the initial results. Further experiments 
were performed with two housekeeping genes: GAPDH and 18S RNA and repeated 
four times in triplicates.  
6.5.3 Sequencing problems 
In the initial experiments Taq DNA polymerase was used for amplification of gene 
of interest prior to sequencing. The results were different when verified using 
thermostable Pfu (Pyrococcus furiosus) DNA polymerase with 'proofreading' 
properties. Taq (Thermus aquaticus) polymerase has an error rate of about 1.3 x 
10-5 and mutation frequency of 5.1 %. Therefore, it is possible that the mutations 
observed in the initial experiments were introduced and amplified during the 
course of the experiment. Thermostable Pfu (Pyrococcus furiosus) DNA Polymerase 
with 3  →5  exonuclease proofreading activity exhibits a higher fidelity than Taq 





mutation frequency. No mutations were observed when Thermostable Pfu 
(Pyrococcus furiosus) DNA Polymerase was used. 
Sequencing of FOXP3 domain 2 of nuclear sequence localisation resulted in 
multiple bands shorter then expected product. The primers for domain 3 spanned 
a large gene area of 1.4k and had a low melting temperature of 53.5°C therefore; 
the multiple bands probably were due to non-specific banding rather then true 
splice variants. It was not sufficient for sequence analysis. 
This study did not demonstrated mutations within FOXP3 gene, which were 
previously shown by other authors (Zuo et al., 2007), who used genomic DNA in 
their experiments. This study was based on DNA reverse transcribed from RNA 
derived from cell culture. Futher experiments using genomic DNA sould be 
performed. The genomic DNA may be obtained from breast FNA (fine needle 
aspiration) or tumours dissected from paraffin embedded breast tissue.  
6.5.4 Difficulties with generation of stable transfectants 
The limitations of chemotaxis experiments are only 3 colonies of MDA-MB-231 
stable transfectants, which only increased FOXP3 expression 3-4 fold. Multple 
attempts of producing more stable transfectants resulted very slow growing 
colonies (at least 6 weeks). It has been previously observed that FOXP3 inhibits 
proliferation in ovarian cancer and subsequently generats slowly growing 
transfected colonies (Zhang and Sun, 2010). In futher studiues the transfectants of 
MDA-MB-231 with inducible FOXP3 vector could be used. It would be easier to 
generate these transfectants, as the proliferation of their colonies would not be 
inhibited.   
6.6 Future directions 
Results presented in this work provide a better understanding of the role of FOXP3 
in the development of breast cancer metastases. Here, I outline a few possible 





6.6.1 Identification of mutation in FOXP3 gene in breast cancer 
During the course of this study loss of FOXP3 nuclear expression in breast cancer 
cells have been observed. It was successfully reversed to physiological nuclear 
expression following transfection with the normal FOXP3 plasmid. Somatic 
mutations of FOXP3 gene in breast cancer cells or expression levels of FOXP3 
isoforms may lead to development of malignant phenotype deficient in nuclear 
FOXP3 expression. The sequencing analyses of FOXP3 three nuclear localization 
sequences did not demonstrate any mutations. Future work could involve 
extending this study to the full FOXP3 nucleotide sequence to investigate presence 
of mutations within FOXP3 gene on breast cancer. This work provided an 
experimental confirmation of nucleotide sequence of FOXP3 isoform 3 that may 
play a role in nuclear FOXP3 localization. 
6.6.2 Examination of functional significance of mutations of FOXP3 gene and FOXP3 
isoform 3 on FOXP3 nuclear localization  
If mutations of FOXP3 gene in breast cancer cells are identified, the mutants DNA 
should be isolated in order to construct a plasmid with mutant FOXP3 DNA 
inserted. It could be used for transfection of cells and comparative analysis of 
FOXP3 intracellular location in cells transfected with normal and mutant FOXP3 
plasmid. The same experiment could be performed with the isoform 3 DNA 
sequences. 
6.6.3 Examination of functional significance of mutations of FOXP3 gene and FOXP3 
isoform 3 on FOXP3 regulated genes expression 
The study could also be extended to investigate functional significance of 
mutations in FOXP3 gene and presence of isoform 3 on FOXP3 regulated genes 
expression. In breast cells FOXP3 can regulate the expression of multiple genes, 
including both tumour suppressors and oncogenes. The genes involved in cancer 
are the most affected group. The functional significance of mutations of FOXP3 
gene in breast cancer cells could be studied by examination of the expression of 






6.6.4 Examination of differences between cytoplasmic and nuclear FOXP3 
In order to investigate FOXP3 separately in nucleus and cytoplasm the proteome 
studies could be used in the future experiments.  The successful approach could be  
the fractionation of cellular compartments. 
6.6.5 Investigation differences in FOXP3 function on Treg cells and epithelial cells 
One of ways to investigate differences in FOXP3 function in cancerogenesis on Treg 
cells and epithelial cells is RANKL-CXCR4-FOXP3 signalling. RANK signallimg in 
mammary carcinoma cells that overexpress the proto-oncogene Erbb2, which is 
frequently amplified in metastatic human breast cancers, was important for 
pulmonary metastasis (Tan et al., 2011). Metastatic spread of Erbb2- transformed 
carcinoma cells also required CD4 positive CD25 positive T cells, whose major pro-
metastatic function was RANKL production. Most RANKL-producing T cells 
expressed FOXP3. The dependence of pulmonary metastasis on T cells was 
replaceable by exogenous RANK, which also stimulated pulmonary metastasis of 
RANK human breast cancer cells (Tan et al., 2011). Our study could be expanded by 
investigating interactions of RANK with CXCR4 and FOXP3 not only on T-cells, as 
described above, but also on cancer cells. 
6.6.6 Investigation of the correlation between CXCR4 and CXCR7 in breast cancer  
Since CXCL12 is expressed preferentially in lymph nodes, this may support our 
data that CXCR4 expression was significantly correlated with lymph node 
metastasis in human breast tumour samples. As CXCR7 expression also promotes 
cancer metastasis in breast cancer and is a receptor for CXCL12 (Miao et al., 2007), 
it would be important to investigate the correlation between CXCR4 and CXCR7 in 
breast cancer in future studies. 
6.6.7 Further functional studies to ascertain effect of the FOXP3 expression in 
breast cancer metastasis 
Having demonstrated upregulation of FOXP3 expression as well as its functional 
effect upon the migration of CXCR4 expressing cancer cells, further investigations 





vitro studies should be performed. This could be examined by comparing the 
invasion of extracellular matrix (Matrigel) and ability to modulate signal 
transduction pathways (pSMAD2/3). The other way to confirm FOXP3 –CXCR4 
relationship on the breast cancer could be to silence FOXP3 gene in vitro in order 
to detect changes in CXCR4 expression.  
6.6.8 Use of MDA-MB-231-luc-D3H1 Bioware® cell line as in-vivo metastasis model  
This study has suggested the role of FOXP3 in CXCR4 driven chemotaxis of breast 
cancer cells by the series of in vitro experiments.  In vivo experiments could be 
perform to examine the effect of FOXP3 up regulation on the tumour metastasis 
formation. The MDA-MB-231-luc-D3H1 Bioware® cell line can be used in vivo to 
establish an experimental metastasis model. Throughout the experiments 
bioluminescent imaging could be used to detect metastatic sites, monitor tumour 
progression, metastases growth rate and any changes following induction of 
FOXP3 expression. 
6.6.9 Investigate stem cells niche expression of CXCR4  
Breast cancer cells express the chemokine receptor CXCR4 and frequently 
metastasize to organs with an abundant source of the CXCR4 ligand, stromal cell-
derived factor 1 (SDF-1). The chemokine receptor CXCR4 plays an active role in the 
metastasis of breast cancer. CXCR4 molecule is a potential target to control breast 
tumor growth as well as metastasis and could be further explored. 
6.6.10 New approaches for cancer therapy  
Considering that the majority of tumors have at least one wild type FOXP3 allele, 
and given the detrimental effect of loosing FOXP3 expression on tumor cell growth, 
it would be of great value to develop a drug that can reactivate the FOXP3 gene in 
cancer. Therefore, better understanding of FOXP3 expression in normal and cancer 






In conclusion, the current study confirms failure of FOXP3 nuclear localisation in 
breast cancer and an inverse correlation between this failure and CXCR4 
expression. Out of the nucleus, FOXP3 transcription factor cannot maintain its 
physiological properties. Transfection of breast cancer cells with FOXP3 reversed 
its expression to the physiological nuclear pattern and subsequently inhibited 
migration and proliferation of breast cancer cells in vitro. Hence, inactivation of 
FOXP3 may suggest a mechanism of cancer invasion and metastatic spread.  The 
study gives further evidence of FOXP3 splice variants in breast cancer. It also 
provides the first description of nucleotide sequence of FOXP3 isoform 3 that may 
play a role in localization of FOXP3 in cellular nuclei. These results of this work 
would need to be further confirmed by additional in vitro and in vivo studies.  
6.8 Model of CXCR4-FOXP3 interactions in breast cancer  
On the basis of the findings obtained in this study and the current evidence, the 
following simplified model of the interactions between FOXP3 and CXCR4 in breast 
cancer has been proposed (Figure 6-1).  
FOXP3 suppresses breast cancer by inducing tumour suppressor gene p21 while 
repressing oncogenes HER2 and SKP2. The genes indicated are all direct targets 
for FOXP3 and their regulation is essential for growth inhibition by FOXP3 (Liu et 
al., 2009, Zuo et al., 2007c, Zuo et al., 2007b). Therefore, FOXP3 is an X-linked 
breast cancer suppressor gene in both mice and humans. 
Amongst others they are several factors inducing the expression of CXCR4 
receptor: NF-kappa B (Helbig et al., 2003), HER2/ERBB2 (Li et al., 2004), SKP2 
(Zuo et al., 2007b), Neuropilin-2 (Nrp2) receptor (Yasuoka et al., 2009). Thus 
FOXP3, the inhibitor of above factors should reduce breast cancer metastasis by 







Figure 6-1: Model of CXCR4-FOXP3 interactions in breast cancer. 
FOXP3 suppresses breast cancer by inducing tumour suppressor gene p21 while repressing 
oncogenes HER2 and SKP2. The genes indicated are all direct targets for FOXP3 and their 
regulation is essential for growth inhibition by FOXP3 (Liu et al., 2009, Zuo et al., 2007c, Zuo et al., 
2007b). Therefore, FOXP3 is an X-linked breast cancer suppressor gene in both mice and humans. 
Amongst others there are several factors inducing the expression of CXCR4 receptor: NF-kappa B 
(Helbig et al., 2003), HER2/ERBB2 (Li et al., 2004), SKP2 (Zuo et al., 2007b), Neuropilin-2 (Nrp2) 
receptor (Yasuoka et al., 2009). Thus FOXP3, the inhibitor of above factors should reduce breast 
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